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Abstract 
Shivprasad Shahajirao Deshmukh  
Investigation of injection moulding for novel drug delivery systems 
An investigation into the use of injection moulding to produce pharmaceutical 
dosage forms and to understand the relationship between materials, 
processing conditions and performance, in particular drug release and stability 
Key words: Hot melt extrusion, injection moulding, solid dispersion, 
crystallisation, Ibuprofen, felodipine, HPMCAS, Soluplus®, controlled release 
The feasibility of the injection moulding (IM)  was explored for the 
development of novel drug delivery systems. Controlled release formulations 
were developed using a substituted cellulose derivative, hydroxypropyl methyl 
cellulose acetate succinate (HPMCAS) and a graft co-polymer (Soluplus®).  
BCS class II drugs ibuprofen and the felodipine were selected based on their 
physicochemical properties.  
In the present work, a homogenous dispersion of drugs in the polymer 
matrices was achieved using Hot Melt Extrusion (HME) and extruded pellets 
obtained were used for the development of the injection moulded systems. 
Four systems were developed using the IM consisting of ibuprofen-HPMCAS, 
ibuprofen-Soluplus®, felodipine-PEO-HPMCAS and felodipine-Soluplus®.  
The ibuprofen acts as a good plasticiser compared to felodipine 
therefore, felodipine containing IM systems required a plasticiser (PEO) when 
processed with HPMCAS. The analysis of extruded pellets and injection 
moulded systems using modulated DSC (MDSC) and Raman spectroscopy 
confirmed the formation of an amorphous molecular dispersion (i.e solid 
 ii 
 
solution) in the case of all four systems. The phase separation behaviour and 
the amorphous stability of the systems was studied at various stress 
conditions. This revealed the “surface crystallisation” behaviour of the 
ibuprofen-HPMCAS systems. Temperature-composition phase diagram 
constructed based on the melting point depression and  the Flory-Huggins 
lattice solution theory provided the explanation for the phase separation and 
crystallisation behaviour of ibuprofen-HPMCAS systems. The advanced 
characterisation techniques like DMA, 2D XRD and 3D laser microscopy 
provided the detailed understanding of crystal habits, phase seperation and 
surface crystallisation. The significant effect of the stress conditions on the rate 
of shrinkage was observed where, higher shrinkage tendency of a HPMCAS 
IM system was observed  compared to Soluplus® IM systems.  
The extruded pellets provided the faster drug release compared to the 
moulded tablets suggests the effect of particle size as well as the densification 
during IM on the dissolution rate of the dosage form. The nature of the polymer 
and processing history were the contributing factors for the dissolution of the 
dosage forms.  
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        Chapter 1 
1 Introduction 
 
Hot melt extrusion (HME) is a widely applied technique in the plastics 
industry, which has recently become viable for the processing of 
pharmaceuticals. In a short time, this technique has become a part of 
pharmaceutical product development. It offers several advantages such as 
solvent free continuous processing, homogenous particulate dispersion (i.e. solid 
dispersion) or molecular dispersion (i.e. solid solution) of actives in a polymer 
matrix. Moreover, acceptance in the pharmaceutical development relies on its 
flexibility to process complex mixtures of drugs with a wide range of excipients 
and to produce various dimensions of dosage forms. However, the end products 
of melt extrusion are generally obtained in the form of intermediate products such 
as pellets or granules which need further processing to develop into the finished 
products or dosage forms.  
Injection moulding (IM) is another commonly used manufacturing process 
for the fabrication of intricate polymeric parts with excellent dimensional 
accuracy. A wide variety of products are manufactured using injection moulding, 
which vary greatly in their size, complexity and application. Hence, application of 
this process for development of moulded drug delivery systems for 
pharmaceuticals could expand applications of existing melt processes. This 
process has been widely used for the manufacturing of pharmaceutical 
packaging materials and more recently for production of biomedical devices such 
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as scaffolds, microneedles and microfluidic devices (Gomes et al., 2001) 
(Haugen et al., 2006). In the context of scalability, the unique features of IM are 
that it consists of a single unit operation, has a higher speed, greater product 
range and higher throughput. 
Although the IM process has great potential to process material, it has 
limitations in terms of the suitability of materials. Not all polymeric systems are 
suitable for injection moulding due to the high temperatures and pressures 
encountered. Polymers are highly sensitive to temperatures and pressures and 
their physical properties including viscoelasticity, flammability, miscibility, and 
surface properties need to be considered for their acceptability with the IM 
process. In IM the material experiences high pressures and the pressure history 
in processing affects material properties such as shrinkage and residual stresses 
at the end of the process (Bayer et al., 1984). The injection and clamping 
pressure effects material densification or reduction in specific volume (Carrasco 
et al., 2010) 
Challenges with the injection moulding process with respect to 
pharmaceutical drug product development are inevitable; therefore the selection 
criteria for materials or polymers for injection moulding need to be established. 
Although injection moulding was introduced by Speiser in 1964 as a 
pharmaceutical technology to produce sustained-release dosage forms and solid 
solutions, its use within the pharmaceutical industry has been limited to date to a 
few specific applications (Speiser, 1969) (Wacker et al., 1991). Recently, 
researchers have been exploring the application of an injection moulding 
technique to fabricate matrix-releasing tablets (Quinten et al., 2009) (Vervaet et 
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al., 2008), capsules of pharmaceutical polymers (Eith et al., 1986) and drug 
releasing polymer matrices (Cuff and Raouf, 1998), (Barshalom et al., 2003). 
Nowadays, researchers are trying to develop and adapt new technologies 
for processing of pharmaceuticals. The IM process can be either explored as a 
down-stream or independent single unit operation to develop drug delivery 
systems. The development of the moulding processes to design drug-polymer 
systems with advanced properties could result in new geometries of dosage 
forms with distinct properties compared to conventional drug delivery systems.  A 
schematic representation of the HME and IM processes for pharmaceutical 
product development is provided in Figure 1.1. The formation of solid dispersions 
of poorly soluble API with pharmaceutical grade polymers and use of IM process 
to provide the solid dispersion and final dosage form in single unit operation is 
illustrated in this figure. 
 
Figure 1.1 Schematic representation of application of HME and IM for NDDS 
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1.1 Theoretical considerations 
The development of pharmaceutical drug-polymer systems using IM has 
several challenges associated with the process and product performance. 
Challenges associated with material properties can be addressed using 
theoretical calculations which provide pre-formulatory information about the 
selected materials. Prior to formulation development, the theoretical knowledge 
of drug-polymer miscibility and solubility in amorphous solid dispersions provides 
a better understanding of drug crystallisation and phase separation during shelf-
life. The following parameters provide a better understanding about the miscibility 
and drug solubility in the polymeric carriers.  
I. Solubility parameters (𝛿  ) 
II. Interaction parameters (χ) 
III. Free energy of mixing(∆𝐺𝑀𝑖𝑥) 
IV. Glass transition temperature of mixtures (Tg) 
V. Temperature-composition phase diagram  
Details of the methods used to estimate these properties are provided in the 
pre-formulation chapter (chapter 4). 
1.2 Challenges associated with IM of pharmaceutical drug-polymers 
systems 
The challenges associated with injection moulding are mainly related to 
process and product performance.   
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1.2.1 Processing challenges 
Most of the pharmaceutical polymer/carriers are not designed specifically 
for melt processing applications. Only a limited numbers of polymers such as 
Soluplus®, Affinosol® have been developed recently for HME application. 
However, IM of pharmaceutical grade polymer is challenging as it needs to have 
a suitable melt viscosity and melt rheology so that melt can flow inside the runner 
system and fill the mould cavity. Amorphous polymers soften on heating and 
exhibit poor lubricity hence often needs a plasticiser to aid the process by 
lowering processing temperatures and provide help to achieve optimum melt 
rheology. Most of the injection moulded part has a runner system for the filling of 
molten material in the mould cavity and when the part is cooled and ejected, the 
extra component gets separated from the main part and disposed. In the case of 
pharmaceutical drug delivery systems the wastage of moulded part is associated 
with high cost, health risks and regulatory concerns. The use of hot runner system 
could overcome the problem of wastage where the runner systems can be used 
as part of next injection moulding cycle. 
 
Figure 1.2: 100 APIs classified based on glass transition temperature (Tg) 
(Fukuoka et al., 1989) 
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Tg data of 100 APIs was compiled from the reported literature and 
classified in into three categories (Fukuoka et al., 1989). Figure 1.2 shows that 
approximately 1/3 of drugs ( 36) fall in the range of - 50oC to 25 oC and which 
have a Tg less than the room temperature (RT) labelled as ‘low Tg’ drugs. 
Approximately 50% of the drugs fall in the range of 25oC to 75 oC labelled as 
‘medium Tg’ drugs. 15% of drugs fall under ‘high Tg’ drugs and have Tg in the 
range of 75oC to 150 oC. Among which only 3% of show Tg higher than 100oC. 
The overall conclusion based on this figure can be drawn as most of the drugs 
fall in the low and medium Tg range and more than 60% of the drugs have Tg 
less than 50oC. Ibuprofen and felodipine (APIs) selected in this research have 
low and medium Tg, respectively. Rationale for the selection of APIs in this work 
was mainly based on their poor solubility and low Tg.  
The selection of amorphous polymers for the solid dispersion usually 
depends on the intended application of the dosage form e.g immediate release, 
controlled release, fast release, delayed release etc. The Tg of amorphous 
polymers is an important consideration during selection, as high Tg polymers 
provide the higher Tg to the amorphous solid dispersion (formulation) and thus 
enhance its stability. However, high Tg polymer becomes a challenge for melt 
processing and often need plasticisers to aid the process. The majority of plastic 
grade polymers are semi-crystalline in nature and exhibit shear thinning 
behaviour and good melt rheology. The use of “low Tg” and/or “medium Tg” drugs 
as a plasticiser for pharmaceutical polymers will enhance the processability of 
polymers by HME and IM. In addition the need for other plasticisers which might 
destabilize the systems could be avoided.  
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1.2.2 Biopharmaceutical challenges: 
Drug delivery products developed using injection moulding are highly 
dense, non-disintegrating and potentially challenging for oral drug delivery. Due 
to densification during injection moulding the dissolution of the dosage forms can 
be the rate limiting step hence the development of immediate release dosage 
form becomes challenging.  
1.3 Research objectives  
The main aim of this research is to investigate the injection moulding 
process to develop novel drug delivery systems (NDDS). The broad objective of 
the work is to understand the processing of pharmaceutical polymers by IM, 
explore injection mouding technology to produce pharmaceutical dosage forms, 
and to provide an understanding of the effect of the process variables on the 
properties of the moulded systems.   
Specific objectives of the research work include: 
1. To develop IM processes for pharmaceutical amorphous polymers and 
investigate its application for NDDS. 
2. To understand the effect of IM processing history on the properties of injection 
moulded systems and to study the biopharmaceutical performance of 
amorphous solid dispersions or solid solutions achieved by HME and IM.  
3. To understand the effect of additives such as modifiers and/or retardants on 
the performance of the moulded systems.  
4. To investigate into the use of injection moulding to produce pharmaceutical 
dosage forms and to understand the relationship between materials, 
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processing conditions and performance, in particular drug release and 
stability. 
In the present work, combinations of drug-polymers with different 
physicochemical properties were selected. Two poorly soluble model APIs 
belonging to biopharmaceutical classification system (BCS class II) and two 
pharmaceutical grade polymers were selected with the objective of obtaining 
NDDS with unique properties and drug release performance. A schematic 
representation of the drug-polymer combinations and systems developed in this 
work are presented in Figure 1.3. The Ibuprofen and felodipine exhibits low (-45 
oC) and medium Tg (45 oC) respectively; whereas Soluplus® possess the low Tg 
(72 oC) compared to HPMCAS (120oC). The understanding of IM processing and 
stability of drug delivery systems obtained using these drug and polymer 
combinations was one of the main interest of this work.  
 
Figure 1.3: Drug polymer combinations used for processing using HME and 
IM  
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1.4 Thesis outline 
Chapter 2 provides a general background and literature review and is 
divided into three sections. The first section provides information on poorly 
soluble drugs, biopharmaceutical classification systems and solubility 
enhancement approaches used for BCS II drugs. The middle section is focused 
on the concept of solid dispersions, drug carriers, polymers and methods of 
preparation. The final section provides an overview of HME and IM including their 
challenges and applications for drug delivery. The thesis structure is provided in 
Figure 1.4. 
Chapter 3 describes the details of materials and methods used for this 
study and this chapter is sub-divided into two major sections; HPMCAS injection 
moulded systems and Soluplus® injection moulded systems. HPMCAS IM 
system provides information of both the HME and IM methods used to obtain 
Ibuprofen-HPMCAS systems and felodipine-PEON750-HPMCAS systems. 
Similarly; the Soluplus® IM system provides details of experimental conditions 
used to produce ibuprofen- Soluplus® systems and felodipine- Soluplus® 
systems.  Details of all characterisation techniques used are provided within each 
section. 
Chapter 4 provides the results and discussion of pre-formulation studies 
performed to understand the material properties. 
Chapter 5 contains results and discussion of HPMAS IM systems; 
ibuprofen-HPMCAS systems and felodipine-PEON750-HPMCAS systems. The 
ibuprofen-HPMCAS moulded systems were investigated in detail to understand 
the processing and stability. Important outcomes of this research, such as 
understanding of surface crystallisation of ibuprofen, crystal habit, 
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biopharmaceutical performance, shrinkage and stability of IM systems are 
presented.  
 
Figure 1.4: Schematic representation of the research structure  
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Chapter 6 contains the results and discussion of Soluplus® IM systems; 
ibuprofen-Soluplus® and felodipine-Soluplus®. The processing challenges 
associated with Soluplus® using HME and IM with the addition of ibuprofen and 
felodipine are discussed. Controlled release behaviour of the IM systems is also 
discussed. 
Chapter 7 combines global discussion of results of pre-formulation, HPMCAS and 
Soluplus® injection moulded system 
Chapter 8 contains an overall summary and conclusion of the work; 
Chapter g suggestions for future work are presented in this chapter 
Reference used within this thesis and appendix are provided in last section of 
thesis. 
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      Chapter 2 
2 Background 
This chapter will provide relevant background information and a literature review 
of poorly soluble drugs, the biopharmaceutical classification system (BCS), and 
solid dispersion strategies used for solubility enhancement of active 
pharmaceutical ingredients (API). The objective of this chapter is also to review 
melt processing technologies used for development of solid dispersions and 
novel drug delivery systems. A schematic representation this chapter is shown in 
Figure 2.1. 
 
Figure 2.1: A schematic representation of background chapter 
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2.1 Poorly soluble drugs 
  Combinatorial chemistry and high throughput screening approaches are 
processes used in drug discovery to choose potential drug-like candidates after 
screening million’s of compounds. The ‘drug-like’ compounds in early drug 
discovery are defined as compounds that have sufficient absorption, distribution, 
metabolism, excretion (ADME) properties and have sufficiently acceptable 
toxicity properties (Lipinski, 2000). The drug candidates chosen after this 
meticulous screening, however, can produce a drug with high or low aqueous 
solubility with high or low lipophilicity. The numbers of drug candidates with poor 
aqueous solubilities have increased in recent years and it is estimated that 
approximately 70% of new drug candidates have shown poor aqueous solubility 
(Ku and Dulin, 2012). Figure 2.2 shows currently marketed drugs and those under 
development (Babu and Nangia, 2011). Studies of the current globally marketed 
top 200 immediate release (IR) oral products showed that 40% of drugs are 
practically insoluble (<100 μg/ml) (Takagi et al., 2006). 
 
Figure 2.2: Low solubility drugs in the market and in the development 
pipeline according to the BCS  (Babu and Nangia, 2011) 
  The poor aqueous solubility of drug candidates is critical in determination 
of its performance. In the case of orally administered drugs, a drug candidate 
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must undergo dissolution to get absorbed into the systemic (blood) circulation, 
and thus become bio-available.  Complete absorption of the drug candidate after 
oral administration will be based on the events depicted in Figure 2.3.  Moreover, 
the events are relatively important to each other and the rate at which they occur 
(Dressman and Reppas, 2000). Hence, in the case of poorly soluble drugs the 
dissolution becomes a rate-limiting step for absorption. When the solubility of the 
drug candidate is less than 0.1mg/mL (<100 μg/ml), it is considered to be 
practically insoluble (Table 2.1).  
Table 2.1: Solubility definitions in the USP (Stegemann et al., 2007) 
Description forms 
(solubility 
definition) 
Parts of solvent 
required for one 
part of solute 
Solubility 
range 
(mg/ml) 
Solubility 
assigned 
(mg/ml) 
Very soluble (VS) <1 >1000 1000 
Freely soluble (FS) From 1 to 10 100-1000 100 
Soluble From 10 to 30 33-100 33 
Sparingly soluble 
(SPS) 
From 30 to 100 10-33 10 
Slightly soluble (SS) From 100 to 1000 1-10 1 
Very slightly soluble 
(VSS) 
From 1000 to 10,000 0.1-1 0.1 
Practically insoluble 
(PI)a 
>10,000 <0.1 0.01 
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Figure 2.3: Events in the gastrointestinal tract following administration of 
an oral dosage form (adapted from Dressman and Reppas, 2000)  
2.2 Biopharmaceutical classification system (BCS) 
  The BCS is a scientific framework used for the classification of drug 
substances based on their aqueous solubility and gastrointestinal permeability 
(FDA, 2000). It basically classifies a drug candidate into one of the four categories 
based on the solubilities and the permeability characteristics (Figure 2.4). Class 
I drug candidates are highly soluble and highly permeable. The drug candidates 
classified in class I should not be less than 90% absorbed. Class II and Class III 
candidates are the mirror images of each other. Class II drugs are poorly soluble 
therefore, exhibit poor performance during the dissolution; however, they are 
highly membrane permeable. Class III drugs are highly soluble but challenging 
because of poor lipophilicity. Class IV drugs have neither sufficient solubility nor 
permeability for complete absorption.  From the biopharmaceutical point of view, 
the BCS scheme is a very useful and used as a decision-making tool in 
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formulation development. It is now a widely used tool for making strategies for 
formulation development of drug candidates.  
 
Figure 2.4: BCS classification of drugs (Rautio et al., 2008) 
  Recently, modified version of BCS called Biopharmaceutics Drug 
Disposition Classification System (BDDCS) was proposed to better predict drug 
disposition (Wu and Benet, 2005).  BDDCS was developed based on the 
realisation that the high permeability characteristics of BCS class I and class II 
drug allow ready access to metabolising enzyme within hepatocytes and thus 
there is also good correlation between the drug metabolism and permeability 
defined under BCS. Instead of permeability the BDDCS categorises drug 
substances using major route of drug elimination or drug metabolism as follows 
(Chen and Yu, 2009; Larregieu and Benet, 2014):  
Class I:  High solubility, extensive metabolism  
Class II: Low solubility, extensive metabolism 
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Class III: High solubility, poor metabolism  
Class IV: Low solubility, poor metabolism  
2.3 Formulation strategies based on BCS  
  As presented in Figure 2.4; the BCS classification is a great help in the 
understanding of physicochemical and biopharmaceutical properties of the drug 
candidates. A common approach for formulation development after its 
classification will be to try to shift all other classes of drugs to class I, which has 
both good solubility and lipophilicity. Low permeability of the drugs in class III and 
class IV would lead to strategies for optimisation of drug candidate properties; for 
example, lead optimisation which involves chemical structure modification, 
formation of prodrugs (Amidon et al., 1995) (Rautio et al., 2008). The absorption 
of class III is generally modified by formulation of dosage forms containing 
permeation enhancers such as fatty acids, bile salts, surfactants, 
polysaccharides etc. As the majority of drugs fall drugs into BCS II and most of 
the new drug discovered also show poor solubility despite their good lipophilicity. 
Therefore, formulation strategies are mainly focused on solubility enhancement 
of poorly soluble drugs.  
2.4 Strategies for poorly soluble drugs (BCS II)  
  Solubility of a material is an intrinsic property that can be only influenced 
by the chemical modification of the molecule such as a salt formation or pro-drug 
formation. Dissolution of material, in contrast, is an extrinsic property which can 
be influenced by various factors such as chemical, physical or crystallographic 
modifications such as like particle size, complexation, surface property 
modification, co-crystallisation etc. (Stegemann et al., 2007). Formulation 
approaches for BCSII drugs are presented in Figure 2.5 .  
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Figure 2.5: Formulation approaches used for solubility enhancement of 
poorly soluble drugs 
2.4.1 Crystal modification  
  Polymorphism and salt formation are widely used approaches in the area 
of crystal modification of pharmaceutical drugs. Polymorphs are defined as a 
material with the same chemical composition, but differ in their lattice structure 
and/or molecular conformation (Rodriguez-Spong et al., 2004). Polymorphs 
exhibit different physicochemical properties such as melting point, solubility, 
density and stability. Generally a metastable polymorph shows higher kinetic 
solubility than a more thermodynamically more stable polymorph (Blagden et al., 
2007). Salt formation is the common approach used for ionisable drugs in the 
pharmaceutical industry for the enhancement of solubility and the dissolution 
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rate. Salts are formed by transfer of a proton from an acid to a base.  When the 
pka  difference (ΔpKa) between an acid and a base is greater than 3, a strong 
ionic bond can be formed (Childs et al., 2007). The dissolution rate enhancement 
of the corresponding salt form compared to the free form is mainly because of 
the counter ion containing salt changes the pH at dissolving surface of the salt 
particle in the diffusion layer (Serajuddin, 2007). In recent years, the formation of 
co-crystals of poorly soluble drugs has been also widely investigated for crystal 
modification to improve the dissolution rate. Co-crystals are broadly defined as 
crystalline materials comprised of at least two different components (Schultheiss 
and Newman, 2009). 
  Pharmaceutical co-crystals are typically composed of active 
pharmaceutical ingredient (API) and co-formers in stoichiometric ratio. In many 
cases, it was seen that the API and co-formers require the formation of  a 
hydrogen bond (H-bond) to form stable co-crystals. Generally ΔpKa is considered 
to be a reliable indicator for distinguishing salts and cocrystals, molecular 
complexes are thought to be co-crystals when the  ΔpKa difference is less than 
0 (Childs et al., 2007). There are many reports about the use of co-crystal 
approaches to modify the physiochemical properties of several APIs including 
carbamazepine, theophylline, itraconazole, norfloxacin, indomethacin 
(Vishweshwar et al., 2006) (Jones et al., 2006) (Childs et al., 2007) (Basavoju et 
al., 2006), to enhance the dissolution rate and oral bioavailability (Jung et al., 
2010) (Jung et al., 2010) (McNamara et al., 2006) (McNamara et al., 2006) (Bak 
et al., 2008). 
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2.4.2 Particle size reduction  
  Reduction of the drug particle size to the micron or nano size is a widely 
used approach for solubility enhancement of poorly soluble drugs. According to 
the Noyes-Whitney equation the rate of dissolution (J) is directly proportional to 
the surface area (A) of the particles and inversely proportional to the boundary 
layer thickness (h).  
𝐉 =
𝐃 𝐀
𝐡
  (𝐂𝐬 − 𝐂)      Equation  2.1  
   Where J is the rate of dissolution, D is the diffusion co-efficient, h is 
boundary layer thickness, Cs is the saturation solubility, C amount of drug 
dissolved at time T. 
  Therefore, a reduction in particle size will increase the dissolution rate to 
a significant extent by increasing the surface area (Horter and Dressman, 2001) 
and decreasing boundary layer thickness (Mosharraf and Nystrom, 1995). 
Therefore, the micronisation of drug particles leads to a decrease in particle size 
by a factor of 5 which will enhance dissolution by 5 fold. A micronisation approach 
has successfully enhanced the bioavailability of some poorly soluble drugs such 
as griseofulvin, digoxin and felodipine  (Atkinson et al., 1962) (Jounela et al., 
1975; Scholz et al., 2002). 
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Figure 2.6: Surface area of the drug particles vs thermodynamic stability 
(Kolter et al., 2012) 
  Reduction of the drug particles to a nanometer size (< 1 μm) could be 
more advantageous as it will provide a greater surface area and decrease the 
boundary layer thickness (Figure 2.6). In addition to this factor, it will also 
increase the saturation solubility (Muller and Peters, 1998). Nanocrystals can be 
produced  by wet milling, high-pressure homogenisation and controlled 
precipitation (Shegokar and Mueller, 2010). There are numerous reports on the 
solubility enhancement of poorly soluble drugs by  nanosizing techniques. Drug 
candidates like Cilostazol, Curcumin, Danazol, Fenofibrate and Nitrendipine are 
the examples which have been formulated in nanocrystals and showed a 
significant enhancement in bioavailability. 
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2.4.3 Complexation: Cyclodextrin complexation  
  Cyclodextrins are useful functional excipients in the formulation of poorly 
soluble drugs and have wide popularity from a pharmaceutical perspective 
because of their ability to interact with drugs and form inclusion complexes 
(Rajewski and Stella, 1996). There are more than 10 marketed solid, liquid and 
semisolid dosage forms available with cyclodextrin complexes (Brewster and 
Loftsson, 2007). Cyclodextrins are oligosaccharides, contain a relatively 
hydrophobic or lipophilic central cavity and hydrophilic outer core and surface 
(Loftsson and Brewster, 1996). Cyclodextrins are used either as solublisers or to 
form solid dispersions with  poorly soluble drugs to enhance their bioavailability 
(Figueiras et al., 2007) (Al Omari et al., 2006) (Cirri et al., 2005) 
2.4.4 Amorphisation  
  In a crystalline solid, three-dimensional long range order normally exists, 
whereas in the case of the amorphous state, this order does not exist and the 
position of molecules relative to one another is more random as in the liquid state. 
The amorphous character may be induced in the solid by four common means 
(Figure 2.7). These include condensation from vapour state, supercooling of melt, 
mechanical activation of the crystalline mass and rapid precipitation from solution 
(Hancock and Zograf, 1997). Amorphous solid forms are markedly more soluble 
than their crystalline counterparts (Hancock and Parks, 2000). Formation to 
amorphous solids or formulation to amorphous solid dispersion (ASD) is used as 
a tool to enhance bioavailability by taking the solubility advantage offered by the 
amorphous solid.  
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Figure 2.7: Schematic representation of most common ways by which the 
amorphous form is induced in pharmaceutical systems.  
  Figure 2.8 represents the enthalpy (H) or specific volume (V) of a material 
as a function of temperature. In crystalline materials, we may see at very low 
temperatures a small increase in enthalpy and specific volume with respect to the 
temperature indicative of a certain heat capacity (Cp) and thermal expansion 
coefficient (α). When a crystalline material reaches its melting temperature (Tm) 
discontinuity in both H and V represent a first-order transition to liquid state. Upon 
rapid cooling beyond its melting temperature values of H and V may follow 
equilibrium or first order in “supercooled region”. On further cooling a change in 
slope is seen at a characteristic temperature called the “glass transition 
temperature” (Tg) (Figure 2.8). Tg is a significant property for the characterisation 
of pharmaceutical solids. At  Tg the properties of the glassy material deviate from 
those of the equilibrium supercooled liquid to give a nonequilibrium state having 
even higher H and V than the supercooled liquid (Hancock and Zograf, 1997). 
The critical temperature TK is known as the Kauzmann temperature and is 
thought to mark the lower limit of the experimental glass transition (Tg) and to be 
 24 
 
the point at which the configurational entropy of the system reaches zero (Ediger 
et al., 1996) (Angell et al., 1986).  
 
Figure 2.8: Schematic depiction of the variation of enthalpy (or volume) with 
temperature (adapted from Hancock and Zograf, 1997)  
  The amorphous state possesses higher internal energy than 
crystalline solids e.g Pikal et al. studied the series of β-lactam antibiotic 
(cephalosporins ≈25 kJ‚mol-1) using a solution calorimetry method (Pikal et al., 
1978). This indicates that an amorphous state should have higher 
thermodynamic properties such as enthalpy, entropy, heat capacity than the 
crystalline state and greater molecular motions. The high internal energy and 
specific volume of an amorphous state can lead to an increased dissolution rate 
and enhanced bioavailability (Hancock and Zograf, 1997). However, these 
properties would also create the possibility that during processing or storage, the 
amorphous state may spontaneously convert back to the crystalline state 
(Yoshioka et al., 1994). The stabilisation of amorphous form or to obtain a stable 
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amorphous formulation, the solid dispersion (SD) approach has received wide 
acceptance in the area of pharmaceutical drug delivery. 
2.5 Solid dispersion   
  During the last 30-40 years, the solid dispersions approach has become 
greatly accepted, adapted and recently commercialised for the formulation 
development of drug candidates which suffer from poor solubility. The definition 
of solid dispersion was first given in 1971 by Chiou and Riegelman in their 
excellent review “Dispersion of one or more active ingredient in an inert carrier or 
matrix at solid state prepared by the melting (fusion), solvent, or melting-solvent 
method”. (Chiou and Riegelman, 1971) 
2.5.1 Classification of solid dispersion  
  There are a number of ways by which the solid dispersions are classified. 
Classification based on molecular arrangements is given in Table 2.2. 
Table 2.2: Classification of solid dispersion (Singh et al., 2011) 
Type  Matrix 
*  
  
Drug 
* *  
 
Remarks No. of 
phases 
1 Eutectic  
 
C  C  The first type of prepared 
solid dispersion  
2 
2 Amorphous 
precipitation in 
crystalline 
matrix 
C  A  Rarely encountered  2  
3 Solid solution  C  M    
Continuous solid 
solution  
 
C  M  Miscible at all 
compositions, never 
prepared 
 1 
 
 Discontinuous 
solid solution  
 
C  M  Partially miscible, 2 
phases even though drug 
is molecularly dispersed  
 
2  
 26 
 
Substitutional 
solution  
 
C  M  Molecular diameter of 
drug differs than 15%  
from the matrix diameter. 
In that case the drug and 
matrix are substitutional. 
Can be continuous or 
discontinuous.  
When discontinuous 2 
phases even though drug 
is molecularly dispersed.  
1 or 2  
Interstitial solid 
solutions  
 
C  M  Drug molecular diameter 
less than 59% of matrix 
diameter. Usually limited 
miscibility, discontinuous  
 
 
4 Glass 
suspension  
 
A  C  Particle size of dispersed 
phase dependent on 
cooling rate. Obtained 
after crystallisation of drug 
in amorphous matrix.  
 
 
5 Glass 
suspension  
 
A  A Particle size of dispersed 
phase dependent on 
cooling rate. Obtained 
after crystallisation of drug 
in amorphous matrix.  
 
6 Glass solution  
 
A  M  Requires miscibility or 
solid solubility, complex 
formation or upon fast 
cooling, evaporation 
during preparation  
 
*A: matrix in amorphous state, C: matrix in crystalline state  
** A: drug dispersed as an amorphous cluster in the matrix, C: drug dispersed as 
crystalline particles in the matrix, M: drug molecularly dispersed throughout the 
matrix 
  The Chiou and Riegelman proposed classification based on the major fast 
drug release mechanisms accordingly it was classified into six groups as 
explained below:  (Chiou and Riegelman, 1971) 
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2.5.1.1 Simple eutectic mixtures 
  Eutectic mixtures can be prepared by rapid solidification of fused liquid of 
two components which shows a complete liquid miscibility and negligible solid-
solid solubility (Figure 2.9). When a mixture of component A and component B 
with composition E is cooled both A and B will crystallise out simultaneously to 
form a eutectic mixtures. These mixtures are usually prepared by rapid cooling 
to comelt two components in order to obtain the fine crystals of two components. 
The carriers are usually crystalline in nature, e.g. urea, which dissolve rapidly in 
aqueous medium and release the fine drug crystals thus resulting in an enhanced 
dissolution rate and improved bioavailability. 
 
Figure 2.9: Phase diagram for a eutectic system (adapted from Leuner and 
Dressman, 2000) 
e.g  Eutectic mixtures of sulphathiazole-urea system (Sekiguchi and Obi, 1961) 
Urea-acetaminophen (Goldberg et al., 1966) 
2.5.1.2 Solid solutions 
Solid solutions are comparable to liquid solutions and consist of one phase 
irrespective of the number of components (Leuner and Dressman, 2000).  Solid 
solutions consist of a solid solute dissolved in a solid solvent.  In the  case of solid 
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solutions, poorly soluble drug molecules are dispersed in an inert carrier with a 
relatively good aqueous solubility and dispersed drug particle size is reduced to 
molecular dimensions (Goldberg et al., 1965). 
Continuous solid solutions 
 Continuous solid solutions are an ideal type of solid solution where two 
components are miscible in all preparations. Theoretically, this means that 
bonding strength between the two components is stronger than the bonding 
strength between molecules of the individual component. There are no reports of 
this type of solid solution in the pharmaceutical literature to date.  
Discontinuous solid solutions 
In the case of discontinuous solid solutions, there is a limited solubility of 
one component in the other. Goldberg suggested the  that the term ‘solid solution’ 
should only be applied when the mutual solubility of the two components exceeds 
5% (Goldberg et al., 1965). Chiou and Riegelman in 1969 reported the first 
amorphous solid solutions system for solubility enhancement of the  griesofulvin 
(Chiou and Riegelman, 1969) . 
Substitutional crystalline solid solutions, interstitial crystalline solid 
solutions and  amorphous solid solutions 
Classical solid solutions have a crystalline structure, in which a solute 
molecule either substitutes for a solvent molecule in the crystal lattice or fits into 
the interstices between the solvent molecules. In the case of substitutional 
crystalline solid solutions, substitution of a solute molecule for a solvent molecule 
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can only be possible when the size difference between the two molecules is less 
than 15% (Figure 2.10) 
 
Figure 2.10: Solid solutions (referred from (Leuner and Dressman, 2000).   
Whereas, in the case of interstitial crystalline solid solutions the dissolved 
molecule occupies the interstitial space between the solvent molecules in the 
crystal lattice (Figure 2.10B and Figure 2.10C). The two crucial criteria for the 
formation of interstitial crystalline solid solutions are first, the solute molecule 
diameter should not be longer the 0.59 of the solvent molecule’s diameters 
(Reed-Hill, 1964). Second, the volume of the solute molecule should be less than 
20 % of the solvent.  
In amorphous solid solutions, the solute molecules are dispersed 
molecularly but irregularly within an amorphous solvent. (Figure 2.10D). The 
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dispersion of griseofulvin in citric acid was the first report of an amorphous soild 
solution where the dissolution rate of the griseofulvin was increased significantly 
due to the formation of a molecular level dispersion (Chiou and  Riegelman 1969). 
Other carriers reported in early studies were urea, sucrose, dextrose and 
galactose. Recently the use of polymeric carriers to form amorphous solid 
solutions has increased as the polymer itself is present in an amorphous polymer 
chain network. Moreover, solute molecules may act like plasticisers, leading to a 
reduction in Tg of a polymer. The details of polymeric carriers are presented in 
tabular format in the next section (Table 2.3). 
2.5.1.3 Glass solutions and glass suspensions 
  A glass solution is defined as a homogenous glassy system in which a 
solute dissolves in a glassy solvent or carrier.  Citric acid is capable of forming a 
amorphous glass. Glassy solutions of griesofulvin, phenobarbital and 
hexobarbital were reported with citric acid, which showed a marked increase in 
dissolution rate  (Chiou and Riegelman, 1969). The term glass suspension refers 
to a mixture in which precipitated particles are suspended in a glassy solvent. e.g 
crystallisation of benzophenone in hydrocarbon glass forms an invisible to 
opaque appearance (Keller and Breen, 1965).  
2.5.1.4 Amorphous precipitation of drug in crystalline carrier 
  This is a similar dispersion to a eutectic mixture, the only difference being 
that the drug may precipitate as an amorphous form in a crystalline carrier.  In 
eutectic mixtures both the drug and carrier crystallise out simultaneously from 
melting and solvent evaporation. Amorphous precipited novobiocin has a higher 
solubility than its crystalline form (Mullins and Macek, 1960). 
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2.5.1.5 Compound or complex formation between drug and carrier  
  This group is not directly considered as class of solid dispersion; however 
the possibility of forming complexes cannot be overlooked. This group generally 
describes the possibility of formation of complexes between drug and inert carrier 
and that could ultimately change the dissolution rate. e.g the formation of 
insoluble complexes of anti-depressant (phenobarbital) with Polyethylene glycol 
4000 or 6000 was shown to reduce its dissolution rate and permeation through 
the gut wall of rats (Singh et al., 1966).  
2.5.1.6 Miscellaneous 
  It is possible that a solid dispersion may not entirely belong to one of the 
classes above mentioned, but may be formed from a combination of different 
groups.  e.g Griseofulvin dispersed at high concentrations in  polyethylene glycol 
may exist as individual molecule and as microcrystalline particles. The 
coprecipitates of reserpine with bile steroids (deoxycholic acid) were shown to 
increase blepharoptotoc activity of reserpine in mice. Exact physical properties 
of this system have not been elucidated, however the possibility of formation of 
a clathrate compound (inclusion compound) was considered in which a molecular 
dispersion of reserpine forms in hollow channels of bile clatharates (Ferguson, 
1964). 
2.5.2 Current trends and future prospective of solid dispersion  
  In general solid dispersion technology deals with a group of solids 
containing at least two components usually a hydrophobic drug and hydrophilic 
carrier. The carrier or matrix former could be crystalline or amorphous in nature. 
Figure 2.11 gives an overview on the compositions and properties of four 
generations of solid dispersions (Vo et al., 2013) .  
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  The first generation of solid dispersion is where usually crystalline matrix 
formers such as urea, mannitol, citric acid were used to form eutectic mixtures.  
Due to the crystalline nature of the carriers, this type of solid dispersion exhibited 
low solubility and possessed low stability. During the development of second 
generation dispersions, the concept of the dispersion of an active into an 
amorphous polymer matrix became popularised e.g. polyethylene glycol, 
polyvinyl pyrrolidone. This generation of solid dispersions had improved 
dissolution rate and thereby improved bioavailability. In an amorphous solid 
dispersion, the API  is dispersed at a molecular level amorphous particles or small 
crystals and exists in a supersaturated state in amorphous carriers because of 
forced solubilisation (Tanaka et al., 2006) (Urbanetz, 2006). Amorphous carriers 
can also increase  dispersability and wettability of the API as well as may serve 
to inhibit the precipitation of drug during dissolution in aqueous media (Chauhan 
et al., 2013). 
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Figure 2.11:Composition and properties of four generations of solid 
dispersions. CC: crystalline carrier, AP: amorphous polymer, SFP: 
surfactant polymer, WIP: water insoluble polymer, SP: swellable polymer, 
SF: surfactant, (↑): increase, (↓): decrease (adapted from Vo et al., 2013) 
 
  The third generation of solid dispersion involves the use of surface active 
agents or self-emulsifiers. These agents were introduced as carriers or additives 
and showed a significant improvement in overcoming the above problems such 
as precipitation and recrystallisation. e.g Poloxamer, Compritol 888 ATO , 
gelucire 44/14 Soluplus® and emulsifiers such as sodium lauryl sulfate 
(SLS) Tween 80, d-alpha tocopheryl polyethylene glycol 1000 succinate (TPGS 
1000). 
  Fourth generation solid dispersions are controlled release solid 
dispersions (CRSD) usually containing poorly water soluble drugs with a shorter 
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biological half-life. CRSD are designed to achieve two targets: firstly, solubility 
enhancement and secondly, extended release of the API in a controlled manner. 
There are many advantages of this type of solid dispersion: improved  patient 
compliance due to reduced dosing frequency, decreased side effects, constant, 
prolonged therapeutic effect of poorly soluble drug release (Desai et al., 2006). 
The CRSDs have two main drug release mechanisms: diffusion and erosion. The 
use of water insoluble amorphous carriers and swellable polymers can dictate 
the mechanism of drug release. e.g Eudragit RSPO and ethyl cellulose are pH 
dependent solubule and water insoluble polymers respectively, and were used to 
obtain a sustained release of nitrendipine (Cui et al., 2003). Whereas the water 
soluble nature of polyethylene oxide (PEO) gave a controlled release of 
aceclofenac by diffusion through a swellable matrix of PEO  (Tran et al., 2010).  
The details of carriers used in solid dispersions are compiled in Table 2.3. 
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Table 2.3: Carriers used for Solid dispersion and their properties (Paudel et al., 2013) 
Carriers M.Wt 
(Range) 
(kDa) 
Tg (Tm) 
(°C) 
Solubility 
parameters 
(cal/cm3)1/2 
Hygroscopicity 
(moisture at 
75%RH/RT) 
Cellulosic derivatives: hydroxyl (ether)*    
HPMC 2910 10–1500 148.2–151.1 23.8 ∼10 
HPMCAS-MF 80 117.3–120 31.2 6–7 
HPMC-E5 (2906) 10–1500 152 – – 
Na-CMC 90–700  – – 
HPMC-P 55 10–1500 138 28 7–8 
HPMC-AS HG 55–93 117.9–120 – – 
HPC (L-HPC) 50–1250 105 (220)  6–7 
MCC 36 (260–270)  - 
Vinyl polymers      
(OH of secondary alcohol)*-PVA     
PVP K 30 50 170–174 27.7 40% 
PVP K 25 28–34   35–40% 
PVP-VA64 45–70 106.0–110.0  <10% (50% RH) 
PVP VA 37     
Kollicoat IR 45    
PVA 22000 20    
Soluplus® 90-140 72 31.22 ∼12 
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Carriers M.Wt 
(Range) 
(kDa) 
Tg (Tm) 
(°C) 
Solubility 
parameters 
(cal/cm3)1/2 
Hygroscopicity 
(moisture at 
75%RH/RT) 
Lipidic carriers     
Gelucire 44/14  -44  ≈1% (<60% RH) 
Gelucire 50/13  -50   
Compritol 888 ATO     
Sterotex K NF     
Poly(ethylene oxide) & derivatives     
Polyox N750  - 50   
PEG 4000 2.6–3.8 (50–58)  <2.5% 
PEG6000 7.3–9.3 −22.71 (55–63) <1% 
PEG20000 15–25 −41 (60–63)  NH 
Poloxamer 407 9.84–14.6    
Carbohydrates: hydroxyl (ether)*- dextrin    
Lactose 0.3423 232   
Arabia gum     
Stevia-G     
Glucosyl hesperidin     
PHPMA (poly[N-(2-
hydroxypropyl)methacrylate]) 20 -   
Eudragit E 100 47 48 19.3  
NaPMM 135    
Polyacrylic acid (PAA) 100 100–105 & 126  
Carbopol 940 104.4 100–105   
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2.5.3 Polymers   
  A polymer is defined as a chemical compound or mixture of compounds 
consisting of repeating structural units, created through a process of 
polymerisation.  This term describes a molecule whose structure is composed of 
multiple repeating units, from which originates a characteristic of high relative 
molecular mass and properties. The chemical structure, physico-chemical 
properties and applications of three pharmaceutical grade polymers selected in 
this research are presented in this section  
2.5.3.1 Hydroxy propyl methyl cellulose acetate succinate (HPMCAS) 
  HPMCAS is cellulose ether, formed by alkylation of cellulose ether. 
Hypromellose acetate succinate is a mixture of acetic acid and monosuccinic acid 
esters of hydroxypropylmethyl cellulose. The nature of substituted i.e Alkyl, aryl, 
hydroxy-alkyl, other substituted alkyls, etc., degree of substitution, i.e. number of 
free and esterified hydroxyl groups dictates the polymer’s physical properties 
(Figure 2.12). 
 
 
 
Figure 2.12: Structure of HPMCAS  
  HPMCAS is available in several grades which mainly vary with the extent 
of substitution of acetyl and succinoyl groups. An increase in substitution of 
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methoxy and acetyl groups increases the hydrophobicity of the polymer. Succinic 
acid remains un-ionised below pH 5 (Table 2.4). In pharmaceutical applications, 
it is mainly used for film and enteric coatings of oral dosage forms such as tablets 
and granules. It is insoluble in stomach fluid, but dissolves rapidly in the upper 
intestine. It is widely used for solid amorphous dispersion applications and is 
reported to have a higher drug dissolution rate (e.g nifedipine) and inhibit the 
recrystallisation of drugs from the polymer matrix (Tanno et al., 2004). 
Table 2.4: Various grade and nature substitution of HPMCAS  
 
Properties and application of HPMCAS 
  The unique properties of HPMCAS make it suitable for amorphous solid 
dispersions and spray-dried dispersions. Some of the properties of HPMCAS are 
summarised below (Friesen et al., 2008): 
1. It has a high Tg in its un-ionized state. The high Tg of HPMCAS directly 
correlates to the drug having low molecular mobility, and is thus 
responsible for the physical stability of HPMCAS amorphous dispersions. 
2. It is highly soluble in organic solvents, e.g. acetone, methanol; this allows 
applications for enteric coating and spray dried dispersions.  
Type Content of substituent’s (%) Soluble 
at pH  
Succinoyl Acetyl Methoxyl Hydroxypropoxyl 
HPMCAS-
LF 
14.8 7.3 7.1 22.7 5.5 and 
higher 
HPMCAS-
MF 
11.0 9.3 7.4 23.0 6.0 and 
higher 
HPMCAS-
HF 
7.8 11.1 7.4 23.5 6.5 and 
higher 
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3. HPMCAS gets partially ionized and at pH above 5, the charge on the 
polymer minimises the formation of large polymer aggregates, allowing 
drug-polymer colloids (e.g amorphous nanostructures) to remain stable. 
4. HPMCAS is amphiphilic in nature; hence it is a polymer of choice for 
solubility enhancement of poorly soluble drugs and stabiliser of re-
crystallisation during dissolution from amorphous dispersion. 
5. The amphiphillic nature of HPMCAS allows insoluble drug molecules to 
interact with a hydrophobic region, whereas hydrophilic regions allow 
these structures to be stable as colloids in aqueous solutions. 
  As reported in Table 2.4 HPMCAS is available with various degrees of 
substitution of acetate and succinate groups. The degree of substituents and the 
nature of substitution on the HPMCAS backbone decides its pH dependency and 
hydrophilic-lipophillic properties. The official monograph in national formulary 
(NF) reported that HPMCAS is a cellulosic polymer substituted on the hydroxyls 
: methoxy, with a mass content of 12-28 wt %; hydroxypropyl with a mass content 
of 4-23 wt %; acetate, with a mass content of 2-16 wt %; and succinate, with a 
mass content of 4-28 wt % The nature of these substitution gives unique 
properties to the polymer (Figure 2.13).  
 
Figure 2.13: Schematic of nature of substituent and degree of substitution 
(adapted from ShinEstu AOQAT) 
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  The succinate (hydrophilic) groups of HPMCAS have pKa of 5, Therefore, 
at pH below 4 less than 10% of polymer will be ionised and at least 50% of 
polymer will be ionised about pH value 5 or higher (Figure 2.14) The methoxy 
and acetate substituents are relatively hydrophobic and due to these HPMCAS 
is water-insoluble when un-ionised (about pH > 5) and remains predominantly 
colloidal at intestinal pH levels (6-7.5).  
 
Figure 2.14: HPMCAS film solubility at various pH (adapted from ShinEstu 
AOQAT) 
  The substitutions also the affect Tg of the HPMCAS as reported by Friesen 
(Friesen et al., 2008). Under dry conditions Tg of HPMCAS is 120oC. The 
HPMCAS-LF grade shows a decrease in Tg due to the plasticisation effect of 
water compared to other grades owing to its higher substitution of succinic acid 
groups (hydrophilic groups) (Figure 2.15). However, relative water absorption 
was less even at 75% RH, only 6% water absorbed by the HPMCAS, HPMC 
absorbed 10% while PVP absorbed 23% of water. As a result the Tg of HPMCAS 
remained at 70oC even when equilibrated at high RH (75%). This observation 
indicates the excellent physical stability of HPMCAS based solid dispersions. 
HPMCAS has been used as a carrier or stabiliser for a number of Pfizer 
compounds of spray dried solid dispersions (Friesen et al., 2008).  A floating and 
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sustained release dosage form composed of nicardipine hydrochloride and 
HPMCAS was prepared using a twin-screw extruder. 
     
 
Figure 2.15: Effect of RH on polymer properties: (a) Tg versus the RH to 
which samples were equilibrated (at ambient temperature) for HPMCAS and 
(b) equilibrium water absorption versus RH for HPMCAS, PVP, and HPMC 
measured at 25 °C ( adapted from Friesen et al; 2008) 
2.5.3.2 Soluplus® 
  Soluplus® is a polyvinyl caprolactum-polyvinyl acetate-polyethylene glycol 
graft co-polymer. It has an amphiphilic chemical structure and is regarded as a 
polymeric stabiliser. It is an innovative excipient developed by BASF and was 
specifically designed to be used in HME to obtain solid solutions of poorly soluble 
drugs.  
 
Figure 2.16: Chemical structure of Soluplus®  
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Table 2.5: Properties of Soluplus® 
Chemical structure : PEG6000/Vinylcaprolactam/vinylacetate (13/57/30) 
Appearance:  White to yellowish free-flowing granules 
Molecular weight :  118 000 g/mol 
K value (1% ethanol) :  31- 41 
Tg :  72 oC 
CMC 7.6mg/L˷ 7.6ppm 
Solubility acetone (up to 50%) methanol (up to 45%), ethanol 
(up to 25%) and Soluble in water. 
   
  Soluplus® at higher concentration forms colloidal polymer micelles in 
aqueous solution thus may result in a cloudy or turbid solution. This phenomenon 
is more pronounced at elevated temperatures above the lower critical solution 
temperature (LCST) hence heated above this temperatures Soluplus® forms 
large polymeric micelles and turns into a more turbid solution this process is 
reversible upon cooling the solution. 
  Soluplus® is a good solubiliser for poorly soluble drugs and the saturation 
solubility of various drugs has been studied in 10% polymer solution and 
phosphate buffer (Kolter et al., 2012)  
 
Figure 2.5: Saturated solubility of various drugs (Kolter et al., 2012)  
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The saturation solubility of drug in polymer solution is increased compared to the 
phosphate buffer which clearly shows solubilisation effects of Soluplus®. 
Soluplus® is used for solubility enhancement and for obtaining solid solutions with 
poorly soluble drugs. Soluplus® was used as a carrier for solubility enhancement 
of poorly soluble drugs (BCS II) such as fenofibrate, danazol, itraconzole. Both 
in-vivo and in-vitro testing showed higher solubility and high level of Cmax and 
AUC with almost a 5 fold increase compared to the crystalline drug (Linn et al., 
2012) .   
2.5.3.3  Polyethylene oxide (PEO) 
  PEO is a white, water soluble, non-ionic polymer. The typical properties of 
PEO are mentioned in the Table 2.6. 
Table 2.6: Typical properties of PEO 
 
 
 
Appearance Off-white powder 
Crystalline melting point( DSC), oC 62-69 
Odour Slightly smells ammonic 
Melt flow temperature, (oC) >98 
Volatiles content, as packaged, % by wt (at 
105oC) 
<1.0 
Alkaline earth Metals, % by wt as CaO, max 1.0 
Powder bulk density (kg/m3)  (304-593) 
Polymer density, (kg/m3) 1.15-1.26 
Moisture content, as Packaged, % <1 
Heat of Fusion, cal/gm 33 
Solution pH 8-10 
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Properties and applications of PEO  
1. PEO can be cross-linked to form hydrogels (Di Colo et al., 2001) and therefore 
exhibits water retention characteristics. It is a good film former and PEO films 
can be made by both melting and solvent casting methods.  
2. Upon exposure to water or gastric juices, PEO hydrates and swells rapidly to 
form a hydrogel, hence it can be used to make a controlled release matrix 
system. Controlled release of drugs can be obtained by swelling and diffusion 
or swelling and erosion from PEO matrices (Kim, 1998) 
3. PEO has mucosal bioadhesive properties and generally the higher molecular 
weight grades of PEO (4000000) have the highest levels of adhesion 
(Cappello et al., 2006). 
4. PEO has good flow lubricity and compaction properties and hence is suitable 
for direct compaction (Dimitrov and Lambov, 1999). It is used as a carrier for 
solid dispersions of poorly soluble drugs using melt extrusion (Prodduturi et 
al., 2007). 
2.5.4 Methods to achieve solid dispersions or solid solutions 
  In the early 1960s, when the concept of solid dispersions of poorly soluble 
drugs in the inert carrier was becoming popular, three principle methods were 
reported; melting/fusion, solvent and solvent-melting. The solvent method 
involved dissolving of physical mixtures of drugs and carriers in a common 
solvent followed by evaporation of the solvent to obtain a solid dispersion. In one 
example of the solvent-melting approach, the drug phase (spirnonolactone) could 
be dissolved in liquid solvent and then incorporating this solution into the polymer 
melt (Polyethylene glycol 6000). Some of the solid dispersion preparations are 
mentioned in Figure 2.17. 
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Figure 2.17: Methods to achieve solid dispersions 
2.5.4.1 Solvent methods (solvent evaporation methods)  
  In the case of solvent evaporation methods the solid dispersion is 
prepared by evaporation of solvent from a solution containing a drug and carrier. 
This technique has solved problems associated with melting methods such as 
decomposition. However, the prerequisite of this method is that the carrier and 
drug should have sufficient solubility in the selected solvent or co-solvent. Usually 
carriers are hydrophilic in nature and drugs are hydrophobic in nature (Sahoo et 
al., 2011), hence the use of water as a solvent is limited. Organic solvents such 
as methanol, ethanol, ethyl acetate, acetone are used alone or used in a mixture 
with water. The complete removal of solvents upon evaporation is nearly 
impossible, hence the residual solvent in the products may cause instability, e.g. 
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water lowers the Tg and acts to plasticise the system leading to phase separation 
(Vo et al., 2013).   
2.5.4.1.1 Spray drying  
  Spray drying is an efficient manufacturing technology for solid dispersions 
because it permits rapid removal of solvent and results in rapid transformation of 
the drug carrier solution to drug-carrier particles (Paudel et al., 2013). In this 
technique, the drug–carrier solution or suspension is pumped from the reservoir 
and atomised into fine droplets which give a higher surface area for evaporation 
and results in the formation of a solid dispersion within seconds. In a solid 
dispersion drug dispersed in an amorphous form leads in higher dissolution and 
solubility. Examples of available solid dispersion products prepared by spray 
drying are Incivek® and Intelence® (Weuts et al., 2011).  
2.5.4.1.2 Freeze drying  
  This process consists of two main steps: freezing and lyophilisation. The 
drug–carrier solution is immersed in liquid nitrogen until it is fully frozen and the 
frozen solution is then lyophilized (van Drooge et al., 2004). The advantage of 
this method is the minimized risk of phase separation whereas a disadvantage is 
that most organic solvents posses the low freezing temperature and do not stay 
frozen during sublimation. Furthermore, the solvents should have a sufficiently 
high vapour pressure.  
2.5.4.1.3 Supercritical fluid processing  
  In supercritical fluid processing, supercritical carbon dioxide (CO2) is used 
as a solubilising agent for the drug and the carrier and sprayed through a nozzle 
into an expansion vessel with lower pressure. The rapid expansion leads to the 
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generation of small solid dispersion particles with desirable size distribution 
(Moneghini et al., 2001). The problem associated with supercritical fluids is scale-
up and selectivity of the process.  
2.5.4.2 Hot melt methods  
  Sekiguchi and Obi reported the hot melt approach for the first time using 
a drug carrier mixture. The example used was sulphathiazole (drug) and carrier 
(Urea). These were melted together at temperatures above the eutectic point and 
rapidly cooled in an ice bath. Cooling leads to supersaturation, but due to the 
solidification the drug becomes trapped in the carrier matrix. This process 
ensures a solid dispersion formation, whether it forms a molecular dispersion or 
not depends on the degree of supersaturation and rate of cooling. In other words, 
the process has an effect on the properties of the dispersion and product 
properties can be varied by changing processing history. Goldberg later 
discussed the advantages of solid solutions over eutectic mixtures in a series of 
the publications (Goldberg et al., 1965) (Goldberg et al., 1966) 
  The significant improvement in bioavailability was attributed to two factors, 
first the reduction in particle size to the molecular level and second, once the 
carrier is dissolved in the dissolution media and released the drug is molecularly 
dispersed in the dissolution media (Goldberg et al., 1966). Taylor and Zografi 
further provided an explanation for the improvement in dissolution rate that the 
drug has no crystal structure in the solid solution and therefore the energy 
required to break the crystalline structure of the drug before it can dissolve is not 
a limitation of the drug getting released from the solid solution (Taylor and Zografi, 
1997). The high dissolution rate of solid solutions thus, maintains the 
supersatured solution for absorption however, supersaturated solutions have a 
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tendency to get crystallised or precipitate out as metastable polymorphs during 
dissolution. In some cases, carriers (polymers) used for solid solutions inhibit the 
precipitation of the drug from supersaturated solution (Simonelli et al., 1976)            
( Simonelli et al., 1976) (Hilton and Summers, 1986) 
  In the case of hot melt methods, the preparation method used for making 
the dispersion also has a significant effect on the nature of the dispersion. Several 
attempts were made to study the effect of melt processing parameters on the 
properties of dispersions. These include reports by Sekiguchi and Obi,  Chiou 
and Riegelman where they accelerated the cooling rate by snap-cooling on a 
stainless-steel plate (Chiou and Riegelman, 1971). Kanig introduced different 
variations of spraying hot melt onto a cold surface (Kanig, 1964). Recent 
approaches include the use of HME and a number of groups have published 
enhancement of poor solubility of drugs by HME. A further approach was used to 
prepare solid solution drugs by injection moulding demonstrated by Wacker in 
1991 (Wacker et al., 1991).  
2.6 Hot melt extrusion 
  HME is the process of pushing a polymer/substance by the action of a 
rotating screw at elevated temperature through a die to form a product. The 
schematic of the extrusion process is shown in the Figure 2.18. In the extrusion 
process, the molten polymer phase can function as a thermal binder and act as 
a matrix former, solubiliser or drug release retardant upon cooling and 
solidification (Repka et al., 2007). Therefore, solvents and binders are not 
necessary which can reduce the number of unit operations, processing steps and 
time consuming post- processing drying steps.  
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Figure 2.18: Schematic diagram of hot melt extrusion (Adapted from 
particle science Inc.)  
  A uniform particulate dispersion within the molten polymer can be 
achieved by intense mixing and agitation imposed by the action of the rotation of 
screws causing de-aggregation of suspended particles. 
2.6.1 Type of extruders 
  Pharmaceutical extruders (Figure 2.19) are much evolved and adapted to 
mix actives with carriers as well as for wet granulation. The pharmaceutical class 
extruder has to meet regulatory requirements and differ from plastics extruder in 
term of contact parts. The contact part must not be reactive, adsorptive with 
pharmaceutical product and also they must meet their design as per regulatory 
guidelines for cleaning and validation. Pharmaceutical extrudes are typically 
made of surgical grade stainless steel. 
 50 
 
 
Figure 2.19: Thermo Scientific Pharmalab HME 16  
  The extrusion process can be categorised either as ram extrusion or screw 
extrusion. Ram extrusion is based on the principle of positive displacement by 
high pressure to push softened or molten material through a die to produce 
uniform extrudate. Screw extruders are based on the conveying mechanism of 
rotating screws that carries material forward through a die and forms intended 
shape. Screw extruders consist of a minimum of three distinct parts; a conveying 
system for transport of the material and intense mixing, a die to form shapes, and 
auxiliary equipment such as cooler, pelletiser, calendaring rollers, for finished 
product. Twin screw extruders are most accepted for the processing of 
pharmaceutical products and have several advantages over single screw 
extruders such as easier material feeding, high kneading and dispersing 
capacities (Figure 2.20). Extruder and screw design have a significant effect on 
shear and residence time (Repka et al., 2007) (Crowley et al., 2007). 
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Figure 2.20: HME screws and kneading elements  
2.6.2 Applications of HME for solid dispersions and drug delivery  
  As explained earlier, there is a significant effect of particle size on the rate 
of dissolution of the drug. HME is one of the main process used to disperse the 
drugs in polymer matrices aiming to obtain a molecular level dispersion 
(Breitenbach, 2002) (Forster et al., 2001a; Kinoshita et al., 2002) 
  In general, the more the particle size is reduced the lower will be the 
thermodynamic stability. Energy is required when a drug is to leave its crystalline 
state. Transforming the drug into an amorphous state means bringing it into a 
higher energy state; in order to achieve this crystal lattice energy must be 
overcome. The crystalline state of a substance is the only thermodynamically 
favoured energy state. When a drug is transformed into an amorphous state both 
the physical and chemical stability is often limited, therefore, amorphous drug 
molecules often tend to re-crystallise to achieve a thermodynamically stable 
configuration. To address this issue the formulation to an amorphous solid 
dispersion is a common approach to stabilise if the “freezing effect” is sufficient 
due to a high Tg of the system or better by interactions, such as hydrogen 
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bonding between the dispersed drug and the carrier (often polymeric or 
amorphous) (Breitenbach, 2002). 
 
Figure 2.21 Stability of crystalline state (Kolter et al., 2012) 
  The question of how does the HME process help to generate an 
amorphous solid dispersion can be explained by referring to Figure 2.21. The 
crystal lattice energy of the drug has to be overcome to transform it into an 
amorphous state (Hancock and Parks, 2000). In addition to this, the drug and 
polymer need to be blended and co-dispersed subsequently. The extruder 
achieves both these functions by applying shear stress to both drug and polymer. 
Under temperature and energy provided by friction due to shear stress 
overcomes the crystal lattice energy and softens the polymer. The rotating 
screws and different kneading elements make conditions suitable for dispersion 
and with the right choice of process parameters and drug-polymer combination a 
solid solution can be obtained. Melt extrusion may be applied to disperse a drug 
in a polymer matrix down to the molecular level, therefore it is a technology that 
gives broad perspective to the amorphous glass or solid solution approach as a 
delivery system. 
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Figure 2.22: Pharmaceutical applications of  HME  
  The range of pharmaceutical products made using HME are mentioned in 
Figure 2.22 and details of the application have been provided in an excellent 
review by Repka (Repka et al., 2007), A number of products made using HME 
are listed in Table 2.7. 
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Table 2.7: Currently marketed and developed drug products produced 
utilizing hot melt extrusion technology ( adapted from (Shah et al., 2013) 
Product name Indication HME 
purpose 
Company 
Lacrisert® (Opthalmic Insert) Dry eye 
syndrome 
Shaped 
system 
Merck 
Zoladex™ (Goserelin Acetate 
Injectable Implant) 
Prostate 
cancer 
Shaped 
system 
AstraZenec
a 
Implanon® (Etonogestrel 
Implant) 
Contraceptive Shaped 
system 
Organon 
Gris-PEG (Griseofulvin) Anti-fungal Crystalline 
dispersion 
Pedinol 
Pharmacal 
Inc. 
NuvaRing® (Etonogestrel, 
Ethinyl Estradiol depot system) 
Contraceptive Shaped 
system 
Merck 
Norvir® (Ritonavir) Anti-viral (HIV) Amorphous 
dispersion 
Abbott 
Laboratories 
Kaletra® (Ritonavir/Lopinavir) Anti-viral (HIV) Amorphous 
dispersion 
Abbott 
Laboratories 
Eucreas® (Vildagliptin/Metform
in HCl) 
Diabetes Melt 
granulation 
Novartis 
Zithromax® (Azythromycin 
enteric-coated 
multiparticulates) 
Anti-biotic Melt congeal Pfizer 
Orzurdex® (Dexamethasone 
Implantable Device) 
Macular 
edema 
Shaped 
system 
Allergan 
Fenoglide™ (Fenofibrate) Dyslipidemia MeltDose®  
(solid 
dispersion) 
Life Cycle 
Pharma 
Anacetrapib (Under 
Development) 
Atherosclerosi
s 
Amorphous 
dispersion 
Merck 
Posaconazole (Under 
Development) 
Antifungal Amorphous 
dispersion 
Merck 
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2.6.3 Examples of NDDS by HME 
2.6.3.1 Contraceptive Intravaginal rings 
  A contraceptive vaginal ring containing ethinyl estradiol and etonorgestrel 
has been prepared by melt extrusion (Figure 2.23). Coaxial fibres containing 
various concentrations of steroids in the polymer (polyethylene vinylacetate 
copolymers) were prepared and the drug release measurements were carried out 
(van Laarhoven et al., 2002). The process involves blending of steroid and a 
polymer mixture in twin screw extrusion and the steroid was completely dissolved 
in molten polymer. After cooling, cooled strands were obtained and converted 
into fine pellets (core). For the preparation of coaxial fibres a co-extrusion process 
was used where the membrane polymer and core polymer were passed through 
a spinneret to form coaxial fibres.  
  
Figure 2.23 : Nuvaring: contracetive vaginal ring (adapted from Merck 
products) 
2.6.3.2 Floating and sustained release dosage forms 
  A floating sustained release dosage form composed of nicardipine 
hydrochloride and hydroxypropylmethylcellulose acetate succinate (HPMCAS) 
was prepared using a twin-screw extruder (Nakamichi et al., 2001). By 
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adjustment of high pressure screw elements in the immediate vicinity of the die 
outlet and by controlling the barrel temperature, a porous or puffed dosage form 
was obtained. This was very successfully used as a floating dosage form 
containing enteric coating polymer used for longer retention in the stomach. A 
sustained release formulation of isosorbide nitrates in combination with polyvinyl 
acetate has processed using HME. In vitro release of isosorbide nitrates with 
polyvinylacetate showed that even at low polymer concentration the sustaining 
effect of the polymer was sufficient to delay the release. 
2.6.4 Advantages and limitation of HME  
  There are a number of advantages and limitations of HME and some of 
those are mentioned in this section.  
2.6.4.1 Advantages 
  Continuous and solvent free process: HME is a single unit operation, 
and continuous process so it avoids problems with batch processes associated 
with conventional pharmaceutical processing therefore avoiding batch to batch 
variability, wastage and time. Moreover, processing without organic solvents 
makes HME a green and solvent free process. 
  High yield and scalable: HME has a high yield capacity and is readily 
scalable from small scale to the manufacturing scale. 
  Versatile and PAT enabled: HME is capable for the development of a 
variety of dosage forms for wide applications. Extrusion also facilitates process 
analytical tools (PAT) for in-line monitoring of process for quality testing as 
emphasised by FDA (FDA guideline 2004). Extrusion barrel can be equipped with 
processing monitoring tools such as NIR (Kelly et al., 2012), Raman (De Beer et 
al., 2011) to characterise properties of the product during and after HME. 
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2.6.4.2 Limitations 
  High temperature and shear can be a major drawback of the HME 
process. To date, the relatively limited number of FDA approved polymers 
available for pharmaceutical applications and very few of those polymers are 
suitable for melt processing.  High processing temperatures, suitable rheology, 
degradation are among the top material related challenges associated with HME. 
However, these issues can be addressed by engineering and formulation 
approaches. The use of plasticisers can lower processing temperatures and 
soften polymers by lowering the Tg. The process variables such as shear, screw 
speed, feed rate and residence time can reduce degradation by affecting the 
mixing intensity. 
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2.7 Injection moulding 
Injection moulding is the most commonly used manufacturing process for 
the fabrication of intricate plastic parts with excellent dimensional accuracy. A 
large number of items associated with our daily life are produced by injection 
moulding. Typical product categories include housewares, toys, automotive 
parts, furniture, rigid packaging items, appliances and medical devices. The 
injection moulding process requires the use of an injection unit, raw plastic 
material and a mould. It is a process of forming an article by forcing molten 
polymer under pressure into a mould where it is cooled, solidified and 
subsequently released by opening the two halves of the mould.  
Injection moulding is widely applied in the plastic processing industry but 
is a relatively new technique to the pharmaceutical industry. Therefore the 
introduction of the injection moulding process to FDA approved pharmaceutical 
polymers and biodegradable materials are of great interest. Recently, 
researchers have begun to explore the application of injection moulding to matrix-
releasing tablets, capsules of pharmaceutical polymers and rods of 
biodegradable materials. 
2.7.1 Key parameters of the injection moulding process  
The injection moulding process is generally influenced by the following 
parameters: 
 Polymer type (semi-crystalline or amorphous) 
 Physical properties of the polymer in its molten and solid form 
 Screw design 
 Mould and runner design 
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 Set injection moulding conditions 
 The polymer type and their physical properties significantly influence 
processing by the injection moulding process. In injection moulding it is very 
important to achieve a suitable polymer melt viscosity to flow and mould.  
Generally, thermoplastic semi-crystalline polymers are melted above their 
melting temperature and the desired melt viscosity can be achieved by set 
temperature. However, amorphous polymers do not melt and soften on heating 
hence, those often requires processing with plasticiser and additives.  Typically, 
injection moulding machines are designed with a single screw and the function 
of the screw is to guide material along the barrel, melt it and inject into mould 
cavity. Sometimes the single screw of injection moulding machine limits its 
application, particularly when materials are in powder form or mixing of 
components is required.  Design of the mould and injection moulding conditions 
decide the properties of moulded part as well as the total time required for the 
injection moulding cycle. 
2.7.2 Injection moulding process 
Injection moulding of polymers is a high speed technique to produce 
quality parts with great accuracy in large numbers. During processing, the 
polymer is melted by the action of a rotating screw and injected in molten form 
under pressure into a mould. The result is that the mould cavity is exactly copied 
by the molten polymer, neglecting shrinkage. Sufficient pressure is applied to 
maintain packing during cooling and solidification. After cooling, the mould opens 
and the part is ejected.  The injection moulding process is then repeated. 
Schematic of an injection moulding machine is provided in the Figure 2.24. 
 60 
 
 
Figure 2.24: Schematic of an injection moulding machine (adapted from 
Rutland plastics) 
2.7.3 Steps of the injection moulding process 
The typical injection moulding process comprises six steps and can be 
tailored to specific material and product specifications. The moulding process 
consists of the following stages: 
2.7.3.1 Clamping 
Clamping unit is what holds the mould under pressure during the injection 
and cooling (Figure 2.25). Basically, it holds the two halves of the mould which 
are called fixed and moving platen. The closing of two halves of mould ensures 
the formation of mould cavity. Injection moulding machine can be categorised 
based on the amount of clamping force that the machine can exert and this force 
keeps the mould closed during injection process. The typical clamping force can 
vary from 5 tonnes to over 9000 tonnes.  
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Figure 2.25: Closing of mould; screw guided back with pressure and ready 
to inject molten polymer (adapted from Rutland plastics) 
2.7.3.2 Injection 
         During injection phase, the pellets feed into the barrel where they are 
heated until they reach molten form. The single screw within the extrusion barrel 
guide the material forward and force to the end of the barrel. Once the enough 
material has accumulated in front of the screw, the injection process begins. The 
screw pushes the molten polymer at a certain speed in to the mould cavity 
through a runner system. The injection pressure and speed are controlled by the 
action of the screw (Figure 2.26). 
 
Figure 2.26: Injection of molten polymer (adapted from Rutland plastics) 
Extrusion 
barrel 
Screw 
Mould 
Extrusion 
barrel 
Mould 
Cavity 
Screw 
Mould 
Injected 
Polymer in 
Mould cavity  
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2.7.3.3 Packing  
After the molten polymer has been injected into the mould, pressure is 
applied to ensure all cavities are filled. The holding pressure applied at this stage 
can influence the properties of the moulded part such as densification and 
shrinkage. 
2.7.3.4 Cooling and plasticisation 
The parts are then allowed to solidify in the mould. Meanwhile, the screw 
is rotated and forced backwards as it prepares the next shot of molten polymer. 
Two processes happen simultaneously at this stage, i.e. part cooling and 
plasticisation. The mold temperature usually set at the required temperature, 
which influences the cooling rate of the part. The properties of the moulded 
product could be greatly influenced by the rate of cooling. The rapid cooling 
provides the “quenching effect” which likely to induce amorphous content in the 
moulded products. Plasticisation ensures the melting and preparation of shot 
volume for the next IM cycle. 
2.7.3.5 Opening   
The moving platen moves away from the fixed platen separating the 
mould tool. 
2.7.3.6 Ejection 
Sliding pins aid ejection of the completed moulding from the injection 
mould tool (Figure 2.27).  
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Figure 2.27: Final step: Opening and ejection of the moulded part (adapted 
from Rutland plastics) 
The length of time from closing the mould to ejecting the finished plastic 
moulding is one injection moulding cycle, known as the cycle time (Figure 2.28 
and Figure 2.29) 
 
 
Figure 2.28: Schematic of the injection moulding process 
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Figure 2.29: Injection moulding cycle 
 
2.7.4 Injection moulding process variables 
High quality injection moulding requires control and monitoring of four 
main parameters: 
I Shot volume: Determines the amount of polymer to be injected. 
II Pressures: Packing pressure, clamping pressure and extrusion back 
pressure during plasticisation. 
III Temperatures: Set temperature of the barrel, nozzle, runners and mould 
cavity. 
IV Speeds: Injection speed determines the rate at which the polymer is injected 
into the cavity. 
2.7.4.1 Pressures 
In injection moulding the material experiences high pressure and this 
pressure history during processing affects material properties such as shrinkage, 
residual stresses and density at the end of the process. ((Bayer et al., 1984). The 
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injection and clamping pressures effect material densification or specific volume 
(Carrasco et al., 2010). Inappropriate selection of shot size and/or injection speed 
can result in incomplete mould filling, sinking or flashing (i.e. excess material).  
2.7.4.2 Temperatures  
Polymer viscosity is dependent on temperature. In injection moulding, melt 
temperature is kept above the materials melt temperature for semi-crystalline 
polymers. Barrel temperature is profiled to optimise solids conveying and melting 
of the polymer. Excessive exposure to high operating temperatures may result in 
material degradation, surface imperfection, burned parts etc.  The mould cavity 
is generally cooled to promote solidification, allowing the part to be ejected. 
Mechanical properties of the part are heavily dependent upon the cooling rate 
particularly for semi-crystalline polymers. 
2.7.4.3 Speeds 
Injection moulding is a high speed process and the amount of time a 
material experiences thermal, shear or deformation forces depends on the speed 
of the process. Injection speed affects the shear strain rates experienced by the 
molten polymer and also governs the time required to fill the mould cavity. 
2.7.5 Advantages of injection moulding  
There are number of advantages of injection mouding process and some 
the advantages are mentioned below 
1. The ability to produce components with excellent dimensional accuracy. It is 
a single unit operation with minimal post production work required. 
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2. Full automation can be achieved with a high throughput; the process is well 
suited to the manufacture of pharmaceutical dosage forms such as tablets 
and capsules, in addition to more complex designs. 
3. Modification of material properties is possible through control of injection 
moulding conditions such as pack pressure and mould temperature; these 
influence polymer densification and crystallisation and can potentially be used 
to alter pharmaceutical performance. 
4. IM is an emerging technology for the development of pharmaceutical fast and 
controlled release dosage forms in a single step and there is a strong potential 
to develop intellectual property (IP).  
2.7.6 Challenges related to injection moulding process with respect to 
pharma formulations  
2.7.6.1 Material properties  
 Polymers exhibit different properties such as rheology and degree of 
crystallinity, hence they show different behaviour during injection moulding. 
Commonly used polymers for injection moulding are thermoplastic and almost 
90% of injection moulded products are made up of these polymers. Both 
amorphous (e.g polyurethane, poly vinyl chloride) and semi-crystalline (e.g nylon, 
polyethylene, poly L-lactic acid) polymers differ from each other in terms of their 
behaviour in the injection moulding process and the finished product 
characteristics (Table 2.8).  
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Table 2.8: Amorphous vs semi-crystalline thermoplastic polymers. 
(Adapted from (Zema et al., 2012) 
  
 The polymer and other process additives for the injection moulding can be 
chosen on the basis of it’s equipment, time, and cost of the process as well as 
considering the desired properties required in the final product to suit the intended 
application. Whenever it’s demand to improve product properties, it may involve 
the use of extra components, critical and expensive processes. Hence, to 
balance the product quality with consideration of formulation and processing 
aspect different polymer additives for injection moulding are employed by the 
plastic industries: 
1) Fillers (e.g talc, mica starch) are used to decrease the thermoplastic 
percentage, thus reduces cost. 
2) Reinforcements (e.g graphite, glass fibre, clays), these are added generally 
in 10-40% by weight in the formulation to give mechanical strength and 
stiffness to the final product. 
3) Colourants e.g diazos, iron oxides, carbon black. 
4) Plasticiser (e.g citrate ester for PLA, dioctyl phthalate for PVC) reduces the 
glass transition temperature of the polymers and hence improves the 
processibility and the flexibility of the moulded product.  
 Amorphous Semi-crystalline 
Injection 
moulding  
behaviour 
soften on heating melt on heating 
poor lubricity good lubricity 
Injection 
moulding  
product 
characteristics 
limited and isotropic 
shrinkage 
marked and anisotropic 
shrinkage 
high impact strength low impact strength 
transparent opaque 
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5) A substance which limits shrinkage and warpage of moulded part e.g carbon 
fibres, or substances which gives electrical conductivity e.g nickels. 
 Application of the injection moulding technique for pharmaceutical dosage 
form development however is very challenging as drug products are limited by 
strict qualitative and quantitative criteria, regulatory guidelines which basically 
ensure the quality, safety, and efficacy of the drug products. Moreover, in the 
case of pharmaceutical actives; dose, physico-chemical properties and stability 
are the main limitations which cannot be modified. Therefore, degradation of 
actives at processing temperatures as well as overall product properties during 
stability or storage needs to be considered.  
 The selected polymer for the injection moulding process should posses 
the following properties: 
- Suitable melt rheology  
- Thermal stability  
- Stable behaviour upon mould cooling 
- Lubricity  
- Provide the desired drug release pattern  
 The application of the moulding process for development of 
pharmaceutical dosage forms is still limited, and generally been restricted to 
simple formulations. With reference to the previous classification, various 
categories of aids have also been used for the development of the moulded 
pharmaceutical formulations.  
1) Reinforcements (e.g microcrystalline cellulose, hydroxylapatite) 
2) Plasticisers are used to lower glass transition temperatures of polymers and 
thus allow process to carry out at lower temperatures; this effect gives a 
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freedom to operate an injection moulding process within the stable thermal 
profile of drug and/or excipients thus ensuring stability. (e.g dibutyl sebacate, 
DBS;  glycerol, polyethylene glycol, PEG400) 
3) Modifiers i.e substances that may be added to trigger or retard drug release 
performance (e.g disintegrants, polymeric carriers) 
2.7.6.2 Screw design 
  Injection moulding machines are designed with a single screw. Hence, 
the material in the powder form cannot be fed or conveyed into screw barrel. It 
also limits application where high shear mixing or complex mixture of APIs and/or 
excipients is required. Therefore, high shear mixing and pelletisation using a twin-
screw extruder is generally required prior to IM. 
2.7.6.3 Shrinkage, densification: 
 Some polymers tend to shrink upon exposure to high temperatures and 
high pressures during moulding. Densification or decrease in the specific volume 
sometime can make the polymer matrix very rigid and less soluble. However, this 
can be minimised by changing processing conditions or addition of modifiers.  
Shrinkage is a phenomenon associated with injection moulded products. 
The change of dimension of injection moulded products with respect to those of 
the cavity. The difference in the dimensions of mould cavity and of the moulded 
specimens may vary according to mould design and operation of moulding 
process (ASTM D955). ASTM D 955 - 08 (2014). Guidelines on “Standard Test 
Method of Measuring Shrinkage from Mold Dimensions of Thermoplastics” are 
intended to measure shrinkage from the mould cavity to moulded dimension of 
thermoplastic when parts will be made by compression or injection processes 
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with specified process conditions. This change in dimension mainly depends on 
the material properties, processing variables, mould and part design. In general, 
three types of shrinkage phenomenon are reported; first, in-mould shrinkage 
(shrinkage during processing), as-mould (skrinkage just after mould opening 
commonly referred as ‘mould shrinkage’) and post-shrinkage (time effects during 
storage, recrystallisation etc.) (Jansen et al., 1998). All materials have a specific 
shrinkage and the values are assigned to them by the material manufacturer. The 
shrinkage is nothing but a value can be used to predict how much difference there 
will be between the plastic product when it is first moulded and the plastic product 
after it has cooled (Bryce, 1996). 
When heated, every material expands and when cooled, it shrinks. 
Plastics are no exception (Bryce, 1996). However, each material has distinct 
value for how much it will shrink when its cooled after heating. This value typically 
referred as shrinkage rate is listed as an inch / inch or meter/meter. ASTM D-955 
(ISO 294-4) provides test guidelines for characterisation of shrinkage in both 
parallel to and across the direction of flow. 
2.7.6.4 Factors and process variables affecting shrinkage: 
Extensive research has been done into the as-mould shrinkage of injection 
moulded parts and experimental studies have reported that shrinkage is affected 
by processing parameters as well as mould geometry (Jansen et al., 1998; 
Rosato et al., 2000) (Isayev and Hariharan, 1985; Tjong et al., 1996). The studies 
reported that holding pressure has the most influential effect on shrinkage; higher 
holding pressures decreased mould shrinkage in all directions. The second most 
influential parameter was the injection temperature, where shrinkage was thought 
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to be reduced due to better pressure transmission. However, if the temperature 
of melt increased further the gate took a long time to freeze off and if this time 
exceeds the holding time of mouldings then shrinkage increases.  
The process variable and factors affecting actual shrinkage are: 
1. Size and shape of the part 
2. Design and size and length of runners, machine nozzle and gates 
3. Part wall thickness 
4. Cooling channels and moulding cooling parameter i.e temperature and time 
5. Flow pattern within the mould 
6. Holding or packing pressure and time 
  Minimum shrinkage will occur when the maximum amount of material will 
be forced into the mould cavity for the longest possible time as a result of 
adequately sized flow channels, and when adequately high hold pressure is 
maintained until the plastic is thoroughly hardened. When low hold pressures are 
applied for a relatively short time, inadequate amount plastic is forced into the 
mould leading to high shrinkage. The viscosity of the molten plastic is also an 
important property to consider when setting the melt temperature, however high 
viscosity of materials sometime cause difficulty in maintaining adequate mould 
pressures.  
2.7.7 Applications of injection moulding in drug delivery 
 Although injection moulding was introduced by Speiser in 1964 as a 
pharmaceutical technology to produce sustained-release dosage forms, its use 
within the pharmaceutical industry has been limited to a few applications. The 
major focus was given to the development of existing products with this 
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technology and aimed to reduce cost and time of manufacture. Later studies 
published on injection moulding have discussed more innovative applications, 
and unique designs as well as composition and functional characteristics of 
product. Table 2.9 lists a compilation of the work reported on injection moulding 
for pharmaceutical applications. 
 Preliminary evaluation of injection moulded tablets was reported using 
polyethylene glycol (PEG) as a carrier and microcrystalline cellulose (MCC) as a 
reinforcement for immediate release application (Cuff and Raouf, 1998). The 
authors reported significant benefits such as dust containment (friability) and 
content uniformity even with low dose drug (<1%). Moreover, the authors 
reported that this technique could be used in the development of non-
disintegrating and prolonged release dosage forms by obtaining solid amorphous 
or solid molecular dispersions of actives in polymer matrices. Different 
geometries of dosage forms have also been developed using injection moulding. 
For example subcutaneous implants (Rothen-Weinhold et al., 1999) and intra-
vaginal inserts (Rathbone et al., 2002) 
2.7.8  Novel Drug Delivery Systems (NDDS) 
2.7.8.1 Eaglet® Technology 
 This is a novel, patented technology for production of controlled release 
dosage forms using an injection moulding technology. In this case, a 
hydrophilic/erodible matrix containing the active substance is coated with an 
impermeable polymeric layer. The delivery device structure is designed to have 
a lateral opening on both sides for the liberation of the drug and release can be 
driven by diffusion or erosion based mechanisms (Figure 2.30). Zero-order 
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release rates can be controlled by restricting the area in contact with biological 
fluids. In particular the Egalet® ADPREM (Abuse Deterrent Prolonged Release 
Erodible Matrix) has developed the technology for administration of opiods 
(morphine and hydrocodone) to patients undergoing pain management therapy 
hence, reducing the need for frequent dosing and risk of abuse. (Hemmingsen et 
al., 2011)   
  
Figure 2.30: Outline and expected release profiles of Egalet® (Barshalom et 
al., 1991) 
 
 Egalet® Technology is based on a novel moulding process which involves 
the injection of two subsequent phases into same mould using a perpendicularly 
positioned nozzle. In the first step, a plunger is placed in the mould cavity which 
creates a tube shaped gap between the wall and the tube surface in which the 
coating material is injected as soon as it cools down, the plunger goes back, at 
the same time, the second phase is injected consisting injection of a drug 
containing layer. After cooling the moulding is ejected by a plunger. 
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2.7.8.2 Co-injection technique for bilayer devices 
 Vaz reported this innovative technology consisting of a bi-layer delivery 
system based on soy protein. This inovlves “sequential injection into a mould of 
skin (inner) and core (outer) from two different plasticating chambers through the 
same runner” (Vaz et al., 2003) (Figure 2.31). The processing aids used for 
processing of a soy protein were a platiciser (glycerol), a cross-linker (glycoxal) 
and re-inforcement with hydroxylapatite. The authors claimed that by changing 
the degree of cross-linking and by varying the skin layer thickness, drug release 
rate could be modified. Author presented the co-injection moulding technology 
for the delivery of encapsulated theophylline and the different release behaviour 
from the single layer and double layer device was obtained where later provided 
the controlled release.  
 
 
 Figure 2.31 Outline of a co-injection process (Vaz et al., 2003) 
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2.7.8.3 Chronocap TM : 
 Another reported device based on injection moulding is ChronocapTM  
which is based on ChronotropicTM oral drug delivery devices. It is a 
swallable/erodable device for pulsatile and/or chrotropic release of drug at the 
target site. e.g colonic release by hydrophilic cellulose derivative (Sangalli et al., 
2004). In particular, ChronocapTM  are shell devices and can be used as carrier to 
convey different formulations. These are made up of various hydroxypropyl 
cellulose (HPC) grades and shells of nominal thicknesses of 300, 600, 900 μm. 
These have exhibited satisfactory technological properties and performance for 
drug release applications. 
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Table 2.9: Injection moulding applications in drug delivery and relevant characteristics.(Zema et al., 2012) 
Product Polymer Formulation  Equipment Application 
Oral capsules 
 
 
Potato starch 
Gelatin 
Starch/water or gelatin/water 
mixtures (around 15% water 
content) 
Horizontal injection 
moulding machine 
(screw type) 
Alternative system 
to gelatin dip-
moulded capsules 
IR(immediate 
release) 
tablets  
PEG 6000 PEG 
8000 
Drug: different active ingredients 
(dispersed/dissolved in the 
molten carrier) 
Horizontal injection 
moulding machine 
(screw type) 
Alternative to 
immediate-release 
compressed tablets 
Reinforcement: MCC 
Oral capsular 
device 
 
HPC Plasticizer: PEG 1500 Bench-top micro-
moulding machine 
(plunger type) 
Functional container 
for pulsatile/colonic 
release 
Oral non-
disintegrating 
matrices 
Wheat starch 
EC 
Drug: model active ingredient 
(sodium benzoate); metoprolol 
tartrate 
Horizontal injection 
moulding machine 
(screw type) 
 
Twin-screw mini-
extruder + lab-scale 
vertical injection 
moulder 
Alternative to 
compressed non-
disintegrating oral 
matrices Plasticizer: glycerol, DBS 
Release modifier: HPMC, L-
HPC, xanthan gum, PEO 
Reinforcement: MCC 
Mould release agent: silicon 
based spray  
Bi-layer 
device 
 
 
 
 
 
 
 
 
 
 
 
 
Drug: theophylline Twin-screw 
extruder + horizont
al injection 
moulding machine 
(screw type) 
Co-injected device 
for controlled 
release Cross-linker: glyoxal 
Plasticizer: glycerol 
Reinforcement: hydroxylapatite 
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Implantable 
matrices 
PLA 
Polyanhydride 
copolymer 
PLC PLGA 
Drug: valpreotide pamoato, 
gentamicine sulfate, 
fluconazole, praziquantel, 5-
fluorouracil 
Horizontal injection 
moulding machine 
(screw type) 
Alternative to 
current implants 
Bench-top micro-
moulding machine 
(plunger type) 
Vertical injection 
moulding machine 
Twin-screw mini-
extruder + lab-scale 
vertical injection 
moulder 
Intravaginal 
inserts 
PLC Ethylene 
vinyl acetate 
Drug: progesterone, davipirine Horizontal injection 
moulding machine 
Alternative to 
current intravaginal 
inserts Twin-screw 
extruder + injection 
moulder (hydraulic 
or plunger-type) 
Oral multi-
layer device 
Impermeable 
shell: 
biodegradable 
polymers (e.g. 
EC) 
Drug: carvedilole, opioids 
(e.g. hydrocodone, morphine) 
Not specified 
 
 
 
 
 
 
 
Double injected 
device for prolonged 
or pulsatile release 
Plug/matrix: 
soluble/erodible 
polymers (e.g. 
PEO) 
Plasticizers (shell): e.g. 
cetostearyl alcohol 
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2.8 Summary  
HME has become one the mainstream technologies for pharmaceutical 
research and development with more than 10 pharmaceutical products currently 
marketed. However, there are some challenges associated with HME in terms of 
material suitability such as thermolabile drugs, high processing temperatures 
required for polymer processing which may be associated with degradation. A 
number of engineering and formulation approaches have been proposed to 
address these issues.  However, products obtained by HME are mostly in the 
form of an intermediate state which needs subsequent downstream processing 
to form into the dosage form. Therefore, injection moulding is thought to be an 
interesting technology as it offers a technological advantage to form a finished 
end product (dosage forms). Moreover, IM processing parameters have a major 
influence on the material properties. Therefore, IM was selected for the 
investigation during this research to further explore its applications in the 
pharmaceutical area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
79 
 
 
Chapter 3 
3 Materials and methods 
 
In this chapter the materials, hot melt extrusion (HME) and injection 
moulding (IM) experimental procedure and the characterisation methods used 
throughout research are described in detail. The method section is sub-divided 
into three parts. The first part describes the methods used to obtain pre-
formulation data on APIs and polymers to understand their miscibility, solubility 
and stability. The following parts describe the HME and IM processing 
parameters and chracterisation methods used for analysis of extruded pellets and 
injection moulded systems. The characterisation methodologies were focused on 
analysis of thermal, spectroscopic and drug release behaviour of the extruded 
and moulded products.  
A general process schematic is provided in  
Figure 3.1. The process consisted of extrusion of the drug and a polymer 
blend using a twin screw extruder. The products obtained were cooled and 
pelletised to 2 mm diameter pellets using a pelletiser. The pellets obtained were 
fed into the hopper of an injection moulding machine and moulded in to two 
shapes: tensile bars and tablets (caplets). Optimised HME and IM parameters 
are provided under each sub-chapter. 
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Figure 3.1: Schematic of HME and IM process for the product development 
 
 
 
Hot Melt Extrusion 
(HME) 
Injection moulding 
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3.1 Materials 
3.1.1 Active pharmaceutical ingredients (APIs) 
 The APIs used for this work and their details are mentioned in Table 3.1. 
Table 3.1: List of APIs and physical properties  
APIS Source Lot no 
Ibuprofen ALBEMARLE, USA  7050-1077 
Felodipine ShinEstu, Japan 1110003 
O
OH
Ibuprofen
Molecular Formula:  C
13
H
18
O
2
Formula Weight:  206.28082
Composition:  C(75.69%) H(8.80%) O(15.51%)
Molar Refractivity:  60.77 ± 0.3 cm3
Molar Volume:  200.3 ± 3.0 cm3
Parachor:  497.6 ± 4.0 cm3
Surface Tension:  38.0 ± 3.0 dyne/cm
Density:  1.029 ± 0.06 g/cm3
Polarizability:  24.09 ± 0.5 10-24cm3
Average Mass:  206.2808 Da
Melting point :  75-77oC
Tg                 :          -45oC
 
N
O
O
O
O
H
Cl
Cl
Felodipine
Molecular Formula:  C
18
H
19
Cl
2
NO
4
Formula Weight:  384.25376
Composition:  C(56.26%) H(4.98%) Cl(18.45%) 
 N(3.65%) O(16.66%)
Molar Refractivity:  95.78 ± 0.3 cm3
Molar Volume:  300.8 ± 3.0 cm3
Parachor:  766.7 ± 6.0 cm3
Surface Tension:  42.1 ± 3.0 dyne/cm
Density:  1.277 ± 0.06 g/cm3
Polarizability:  37.97 ± 0.5 10-24cm3
Average Mass:  384.2538 Da
Melting point :  145oC
Tg:                            45oC
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3.1.2 Polymers 
 Three pharmaceutical grade polymers used for this study and details of 
suppliers, grade and lot numbers are mentioned in Table 3.2 and the chemical 
structure are provided in  
Figure 3.2. 
Table 3.2: List of polymers used in this research 
Polymer Source Lot no. Molecular 
weight  
Tg (oC)  
HPMCAS-LF ShinEstu, Japan 1023032 20133 120 
Soluplus®  BASF, germany HJ076 115000 72 
Polyethylene oxide 
(Polyox N750) 
Colorcon, UK DT375497 300000 - 52 
3.1.3 Chemicals and solvents 
 Specifications of the all solvents and chemicals used for this research are 
listed in Table 3.3 
Table 3.3: Details of Chemical and solvent 
Polymer Source Grade 
Potassium dihydrogen 
phosphate 
Sigma Aldrich, UK AR 
Sodium hydroxide Sigma Aldrich UK AR 
Sodium phosphate 
Monobasic 
Sigma Aldrich UK AR 
Sodium phosphate Dibasic Sigma Aldrich UK AR 
Methanol Sigma Aldrich UK AR 
Sodium lauryl Sulphate Sigma Aldrich UK AR 
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Figure 3.2: Chemical structures of polymers  
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3.1.4 Equipment 
 Specification of all the equipment used this research are provided in Table 
3.4. 
Table 3.4: Equipment specification   
Equipment  Manufacturer  Specifications  
Twin screw extruder  Thermo Scientific, UK  Pharmalab 16 mm co-
rotating  
Strand pelletiser Thermo, UK 2-3 mm size pelletiser 
Injection moulding Fanuc Roboshot, 
Japan 
5Tonne clamping force, 
14 mm screw diameter 
Scanning electron 
microscopy  
FEI, UK  Quanta 400 SEM  
DSC  TA Instruments UK Q 2000  
DMA TA Instruments UK Q800 
NIR Thermo Scientific, UK Antaris II 
Raman Spectroscopy Renishaw, UK Thermo Scientific 
FTIR Perkin Elmer, USA ATR Frontier 
PXRD  Bruker, USA D8 powder 
diffractometer  
TGA  TA Instruments, UK Q 5000IR  
Flow through cell 
(USP IV) 
Sotax , Switzerland CE7 smart open loop 
Dissolution apparatus 
(USPII) 
Copley Scientific UK USP type II paddle test 
apparatus  
 
Hot stage microscope  Linkam, UK Zeiss Axioplan-2 
microscope  
UV Jasco, UK V-730 UV-visible 
3D Laser microscope Olympus, Japan 3D surface 
measurement 
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3.1.5 Software 
Software used for data processing are listed in Table 3.5 
Table 3.5: software used for processing of results 
Software  Purpose  
TA universal analysis  Thermal analysis  
PowDLL converter  PXRD pattern analysis  
TQ Analyst software NIR spectra and Partial least square 
GRAMS/AI™ Spectroscopy 
Software  
Raman spectra analysis, 
FTIR spectra analysis 
Jade 2010 PXRD pattern analysis 
EVA  PXRD pattern software 
Origin Graph and analysis 
ACD/Chem Sketch Chemical drawing software 
 
3.2 Methods 
3.2.1 Pre-formulation studies: Characterisation of drugs and polymers 
The drugs and the polymers were initially characterised to understand the 
solubility parameters (δ), glass transition temperature (Tg) and the drug-polymer 
solubility and miscibility. Temperature-composition phase diagrams were 
constructed for the four systems to predict stability of the amorphous solid 
dispersions. 
3.2.1.1 Prediction of solubility parameters and glass transition temperature 
  Solubility parameters (δ) were calculated for the drugs (ibuprofen, 
felodipine) and the polymers (HPMCAS, Soluplus®) using the Van Krevelen and 
Hoftyzer’s group contribution method (Adamska and Voelkel, 2005). The Tg of 
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each drug-polymer mixture was predicted theoretically using the Fox equation 
(Fox and Flory, 1950) 
  
𝟏
𝑻𝒈
=
𝑾𝒅𝒓𝒖𝒈
𝑻𝒈,𝒅𝒓𝒖𝒈
+  
𝟏−𝑾𝒅𝒓𝒖𝒈
𝑻𝒈,𝒑𝒐𝒍𝒚𝒎𝒆𝒓
             (Equation 3.1) 
Where, Wdrug is the weight fraction of the drug, Tg drug is the glass 
transition temperature of the drug, Tg polymer is the glass transition temperature 
of the polymer.        
3.2.1.2 Drug polymer solubility and miscibility: 
 The Flory-Huggins (F-H) interaction parameter (χ) and Gibbs free energy 
of mixing (∆Gmix) were calculated to understand the drug polymer miscibility and 
solubility using the practical based approach of melting point depression. The 
temperature and composition dependent χ was calculated for drug-polymer 
amorphous solid dispersions made using the solvent evaporation method. The 
temperature composition phase diagram was established for all four systems 
using ∆G and χ.  
 The drug-polymer mixtures were physically mixed together in the different 
weight ratios (total weight 2 gm) and dissolved in 10 ml of acetone and stirred 
using a magnetic bead for 12 hrs to ensure complete dissolution. The solvent 
was removed by air-drying followed by vacuum drying at 30oC for 24hrs to ensure 
removal of any residual solvent. The resulting material was milled gently with a 
mortar and pestle and stored in desiccators before further testing.  DSC studies 
were carried out using a DSC 2000 (TA instrument; UK). Indium standards were 
used to calibrate the DSC temperature and enthalpy scales. Approximately 5 mg 
of samples were hermetically sealed in the aluminium pan and an empty 
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aluminium pan was used as a reference. The pans were heated at 2oC/min in the 
temperature range of 0oC to 120oC for ibuprofen-HPMCAS and ibuprofen-
Soluplus® samples. Similarly, felodipine-HPMCAS and felodipine-Soluplus® 
samples were analysed using the same DSC conditions except heated from 25oC 
to 160oC.  
3.2.1.3 Melt rheology: Capillary rheometery 
 Capillary rheometry is pressure driven technique which mimics the flow 
through an extruder die or injection moulding nozzle. The shear viscosities of the 
HPMCAS, Soluplus®, ibuprofen-HPMCAS, Felodipine-PEO-HPMCAS 
ibuprofen-Soluplus®, (IBS) and felodipine-Soluplus (FDS) were studied using the 
twin bore (RH10) precision advanced capillary rheometer (Malvern Instruments, 
UK) using Flowmaster version 8.3.10 control software. The common crosshead 
was used to drive the piston at a range of speeds causing the melt to flow at a 
certain flow rate through capillary dies and the pressure drop at the entrance of 
the each capillary die was monitored. One barrel of the capillary rheometer was 
fitted with the capillary die of an L/D ratio of 16 and another was fitted with orifice 
die. The dimension of the capillary die used was (length X bore diameter X 
entrance angle): long length die (16X1X180), orifice die (0X1X180). Capillary dies 
were fitted into the bottom of the barrel and pressure transducers were positioned 
directly above the measure pressures with respective barrel. The apparent shear 
rate and shear stress at the wall of the capillary die, during the flow polymer 
through the die can be derived using Poiseulle relationship: 
   𝐒𝐡𝐞𝐚𝐫 𝐫𝐚𝐭𝐞 (𝛄) =  
𝟒𝐐
𝛑𝐑𝟑 
 , 𝐒𝐡𝐞𝐚𝐫 𝐬𝐭𝐫𝐞𝐬𝐬  (𝛕𝐰) =  
𝐑𝚫𝐏
𝟐𝐋 
   , 
  𝐒𝐡𝐞𝐚𝐫 𝐯𝐢𝐬𝐜𝐨𝐬𝐢𝐭𝐲 (𝛈) =  
𝛕𝐰
𝛄
                                                           (Equation 3.2) 
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 Where, γ τw, denotes the wall shear rate (s-1); wall shear stress (Pa) 
respectively, for the flow of fluids through a capillary radius R (m) and length L 
(m) at volumetric flow rate Q (m3/s) across the pressure drop (∆P). η denotes the 
shear viscosity which is a ratio of shear stress to shear rate. 
3.2.2 Hot Melt extrusion (HME):  
 This section describes the general hot melt extrusion process and specific 
processing parameters used for the preparation for all four systems. Extrusion of 
drug- polymer blends was carried out using a co-rotating twin screw extruder 
(Pharmalab HME 16, Thermo Scientific, UK) with a screw diameter of 16mm and 
a screw length to diameter ratio of 40:1 (Figure 3.3). The extruder temperature 
profile was set to the required temperature with constant screw rotation speed. 
The blends were fed into the extruder at a constant feed rate using a gravimetric 
twin screw feeder (Barbender, Germany). Following extrusion the strands were 
cooled and pelletised in to 2mm size pellets.  
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Figure 3.3: Pharmalab HME 16 and screw configuration 
Extruder screw configuration  
  The residence time and shear mixing of materials has a significant 
influence on the property of the extruded materials. The different screw elements 
were used to make the configuration. The screw configuration was used for the 
extrusion described in Table 3.6. 
Table 3.6 Screw configurations ordered from feed to discharge 
Length (D)a Element type 
28 Forwarding 
2.25 30o 
1.25 60 o 
1 90 o 
6 Forwarding 
1.5 Discharge 
a In terms of number of diameters, 1D = 16 mm] 
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3.2.2.1 Ibuprofen HPMCAS IM systems  
 Batches were prepared with the different percentage loading of ibuprofen 
in HPMCAS with ratios of ibuprofen: HPMCAS 1:2 (33%w/w), 1:2.5 (29%w/w) 
and 1:3 (25%w/w). Physical mixtures were prepared in 250 gm batch sizes for all 
batches and fed into a twin screw extruder (Pharmalab, Thermo Scientific, UK) 
at a processing temperature of 100oC at a screw speed of 200 rpm (Table 3.7). 
The feed rate was kept constant at 0.7 kg/hr. For batches containing mannitol the 
amount of ibuprofen was kept constant and the percentage loading of the 
mannitol was changed to keep HPMCAS: (ibuprofen:mannitol) mixture (60:40%) 
(Table 3.7). 
3.2.2.2 Felodipine-PEO –HPMCAS systems 
The blank system i.e PEON750-HPMCAS (20:80%w/w) was extruded to 
understand the processability of the HMPCAS with PEO N750. Felodipine 
containing pellets were prepared using HME contained felodipine-PEON750-
HPMCAS (10:20:70%w/w/w) (Figure 3.4). The pellets were further used to obtain 
IM tablets and tensile bars. The optimised HME parameters for PEO-HPMCAS 
and FDH (Felodipine-PEON750-HPMCAS) are mentioned in the Table 3.8.  
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Table 3.7: Hot Melt Extrusion batches and parameters used for the 
ibuprofen-HPMCAS systems 
Batch 
name 
Composition 
and Ratio 
HME Parameters 
Screw 
speed 
(rpm) 
Temperature Profile 
I33 
Pellets 
Ibuprofen: 
HPMCAS 
1:2 (33% w/w) 
200 Die 10 9 8 7 6 5 4 3 2 
100 100 100 100 100 100 90 70 50 20 
 
I29 
Pellets 
Ibuprofen: 
HPMCAS  
 1:2.5 (29 % w/w) 
200 Die 10 9 8 7 6 5 4 3 2 
100 100 100 100 100 100 90 70 50 20 
 
I25 
Pellets 
Ibuprofen: 
HPMCAS 
 1:3 (25% w/w) 
200 Die 10 9 8 7 6 5 4 3 2 
100 100 100 100 100 100 90 70 50 20 
 
IM33 
Pellets 
Ibuprofen:man-
nitol:HPMCAS 
33:7:60%W/W/W 
200 Die 10 9 8 7 6 5 4 3 2 
110 110 110 110 110 110 90 70 50 20 
 
IM29 
Pellets 
Ibuprofen:man-
nitol:HPMCAS 
29:11:60%W/W/W 
200 Die 10 9 8 7 6 5 4 3 2 
110 110 110 110 110 110 90 70 50 20 
 
IM25 
Pellets 
Ibuprofen:man-
nitol:HPMCAS 
25:15:60%W/W/W 
200 Die 10 9 8 7 6 5 4 3 2 
110 110 110 110 110 110 90 70 50 20 
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Table 3.8: HME parameters for PEO-HPMCAS and FDH batch 
Batch 
name 
Composition 
and Ratio 
HME Parameters 
PEO-
HPMC
AS 
PEON750-
HPMCAS-LG 
(20:70%w/w) 
Screw 
speed 
(rpm) 
   200 
Temperature Profile 
 
Die 10 9 8 7 6 5 4 3 2 
140 140 140 140 140 140 120 70 50 25 
Feed rate(kg/hr) 0.6 
 FDH 
 
Felodipine-
PEON750-
HPMCAS-LG 
(10:20:70% 
w/w/w) 
Screw 
speed 
(rpm) 
200 
Die 10 9 8 7 6 5 4 3 2 
140 140 140 140 140 140 120 70 50 25 
Feed rate(kg/hr) 0.6 
 
 
 
Figure 3.4: HME of Felodipine-PEO-HPMCAS (FDH) systems 
 
 
Mixing Conveying zone 
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3.2.2.3 Soluplus® IM systems 
 The processability of the Soluplus® using HME was studied with and 
without the addition of APIs.  The Soluplus® was dried at 55oC for 12hrs before 
processing by HME. Batches were prepared with addition of 10%w/w of drug. 
The details about batches are as follows: 
 Ibuprofen-Soluplus® (IBS) (10:90%w/w) 
 Felodipine-Soluplus® (FDS) (10:90%w/w) 
The physical mixture for 300gm batch size was prepared and extruded into 
pellets using a Pharmalab HME 16 (Thermo scientific, Germany). The details of 
HME parameters are presented Table 3.9 and Figure 3.5 shows the HME 
products of FDS and IBS batches, respectively 
Table 3.9: HME of Soluplus®, IBS abd FDS batches 
Batch 
name 
Compositi
on and 
Ratio 
HME Parameters 
Soluplus® 100%w/w Screw 
speed 
(rpm) 
200 
Temperature Profile 
 
Die 10 9 8 7 6 5 4 3 2 
150 150 140 140 140 140 120 70 50 25 
Feed rate(kg/hr) 0.40 
 
IBS 
 
Ibuprofen- 
Soluplus® 
(10:90%w/
w) 
Screw 
speed 
(rpm) 
200 
Die 10 9 8 7 6 5 4 3 2 
130 130 130 130 130 130 120 70 50 25 
Feed rate(kg/hr)0.40 
FDS 
 
Felodipine
Soluplus® 
(10:90%w/
w) 
Screw 
speed 
(rpm) 
200 
Die 10 9 8 7 6 5 4 3 2 
150 140 140 140 140 140 120 70 50 25 
Feed rate(kg/hr)0.40 
  
Mixing Conveying zone 
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Ibuprofen-Soluplus® (IBS)Pellets            Felodipine-Soluplus® (FDS) 
Pellets 
Figure 3.5: Hot melt extrusion of Soluplus® systems and extruded pellets of 
IBS and FDS  
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3.2.3 Injection moulding  
Extruded Pellets of were fed into an IM machine (Fanuc Roboshot S-
2000i5A) where they were melted and injected in the mould cavity. The dumbbell 
shaped moulds were prepared and used to explore the mechanical properties of 
the materials. Dimensions of tensile bar were: Length: 76mm. Neck dimensions:  
33mm × 2mm × 5 mm. The injection moulded tablets (caplets) were prepared 
using a mould cavity with the dimension: Length (20mm) x width (6 mm) X 
thickness (4.30 mm). Figure 3.6 shows the IM machine and mould cavity used 
for the moulding. 
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Figure 3.6:  FANUC Roboshot i5A injection moulding machine, tensile bar 
and tablet mould design 
A HAAKE MiniJet (Thermo Scientific, Germany) injection molding machine 
was used to produce the injection moulded tablets. The injection moulding 
machine has a heated cylinder for melting the polymer. For making the tablets, 
Ibuprofen-HPMCAS extruded pellets and Ibuprofen-mannitol-HPMCAS extruded 
pellets were melted at 120oC in the cylinder for 5min to achieve melting. Polymer 
melt was injected at a pressure of 600 bar for 1sec by a pneumatically driven 
piston into a tablet (caplet) shaped mould (Figure 3.6). The mould temperature 
was kept constant at 25oC for all batches. Tablets were packed at three different 
packing pressures i.e 400, 600, 800 bar at same pack time of 5 sec. 
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Table 3.10: Injection moulding batches and parameters 
Batc
h 
Nam
e  
Composition and 
Ratio 
IM Parameters 
 Cylinder  
Temperature 
(oC)  
Injection  Mould Packing 
Cylinder Injection 
pressure  
(Bar) 
Pack 
Pressure 
(Bar) 
Pack 
time 
(Sec) 
I33 
Table
t 
Ibuprofen:HPMCAS 
Pellets 
1:2 (33% w/w) 
120 600 
400 
5 600 
800 
I29 
Table
t 
Ibuprofen:HPMCAS 
Pellets 
1:2.5(29% w/w) 
120 600 
400 
5 600 
800 
I25 
Table
t 
Ibuprofen:HPMC
AS Pellets 
1:3(25% w/w) 
120 600 
400 
5 600 
800 
IM33 
Ibuprofen:Mannitol: 
HPMCAS Pellets  
33:7:60% w/w/w 
120 600 
400 
5 600 
800 
IM29 
Table
t 
Ibuprofen:Mannitol:  
HPMCAS Pellets 
 29:11:60%w/w/w 
120 600 
400 
5 600 
800 
IM25 
Table
t 
Ibuprofen:Mannitol: 
HPMCAS Pellets 
25:15:60%w/w/w 
120 600 
400 
5 600 
800 
All batches were kept for 5min at stated temperature to ensure melting.      
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3.2.3.1 Effect of process parameters using DoE (33% ibuprofen-HPMCAS 
system) 
To investigate the crystallisation kinetics and understand the surface 
crystallisation of ibuprofen the 33% ibuprofen-HPMCAS (I33) batch size was 
selected and extrusion was carried out using parameters mentioned in Table 3.7. 
Extruded I 33 pellets were then used to produce moulded tensile bars and tablets. 
All the products developed for the ibuprofen-HPMCAS system and their 
characterisation scheme presented in the Figure 3.7. A 32 factorial design was 
applied to understand the effect of injection moulding process variables on 
crystallisation kinetics and shrinkage rate. 
 
Figure 3.7 Ibuprofen-HPMCAS extruded and moulded products and 
characterization methods 
3.2.3.1.1 32 factorial design for Injection moulding  
 I33 extruded pellets prepared using HME were used in design of 
experiment studies (for IM (Fanuc Roboshot Japan) to obtain tensile bar 
specimens. Factorial design was applied to understand the effect of process 
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variables on the properties of injection moulded system. The conditions used for 
injection the fixed process parameters such as shot size, injection speed, pack 
time, cooling time are mentioned in the Table 3.11 and process variable are 
mentioned in the Table 3.12. The pack pressure and mould temperature were 
used as the process variables as these parameters were considered to have a 
significant influence on the crystallisation and shrinkage.   
Table 3.11: 32 injection moulding parameter 
 
Table 3.12: injection moulded process variables  
 
 
 
                                            
 
 
 
 
* B1 to B9 is experimental code assigned 
Temp 
(oC) 
Shot size parameter Process parameters 
Shot size 
(mm) 
Screw 
Speed 
(rpm) 
Back 
Pressure 
(bar) 
Injection  
speed 
(mm/s) 
Mould 
Packing 
Time 
(sec) 
Mould 
Cooling  
Time(sec) 
120 19 30 80 100 20 15 
Batch no. Process variable 
Mould packing 
pressure 
 (bar) (X1) 
Mould cooling  
temperature 
(oC) (X2) 
B01 300 10 
B02 500 10 
B03 700 10 
B04 300 20 
B05 500 20 
B06 700 20 
B07 300 30 
B08 500 30 
B09 700 30 
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3.2.3.1.2 Stability (stress) testing 
To study material properties, the nature of the ibuprofen dispersion in the 
polymer matrix and the phenomenon of the surface crystallisation of ibuprofen 
from IM system, the IM bars (B01-B09) were exposed to different stress 
conditions listed in Table 3.13 
Table 3.13: Environmental (stress) conditions 
Accelerated Middle Control (RT) 
Temperatur
e (oC) 
Humidity 
% 
Temperature 
(oC) 
Humidity 
% 
Temperature 
(oC) 
Humidity 
% 
  40 75 40 60 25 60 
3.2.3.2 Felodipine-PEO –HPMCAS systems 
 The extruded pellets were used to produce IM tablets and tensile bars. 
The optimised IM processing parameters for PEO-HPMCAS and FDH moulded 
systems are mentioned in the Table 3.14. 
Table 3.14 Injection moulding condition for tensile bars and tablets: PEO-
HPMCAS and FDH systems 
Batch  Injection moulding conditions 
PEO-HPMCAS  
PEON750-HPMCAS 
(20:70%w/w) 
 
Tensile bars 
• Temperature profile(oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
140 140 140 140 30 
• Shot size : 23 mm 
• Injection speed : 100 mm/s 
• Pack pressure : 300 bar   
• Pack time: 20 sec 
• Mould temperature: 20oC  
• Cooling time: 15 sec 
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PEO-HPMCAS  
PEON750-HPMCAS 
(20:70%w/w) 
 
Tablets 
• Temperature profile (oC) 
Nozzl
e 
Zone 4 Zone 3 Zone 2 Zone 1 
140 140 140 120 30 
• Shot size : 14 mm  
• Injection speed : 120 mm/s 
• Pack pressure : 300 bar, 15 sec, 100 bar 10sec 
• Pack time: 25 sec 
• Mould Temperature :  20oC 
• Cooling time : 20 sec 
FDH 
Felodipine-
PEON750-HPMCAS 
(10:20:70% 
w/w/w) 
Tensile bars 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
140 140 140 120 30 
• Shot size : 23 mm 
• Injection speed : 100 mm/s 
• Pack pressure : 300 bar  
• Pack time: 20 sec 
• Mould temperature: 20oC  
• Cooling time : 20 sec 
FDH 
Felodipine-
PEON750-HPMCAS 
(10:20:70% 
w/w/w) 
Tensile bars 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
140 140 140 120 30 
• Shot size : 14 mm 
• Injection speed : 100 mm/s 
• Pack pressure : 900 bar  
• Pack time: 20 sec 
• Mould temperature: 20oC  
• Cooling time : 20 sec 
 
 
 
 
 
 
102 
 
3.2.3.3 Soluplus® IM systems 
In this section details of IM processing parameters used for ibuprofen-
Soluplus® and felodipine-Soluplus® moulded systems are mentioned in Table 
3.15.  
Table 3.15 Injection moulding conditions for Soluplus® IM batches 
Batch name  Injection moulding conditions 
Soluplus® 
 
Tensile bars 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
150 150 150 150 30 
• Shot size : 23mm 
• Injection speed : 120 mm/s 
• Pack pressure 500 Bar, 15 sec; 100Bar, 10sec 
Pack time: 20sec 
• Mould temperature: 70oC  
• Cooling time: 5 Sec 
Soluplus® 
 
 
Tablets 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
150 150 150 150 30 
• Shot size: 16 mm  
• Injection speed: 120 mm/s 
• Pack pressure: 500 bar, 15 sec; 100 bar, 10sec 
• Pack time: 30 sec 
• Mould Temperature :  60oC 
• Cooling time : 30 sec 
IBS 
Ibuprofen- Soluplus 
(10:90%w/w) 
Tensile bars 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
135 135 135 120 30 
• Shot size : 23 mm 
• Injection speed : 120 mm/s 
• Pack pressure : 500 bar  
• Pack time: 10 sec 
• Mould temperature: 55oC  
• Cooling time : 10 sec  
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IBS 
Ibuprofen- Soluplus 
(10:90%w/w) 
 
 
Tablets 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
135 135 135 135 30 
• Shot size : 16 mm 
• Injection speed : 120 mm/s 
• Pack pressure : 500 bar  
• Pack time: 20 sec 
• Mould temperature: 50oC  
• Cooling time : 20 sec 
FDS 
Felodipine - Soluplus 
(10:90%w/w) 
 
Tensile bars 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
150 150 150 130 30 
• Shot size : 23 mm 
• Injection speed : 120 mm/s 
• Pack pressure : 500 bar  
• Pack time: 20 sec 
• Mould temperature: 55oC  
• Cooling time : 10 sec 
FDS 
Felodipine - Soluplus 
(10:90%w/w) 
 
Tablets 
• Temperature profile (oC) 
Nozzle Zone 4 Zone 3 Zone 2 Zone 1 
150 150 150 130 30 
• Shot size : 17 mm 
• Injection speed : 120 mm/s 
• Pack pressure : 500 bar  
• Pack time: 20 sec 
• Mould temperature: 55oC  
• Cooling time : 20 sec 
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3.2.4 Characterisation of Extruded and Injection moulded systems 
Extruded pellets, injection moulded tablets and tensile bars were 
characterised using thermal, mechanical, and spectroscopic techniques. In vitro 
drug release was also performed to understand the dissolution rate of drug from 
dosage forms.  
3.2.4.1 Differential scanning calorimetry  
Thermal profiles of pure ibuprofen, mannitol, HPMCAS, physical mixtures, 
extruded pellets and injection moulded tablets were characterised using DSC 
Q2000 (TA instruments) at temperature range from 0 to 150oC at a heating rate 
of 10oC/min. For an analysis of the moulded tablets, a section from the middle of 
the tablet was obtained. I33 moulded tablets are soft in nature and thr sample 
from middle was obtained by slicing surface with sharp scalpels. The Tg of 
HPMCAS was characterized using MDSC condition, where the sample was 
heated at an underlying heating rate of 5oC/min with modulation period of 60 sec 
and amplitude of ±1oC/min. The felodipine-HPMCAS (FDH), ibuprofen-Soluplus® 
(IBS), felodipine-Soluplus® (IBS) extruded pellets and moulded samples were 
also analysed using MDSC condition mentioned earlier. The results were 
analysed using TA Instruments universal analysis 2000 software.  
The stability samples of I33 and FDH moulded systems were analysed at 
each stress condition by taking surface samples of the moulded bar using MDSC 
heat only condition. These MDSC conditions were chosen to calculate the degree 
of crystallinity (% crystallisation) and rate of surface crystallisation of ibuprofen 
from moulded bars. The surface of the moulded systems was taken over specific 
time after the exposure to the stress conditions. The samples were heated at an 
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underlying heating rate of 5oC/min and period of 60 sec.  Rate of crystallisation 
I33 systems was monitored for 4 weeks by taking samples after 1, 2, 3, 7, 14, 21, 
and 28 days. 
3.2.4.2 Mechanical characterisation 
The mechanical testing of moulded systems was performed to understand 
the plasticisation effect of drugs on the polymer. Dumbbell shaped mould was 
used to explore the mechanical properties of the material. The dimensions of 
tensile bar were: Length: 76mm. Neck dimensions:  33mm × 2mm (thickness) × 
5 mm (Width). An Instron tensometer (Figure 3.8) was equipped with a 
temperature controlled chamber to maintain temperature. A load cell of 1 KN was 
used and samples were tested at three extension rates 10 mm/min, 100 mm/min, 
and 500 mm/min. 
 
 
 
 
Figure 3.8: Instron tensometer and temperature controlled chamber and 
schematic of injection moulded bar 
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3.2.4.3 Raman spectroscopy 
A laser radiation of wavelength 785nm was focused on the sample by the 
100x objective lens. Raman backscattered radiation was collected by a high 
numerical aperture lens and passed through a con-focal aperture to a detection 
system. Weak signals are first separated from the laser Rayleigh background by 
a notch filter and afterwards analysed spectrally by a Charged Coupled Detector 
(CCD). A ReniShaw Raman Microscope was used. Samples were analysed at 
50% laser power with an exposure of 10 times/sec and a spectral accumulation 
of a 1s with removal of a cosmic ray. Raman spectra of pure Ibuprofen, felodipine, 
mannitol, HPMCAS, Soluplus®, PEO N750, physical mixtures, extruded pellets 
and moulded tablets were analysed using Raman microscopy. 
  For 33% Ibuprofen-HPMCAS I33 moulded tablets, studies were planned 
to observe the surface crystallisation from the moulded tablets and hence 
spectras were acquired from both the middle and the surface of the tablets. 
Furthermore, to study the moisture induced surface crystallisation the I33 tablets 
were exposed at 43% and 75% relative humidity in a closed environment using 
saturated salt solutions of potassium carbonate and sodium chloride respectively. 
A Raman spectrum of the surface samples was monitored over 1 week, 2 weeks 
and 3 months. 
3.2.4.4 Hot stage microscopy: 
The possibility of crystallisation of I33 tablets (ibuprofen) at non-sink 
condition was studied using hot stage microscopy. I33 tablets were studied using 
hot stage microscopy (Carl Zeiss; Axioplan 2 imging). The experimental 
conditions were used to observe the dissolution of tablets at different pH levels. 
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Tablets were immersed in a petri dish containing 10ml of Phosphate buffer pH 
7.2 and in another case 0.1N HCL. The solution temperature was maintained at 
37oC using a hot stage. For this work, plane polarized light was focused using a 
20 x objectives on the edge of the tablet and images were taken every 30 mins 
for 6 hrs.  For imaging and data processing, Axiovision release 4.6.6 SP1 
software was used. 
3.2.4.5 Scanning electron microscopy  
Scanning electron microscopy was used to visualise the morphology of 
the I33 tablet surfaces. Each tablet surface was gold coated with a layer thickness 
of 30nm. SEM images were taken using an FEI Quanta 400 scanning electron 
microscope under high vacuum with a voltage of 20KV and a working distance of 
10mm at various magnification levels. SEM studies were designed to analyse the 
tablet surface after in-vitro dissolution of 33% Ibuprofen-HPMCAS tablets (I 33 
tab) and 33% ibuprofen-mannitol HPMCAS tablets (IM33 tab) at time points of 3 
hrs and 6 hrs.   
3.2.4.6 3D laser microscopy: surface crystal orientation and roughness  
For a detailed understanding of the orientation of the surface crystals the 
scans were performed at various regions of each I33 molded bar exposed to 
different stress conditions. The 3D measuring laser microscope (Lext OLS 4000 
Olympus) with 20x objective lens (Mplan ApoN lens) was used for the surface 
scanning. The scanning area selected was 646 x 646 µm. The surface roughness 
evaluation made using the measured height parameters. 
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3.2.4.7 Dynamic Mechanical Analysis (DMA) 
Thermo-mechanical evaluation was carried out using a DMA Q800 by 
subjecting moulded bars with dimensions of 16 mm gauge length, 5 mm width, 2 
mm thickness to dynamic tensile deformation.  
Test conditions:  
Mode: DMA- multi-strain frequency                                                        
Method: Temperature ramp and frequency sweep 
Frequency:  Amplitude test: 5Hz with 16 μm deformation  
Temperature: 20- 85oC with heating rate of 2oC/min       
3.2.4.8 Near Infrared Spectroscopy (NIR): 
 NIR spectroscopy was performed on the pure crystalline ibuprofen and 
amorphous HPMCAS samples using an Antaris II NIR spectrometer (Thermo 
Scientific, UK). Physical mixtures were prepared by mixing the drug and the 
polymer in different proportions to obtain 10% w/w, 20% w/w, 30% w/w, 40% w/w, 
50 % w/w, 60%w/w ibuprofen-HPMCAS mixtures.  The samples were added to 
10 ml glass vials and placed on the top of the light source for measurement of 
absorbance (Figure 3.9). 
 
Figure 3.9: NIR of extruded pellets  
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 Each sample analysis was performed in triplicate  and  reading consisted 
of 32 individual spectra at a resolution of 8 cm−1, scanned over the region of 
4000–10,000 cm−1 wave-numbers (2500–1000 nm wavelength) using Thermo 
Scientific RESULT software. Measured spectra were then stored for the 
subsequent analysis. A calibration curve was plotted using the calibration 
standards and used for quantification to determine the degree of crystallinity (% 
crystallisation) at each stability point.  
3.2.4.9 2 dimensional (2D) X ray diffraction 
The crystal habit, surface crystal orientation of I33 moulded systems was 
studied using 2D XRDIntact moulded samples were exposed, at room 
temperature, to CoKα radiation (1.7906 Å; 45 kV X 40mA) in a two dimensional 
X-ray diffractometer (D8 Discover 2D, Bruker with a 140 mm diameter window 
VÅNTEC-500 detector) (Figure 3.10).  XRD patterns were collected, using a 0.8 
mm collimator set at 6° angle of incidence and an area detector (angular range 
36°) set at an angle of diffraction at 12° 2θ. The irradiated area can be described 
by an ellipse with a major axis of 5120 µm and minor axis of 1120 µm. Data 
analyses were performed using commercially available software (JADE 2010). 
Figure 3.11 shows the depth profiling samples used for the testing. 
For depth profiling the following experimental conditions were used:  
 Instrument details: Bruker microdiffractometer with copper radiation 
(45kV/40mA), incident beam graphite monochromater, 0.05 mm 
collimator, and a two-dimensional multi-wire detector (Figure 3.10). 
 One measurement frame centered at 18o/9o (2θ/ω) with a 120 s/frame 
dwell 
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 2D detector images converted to 1D intensity vs. 2θ patterns 
 JADE 2010 used for data analysis 
      
Figure 3.10: Depth profiling with 2D diffractometer  
  
Figure 3.11: I33 moulded bar 40oC 75%RH exposed bar (left), 25oC 60% 
exposed bar (right) 
3.2.4.10  Fourier transforms Infra-red spectroscopy (FTIR) 
  FTIR spectroscopic analysis of the samples was performed using a 
Spectrum 100 with a universal single bounces Diamond ATR attachment (Perkin 
Elmer, USA).  This incorporated an optical system that allowed data collection in 
the range of 660 to 3500 cm-1 with resolution of 0.5 cm-1. The spectra obtained 
were analysed using GRAMS/AI™ spectroscopy software (Thermo scientific, 
UK). The spectra were taken to understand the functional group vibrations and 
involvement of drug and polymer functional groups for the formation of hydrogen 
bonds. 
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3.2.4.11 Shrinkage 
Ibuprofen-HPMCAS systems were tend to shrink after moulding hence to 
understand the shrinkage phenomenon the samples were exposed to different 
stress conditions.  The 4cm injection moulded bars of both the HPMCAS and 
Soluplus® IM systems were kept at different stress condition as described in 
Table 3.13. The shrinkage rate at these three conditions was monitored for a 
period of 6 months. Changes in the length, width and thickness were monitored 
and used for the calculation of surface area and % length shrinkage ratio.  
3.2.4.12 In-vitro drug release 
USP II apparatus: Paddle  
A calibration curve was established for the ibuprofen in a phosphate buffer 
pH 7.2 from 2-10 µg/ml. The drug content of extruded pellets was analysed by 
dissolving 450 mg of pellets and tablets of each individual batch in 20 ml of 
methanol and further dilution with phosphate buffer pH 7.2. Dissolution testing 
was performed using USP apparatus II (Paddle). Tablets were weighed and 
placed in a dissolution vessel consisting of 900ml of dissolution media i.e 
Phosphate buffer pH 7.2. The buffer was maintained at 37oC and paddle rotation 
speed of 50rpm. 5 ml samples were withdrawn at each time point (5, 15, 30, 60, 
90, 120, 150, 180, 240, 300, 360, 420 mins) and the same volume was replaced 
with buffer. Ibuprofen content in dissolution samples was analysed using UV 
(Jasco, UK) and the data was processed using PCP disso software V3. 
 
USP IV apparatus: flow through-cell 
A USP apparatus 4 (CE 7 Smart with piston Pump, Sotax AG, Switzerland) 
with 22.6mm flow cell was used for this study. The procedure for preparation of 
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the cell consisted of placing a 5mm ruby ball onto the apex of cell and 
approximately 8 gm of 1mm glass beads were added to the cone area to form a 
glass bead bed. The testing products (i.e pellets and tablets) were positioned on 
the top of glass bead bed. The details of experimental parameters used for testing 
of all four moulded tablets are as follows. 
 Dissolution media: 
•  For ibuprofen-HPMCAS  and ibuprofen Soluplus® tablets: 
Phosphate buffer pH 7.2,  
• For Felodipine-PEO-HPMCAS and Felodipine-Soluplus® tablets: 
Phosphate buffer pH 6.5 with 1% SLS 
 Flow rate: 4 ml/min, 
 Temperature: 37.0±0.5°C, Loop configuration: Open loop  
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   Chapter 4 
 
4 Pre-formulation 
 
 
In this chapter result of preformulation studies performed on the materials are 
discussed. The prediction of solubility parameters, glass transition temperature, 
estimation of drug-polymer miscibility and solubility were the main objectives of 
this study. The temperature-composition phase diagram was constructed to 
estimate the stability and performance. 
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4.1 Pre-formulation studies  
The active pharmaceutical ingredients (APIs) i.e ibuprofen and the 
felodipine and the polymers i.e HPMCAS and Soluplus® were characterised using 
theoretical and practical methodologies to understand the material properties. 
Understanding of the physicochemical properties of the drug- polymer mixtures 
was the main objective of these pre-formulation studies.  
4.1.1 Prediction of solubility parameters and glass transition temperature 
The solubility parameter (δ) can be used to predict the miscibility of the 
two substances by measuring their cohesive energy density (CED) (Greenhalgh 
et al., 1999) (Verheyen et al., 2001). All inter-atomic and/or molecular interactions 
such as van der Waal’s interaction, electrostatic interaction, induced or 
permanent dipole interactions, covalent bonds, ionic bonds and hydrogen bonds 
contribute to the cohesive energy of a substance (Hancock et al., 1997). Among 
the several reported methods to calculate solubility parameters the preferred 
methods used were the Van Krevelen and Hoftyzer’s group contribution method 
(δ (MPa1/2) (Adamska and Voelkel, 2005).The solubility parameter in this 
approach is expressed in (J/cm3)1/2 or MPa1/2 by the equation below   (Van 
Krevelen and Te Nijenhuis, 2009)  
   𝜹𝟐  =  𝜹𝒅  
𝟐  + 𝜹𝒑 
𝟐 + 𝜹𝒉 
𝟐                 (Equation  4.1) 
Where  
 𝜹𝒅 =  
∑ 𝑭𝒅𝒊
𝑽
        𝜹𝒑 =  
√∑ 𝑭𝒑𝒊
𝟐  
𝑽
       𝜹𝒉 =  √
∑ 𝑬𝒉𝒊
𝑽
                                          (Equation  4.2) 
In these equations, δ is the total solubility parameter, δd is the contribution 
from dispersion forces, δp is the contribution from polar forces, δh is the 
contribution from hydrogen bonding, Fdi is the molar attraction constant due to 
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the dispersion component, Fpi is the molar attraction constant due to the polar 
component, Ehi is the hydrogen bonding energy, and V is the molar volume (Van 
Krevelen, 1990). Generally, the selected drug–excipient blends with a difference 
in their solubility parameters (Δδ) of < 7.0 MPa1/2 are predicted to be miscible 
whereas those with Δδ of >10.0 MPa1/2 are predicted to be immiscible with each 
other (Forster et al., 2001b) (Ghebremeskel et al., 2007; Greenhalgh et al., 1999).  
The solubility parameter (δ) and other physical properties of the selected drugs 
(ibuprofen and felodipine) and polymers (HPMCAS and Soluplus®) are presented 
in Table 4.1. 
Table 4.1: Physical properties of ibuprofen, felodipine, HPMCAS, and 
Soluplus® 
Compounds Molecular 
Voume(V) 
(cm3/mol) 
Density 
(g/cm3) 
Molecular 
weight (g/mol) 
Solubility 
parameter (δ) 
(MPa1/2) 
Ibuprofen 200.28 1.03 206.29 18.81 a 
HPMCAS 15852.76 1.27 20133a 26.89 a 
Felodipine 300.19 1.28 384.25 24.39 b 
Soluplus® 116161.66 0.99 115000 31.22 b 
aCalculated using the Van Krevelen and Hoftyzer’s group contribution method 
bAdapted from the reference (Tian et al., 2013) 
 
The solubility parameter difference (∆δ) of the four systems was calculated 
by subtracting solubility parameter of the drug from the polymer (Δδ = δ of 
polymer − δ of drug) and the Δδ values of the four systems is listed in Table 4.2. 
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Table 4.2: The solubility parameter difference (∆δ) of drug polymer 
composition 
Drug- polymer systems 
Solubility parameters 
difference (∆δ) (MPa1/2) 
Ibuprofen- HPMCAS 8.08 
Felodipine- HPMCAS 2.50 
Ibuprofen- Soluplus® 12.41 
Felodipine - Soluplus® 6.83 
 
In general, the solubility parameter difference (Δδ) of the ibuprofen 
containing systems was higher compared to the felodipine containing systems. 
Ibuprofen-HPMCAS and ibuprofen-Soluplus® showed a solubility parameter 
difference (Δδ) of 8.08 and 12.41, respectively, indicating that the ibuprofen-
HPMCAS system could be partially miscible with each whereas the ibuprofen-
Soluplus® system could be immiscible. The lowest difference in solubility 
parameters was observed for felodipine- HPMCAS systems with ∆δ of 2.5 and 
slightly higher for the felodipine-Soluplus® system (∆δ=6.83).  
The prediction of solubility parameters provides valuable information on 
the miscibility of the selected systems. Although this method can be used as a 
tool to predict miscibility of the drug and polymers it has some limitations. For 
instance, it is difficult to estimate highly directional (e.g, hydrogen bonding) or 
long range (e.g., electrostatic) interactions of complex molecules using the group 
contribution method (Gupta et al., 2011). Hence, it is often necessary to confirm 
miscibility using experimental methods such as differential scanning calorimetry 
(DSC).  
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The glass transition temperature (Tg) of systems was calculated using Fox 
equation (Fox and Flory, 1950). The predicted Tg for different weight fractions of 
drug and polymer vs temperature is displayed in Figure 4.1. The Figure 4.1a 
shows a fall in the glass transition temperature of HPMCAS due to the addition 
of a different weight fraction of the ibuprofen and felodipine. Similarly, Figure 4.1b 
show that Tg falls for the Soluplus®, due to the addition of the ibuprofen and 
felodipine respectively (Figure 4.1). 
Actual points in the graphs are representative of a Tg of the total mixture. 
In the case of HPMCAS the addition of ibuprofen has a major effect on the Tg of 
the polymer. HPMCAS has a Tg of 120oC and it is a predicted that the 10%w/w 
addition of ibuprofen will decrease Tg of the mixture to 93oC and 10%w/w addition 
of felodipine will shift Tg to 110oC. This suggests that the addition of a low Tg 
drug such as  ibuprofen (- 45oC) to a high Tg polymer like HPMCAS leads to a 
reduction of  the Tg of the mixture to a higher extent compared to the addition of 
a medium Tg drug like felodipine (45oC). This can be attributed to the higher 
plasticisation effect of ibuprofen than felodipine. Similarly for Soluplus® (Tg  
72oC) the addition of ibuprofen significantly reduced the Tg of the mixture and the 
addition of 50%w/w of ibuprofen in Soluplus® will decrease Tg as low as 0oC 
while 50% w/w addition of felodipine will reduce Tg to 57 oC (Figure 4.1b).  
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Figure 4.1: Glass transition temperature of the systems predicted based on 
the Fox equation – (a) Ibuprofen-HPMCAS, felodipine-HPMCAS (b) 
Ibuprofen-Soluplus®, felodipine-Soluplus® 
4.1.2 Drug-polymer miscibility and solubility 
The solubility of small molecule drugs in a polymer matrix system has a 
significant impact on the development of pharmaceutical dosage forms. The long-
term stability of the formulated product is determined by whether the drug loading 
inside the polymer matrix is oversaturated or undersaturated (Zhao et al., 2011). 
The practical approach of melting point depression can used to calculate the 
Flory-Huggins (F-H) interaction parameters and free energy of mixing (Nishi and 
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Wang, 1975). The Flory-Huggins theory provides a practical indication of the 
miscibility of binary systems. 
4.1.2.1 Theoretical considerations: Flory-Huggins interaction parameters 
(χ) and free energy of mixing (∆G) 
According to the Flory-Huggins (F-H) theory, the Gibbs free energy 
change that accompanies mixing of a drug-polymer binary system may be 
expressed as: 
𝚫𝐆𝐦𝐢𝐱 =  𝚫𝐇𝐦𝐢𝐱 − 𝐓𝚫𝐒𝐦𝐢𝐱             (Equation  4.3)  
Where ΔHmix is the enthalpic parameter and ΔSmix is the entropic 
parameters. For a binary system of a polymer with a small molecule drug, the 
Gibbs mixing function written according to the F-H model is the sum of 
combinatorial terms plus interaction terms. Subsequently, the Gibbs free energy 
may be expressed as F-H interaction χ  
𝚫𝐆𝐦𝐢𝐱 = 𝐑𝐓 (
𝛟𝐝𝐫𝐮𝐠 
𝐍𝐀
 𝐈𝐧 𝛟𝐝𝐫𝐮𝐠 +  
𝛟𝐩𝐨𝐥𝐲 
𝐍𝐁
𝐈𝐧 𝛟𝐩𝐨𝐥𝐲 +  𝛘𝐝𝐫𝐮𝐠−𝐩𝐨𝐥𝐲 𝛟𝐝𝐫𝐮𝐠 𝛟𝐩𝐨𝐥𝐲 )      
(Equation  4.4)                
Where Ф is the volume fraction, N is the molar volume of drug or polymer 
χ is the F-H interaction parameter, R is the molar gas constant, and T is the 
temperature. 
In the case of a drug-polymer mixture NA may be defined as molecular 
size of the drug and NB = mNA, where m is the ratio of volume of polymer chain 
to drug molar volume chain  
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𝑚 =
𝑴𝑾 (𝒑𝒐𝒍𝒚)
𝝆𝒑𝒐𝒍𝒚
𝑴𝑾 (𝒅𝒓𝒖𝒈)
𝝆𝒅𝒓𝒖𝒈
                              (Equation  4.5) 
Where Mw (poly) is the molecular weight of the polymer and Mw (drug) 
the molecular weight of the drug,  and  ρpoly and ρdrug are the density of polymer 
and drug, respectively. Hence equation 4.5 for the free energy of mixing for binary 
(drug-polymer) systems may be written as: 
∆𝑮𝑴𝒊𝒙 =  𝑹𝑻 (𝝓𝒅𝒓𝒖𝒈  𝐈𝐧 𝝓𝒅𝒓𝒖𝒈  +  
∅𝒑𝒐𝒍𝒚
𝒎
 𝐈𝐧 𝝓𝒑𝒐𝒍𝒚  + 𝝌𝒅𝒓𝒖𝒈−𝒑𝒐𝒍𝒚 𝝓𝒅𝒓𝒖𝒈 𝝓𝒑𝒐𝒍𝒚 )                   
…………………………………………………………………(Equation  4.6)   
Hence, the corresponding interaction parameter (χ) at a specific 
temperature may therefore be used for calculation of free energy of mixing 
(ΔGmix). The drug-polymer interaction parameters can be predicted using melting 
point depression data collected from DSC studies (Caron et al., 2011; Marsac et 
al., 2006; Marsac et al., 2009; Sun et al., 2010; Tao et al., 2009).  
𝟏
𝑻𝒎
−  
𝟏
𝑻𝒎𝟎
=  − 
𝑹
∆𝑯
 [𝐈𝐧 𝝓𝒅𝒓𝒖𝒈 +  (𝟏 −  
𝟏
𝒎
) ∅𝒑𝒐𝒍𝒚 + 𝝌𝒅𝒓𝒖𝒈−𝒑𝒐𝒍𝒚 𝝓 𝒑𝒐𝒍𝒚𝟐] 
(Equation  4.7) 
Where Tm and Tmo are the melting points of the drug crystal in the mixture 
of drug/polymer φ volume fraction of drug, respectively, m is the molar volume; 
R is the real gas constant, and ∆H is the heat of fusion of the crystalline drug.  
In practice, the interaction parameter (χ), displays complex dependence 
on the polymer composition, chain length and temperature. The correlation 
between interaction parameters and this variable cannot be simply determined 
(Zhao et al., 2011). Often temperature dependence of the interaction parameter 
is empirically written as the sum of two components to simplify studies. The 
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temperature dependence of interaction parameters can be calculated using the 
following equation 
                  𝝌𝒅𝒓𝒖𝒈−𝒑𝒐𝒍𝒚  = 𝑨 +  
𝑩
𝑻
                                       (Equation  4.8)  
 
Where, A is the value of temperature-independent term (entropic 
contribution), B/T is the value of temperature-dependent term (enthalpic 
contribution). The dependence interaction parameter on volume fraction 
(composition) is negligible relative to the temperature and the first order 
relationship between χ and temperature is an additional assumption of the F-H 
polymer solution theory. The first order relationship between χ and 1/T can be 
used to extrapolate the value of χ for drug polymer systems outside the 
experimental temperature (Lin and Huang, 2010) (Dexi et al; 2010)(Zhao et al., 
2011). Equation 4.9 can be further used to relate χ to temperature and used for 
obtaining F-H constants A and B. F-H constants A and B are important for the 
calculation of interaction parameters at a range of temperature, especially for the 
estimation at a lower temperature than glass transition (Tg) and room 
temperature. This estimation has an importance for calculating free energy of 
mixing (ΔG) of binary systems.  
In this research, the four compositions (Ibuprofen-HPMCAS, ibuprofen-
Soluplus®, felodipine-HPMCAS and felodpine-Soluplus®) were used for the 
injection moulding and drug polymer dispersions were preliminary studied to 
predict their miscibility and the solubility with each other using melting point 
depression approach. 
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4.1.2.2 Melting point depression and relationship between χ and T 
The depression of melting point was developed by Nishi and Wang in 1975 
to describe the interaction between pure amorphous and pure crystalline polymer 
(Nishi and Wang, 1975). The melting point of a drug occurs at a temperature 
when the chemical potential of the pure drug is equal to the chemical potential of 
the molten drug (Flory, 1953). If the drug is miscible with polymer, the chemical 
potential of drug in a mixture must be less than the chemical potential of pure 
amorphous drug. (Marsac et al., 2009). Strong exothermic mixing should cause 
a large depression in melting point while weaker exothermic, athermal, 
endothermic mixing should progressively cause less melting point depression.  In 
contrast, if the drug and the polymer are immiscible with each other no melting 
point depression is expected since the chemical potential of the molten drug is 
unaltered by the presence of the polymer (Marsac et al., 2006; Marsac et al., 
2009; Zhao et al., 2011) .  
In the present study the melting point depression of the drug-polymer 
physical mixture was observed using DSC heating of the sample. A 
representative melting point depression of the ibuprofen - HPMCAS system is 
shown in Figure 4.2. The depression of melting point of the crystalline drug 
(ibuprofen) was observed in the presence of different concentrations of 
amorphous polymer (HPMCAS) due to the interaction between them near to the 
melting temperature of the drug (76oC). Figure 4.2 and Table 4.3 clearly shows 
depression of the melting point and when the concentration of ibuprofen was less 
than 40% w/w the absence of an endotherm confirmed the complete solubility of 
ibuprofen in HPMCAS below 40%w/w.   
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Figure 4.2: DSC thermogram of ibuprofen-HPMCAS mixtures measured at 
2oC/min 
 
Table 4.3 : Melting point depression of ibuprofen-HPMCAS  
Weight fraction of 
drug 
Temperature 1/T * 1000 
0.4 69.6±0.21 2.929 
0.5 70.4±0.23 2.907 
0.6 72. 6±0.21 2.892 
0.7 73.9±0.20 2.881 
0.8 74.6±0.19 2.875 
0.9 75.1±0.17 2.871 
1 76.4±0.15 2.860 
 
 
 
 
124 
 
4.1.2.3 Interaction parameter (χ) 
  Melting point depression data collected from DSC studies was fitted with 
equation 4.8 to obtain the interaction parameter as a function of temperature. 
Ibuprofen-HPMCAS concentrations of less than 40% did not show a melting 
endotherm and for felodipine-HPMCAS no melting endotherm was observed for 
compositions less than 50%. In the case of Soluplus®, the ibuprofen-Soluplus® 
system did not show a melting endotherm below 50% composition and 60% in 
the case of felodipine-Soluplus® compositions. It suggests drug polymer binary 
systems exhibit an upper critical solution temperature (UCST) where the drug is 
completely miscible with the polymer (Tian et al., 2013). The temperature 
dependence of interaction parameters may be described as first order as shown 
by equation 4.9. A plot interaction parameter versus 1/T is shown in Figure 4.3. 
 
Figure 4.3: Variation of the interaction parameter X as a function of 
temperature (The solid line represents the line of best fit of equation 4.8 to 
experimental data) 
A linear relationship between interaction parameter and 1/T was observed 
at a low drug concentration, whereas non-linearity at high drug concentrations 
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was observed. Similar observations were reported for indomethacin/PVA-VA 
system (Zhao et al., 2011). The linear relationship between temperature and 
interaction parameter allowed estimation of the F-H constants A and B as 
described in equation 4.9. Using the equation 4.9 the interaction parameter χ at 
RT (25oC) for the four systems was calculated and as reported in Table 4.4. The 
drug-polymer interaction parameter χ, obtained at 25oC is positive in all systems 
which suggest immiscibility at RT which is expected to decrease at elevated 
temperatures. For example, the HPMCAS composition has χ of 1.29 at 25oC and 
-0.43 at 100oC suggesting the good miscibility at elevated processing 
temperatures. 
Table 4.4: F-H interaction constants A and B determined using linear 
regression analysis of experimental DSC data and interaction parameter, χ, 
calculated at 25°c using melting depression  
Drug polymer 
systems 
F-H constants Interaction 
parameters 
A B χ 
Ibuprofen-HPMCAS -7.29 2560 1.29 
Ibuprofen-Soluplus® -8.44 2927 1.38 
Felodipine-HPMCAS -13.91 5716 5.26 
Felodipine-Soluplus® -9.78 3987 3.59 
 
 The calculated interaction parameters at RT suggest the interaction 
parameters higher than zero suggests immiscibility of the all drug polymer 
systems at 25C. However, the better interaction between the two components 
can be expected at higher temperature. The interaction parameters have a direct 
 
 
126 
 
influence on the free energy of mixing and hence the relationship between the 
temperature and ΔG is the reliable indicator of the miscibility. 
4.1.2.4 Free energy of mixing (∆Gmix) 
The free energy of mixing (∆Gmix) of binary (drug-polymer) system gives 
information about the mixing of two components at a certain temperature. When 
∆Gmix <  0 for two compositions at respective temperature, suggesting the good 
miscibility with each other while immiscible when the ∆Gmix > 0. Interestingly, 
free energy of mixing is dependent on both the temperature and composition 
(weight fraction) hence sometimes it's possible that the ∆Gmix can be negative 
at a lower weight fraction of drug and positive at a higher drug concentration at 
constant temperature.  
The substitution of interaction parameters calculated at different 
temperatures into equation 4.7 can help to understand the variation in the Gibb’s 
free energy of mixing as a function of drug composition and temperature. Figure  
4.4 provides information about that Gibbs free energy of mixing for the four 
systems. Figure  4.4A and Figure  4.4B provides the free energy plot for the 
ibuprofen with  HPMCAS and Soluplus® respectively. These plots are almost 
identical, although ibuprofen-HPMCAS has a slightly lower ∆Gmix compared to 
ibuprofen-Soluplus®. This suggests that mixing will be more favoured in the case 
of ibuprofen-HPMCAS. 
In the case of felodipine containing systems the felodipine-HPMCAS 
system showed higher ∆Gmix than felodipine-Soluplus® Figure  4.4C and Figure  
4.4D  show free energy plots for both systems. It is apparent that near the melting 
point of the drug (140oC) ∆Gmix is negative and convex. At this temperature, the 
homogenous drug-polymer mixtures are generated and that are 
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thermodynamically stable at all drug-polymer weight fractions. For the felodipine-
HPMCAS and felodipine-Soluplus® system temperatures ≥ 120oC favoured 
mixing at lower drug concentration of 40% and 70% respectively and positive 
values of system at higher drug concentration may indicate the systems tendency 
for phase separation at higher drug concentrations (Tian et al., 2013).  
 
 
Figure  4.4: Plot of ∆Gmix/RT as function of drug volume fraction and 
polymer (A) ibuprofen-HPMCAS (B) ibuprofen-Soluplus®; (C) Felodipine-
HPMCAS(D) Felodipine-Soluplus® at various temperatures. 
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4.1.3 Temperature-composition phase diagram  
Complete phase diagrams for ibuprofen-HPMCAS, ibuprofen-Soluplus®, 
felodipine-HPMCAS and felodipine-Soluplus® were obtained after understanding 
how ∆Gmix varied with the temperature (T). The solubility and miscibility curve 
obtained from ∆Gmix were combined with Tg of the mixtures to obtain the phase 
diagrams.  
A typical phase diagram for a binary system is shown in the Figure 4.5. 
This is mainly composed of amorphous drug-polymer miscibility curve, crystalline 
drug-polymer solubility curve and the Tg of the solid dispersion. The concept of 
miscibility is well understood in polymer physics in which each polymer blend is 
stable in the amorphous state (Rubinstein and Colby, 2003). However, in the 
case of drug polymer solid dispersions complexity may arise as the amorphous 
drug dispersed in the solid dispersion is usually in a meta-stable state relative to 
the crystalline state and inclines to crystallise.  Therefore, the drug-polymer 
dispersion would eventually reach equilibrium with regards to the crystalline drug 
and equilibrium composition of drug-polymer mixture would be the solubility of 
crystalline drug in the polymer (Qian et al., 2010). 
The importance of drug polymer solubility and miscibility for the 
development of the stable amorphous dispersion is widely recognised. The 
temperature composition phase diagram can be used as a tool to assess the 
physical stability of the solid dispersion during formulation, process development 
and product shelf-life. The phase diagram consists of solubility, miscibility and Tg 
curves which intersect to form six different zones which provides valuable 
information on the thermodynamic stability of the drug- polymer system. It is 
assumed that the system is partially miscible above Tg (i.e Tc > Tg). 
 
 
129 
 
 
Figure 4.5: Representative drug-polymer phase diagrams 
In theory, for drug concentrations above the miscibility curve, phase 
separation will be thermodynamically favoured and at equilibrium both a drug 
rich-phase and a polymer-rich phase coexist with two distinguished Tg values. 
However, solid dispersions made by practical processes such as spray drying or 
HME are well mixed kinetically and initially show a single Tg regardless of the 
drug loading. For simplicity, the Tg values shown in Figure 4.5 are correspond to 
a single Tg of the system.  
As shown in the Figure 4.5 the miscibility, solubility and Tg curves 
separate the phase diagram into six different zones (zones I - VI) (Table 4.5). 
Since the amorphous form of the drug has a higher chemical potential than its 
crystalline counterpart, drug polymer miscibility (amorphous form solubility) is 
always higher than crystalline drug polymer solubility (Qian et al., 2010) 
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Table 4.5: Thermodynamic nature and destabilisation driving force for solid 
dispersions in zones I–VI of Figure 4.5 
Zone Thermodynamic Nature Destabilization Driving Force 
I Thermodynamically stable glass None 
II Thermodynamically stable liquid None 
III Supersaturated glass Crystallization of supersaturated 
drug 
IV Supersaturated liquid Crystallization of supersaturated 
drug 
V Supersaturated and immiscible 
 glass 
Amorphous phase separation, 
crystallisation of supersaturated 
drug 
VI Supersaturated and immiscible 
 liquid 
Amorphous phase separation, 
crystallisation of supersaturated 
drug 
 
The Tg curve defines the boundary between the equilibrium liquid (Zone 
II, IV, VI) and glass (I, III, V). The Tg curve is generally recognised as a kinetic 
boundary of molecular mobility and which usually represents two regions. Right 
of the Tg curve is the equilibrium liquid and in this region the structural relaxation 
occurs rapidly and solubility and miscibility can be measured at equilibrium. On 
the other hand, the left side of Tg curves is the non-equilibrium, glassy region 
where molecular mobility is considered to be very low and structural relaxation 
occurs slowly thus equilibrium solubility and miscibility cannot be strictly defined 
or measured experimentally.  Interestingly, below Tg the stability of amorphous 
solid dispersions depends heavily on the kinetics of phase separation and/or 
crystallisation instead of thermodynamics.  
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The solubility curve is the boundary between the thermodynamically stable 
(Zone I and II) and meta-stable (zone III and IV). Regions I and II represent the 
maximum drug loading that can be achieved without the thermodynamic 
destabilisation of the system.  Zones III and IV are defined respectively as 
‘supersaturated glass’ and ‘supersaturated liquid’ and together this region is 
called the “metastable region”. Crystallisation of supersaturated drug could arise 
from these metastable states upon destabilization. Especially in zone III a solid 
dispersion could be stabilised both thermodynamically (miscibility) and kinetically 
(restricted mobility). Zone V and VI are well below the miscibility and indicate 
complete phase immiscibility. Moreover, VI should be avoided as there are no 
thermodynamic or kinetic barriers for stability.  
Phase diagrams of the four the systems are presented in Figure 4.6. The 
miscibility, solubility and Tg curves are plotted in order to obtain the complete 
temperature composition phase diagram. The dashed line referes to the spinoidal 
curve and to the right side of the curve the drug is present in an unstable state 
while on the left side of the curve the drug present in the metastable state. In 
case of ibuprofen (Figure 4.6a and Figure 4.6b), HPMCAS shows good miscibility 
and solubility with ibuprofen as compared to Soluplus®. Moreover, Tg of the 
system in the case of ibuprofen-HPMCAS composition was higher so zone III 
(supersatureted glass) was broader thus a kinetic barrier would stabilise the 
system due to restricted molecular mobility than in the case of ibuprofen-
Soluplus® system.  
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Figure 4.6: Binary phase diagram of (a) ibuprofen-HPMCAS; (b) ibuprofen-
Soluplus® (C) Felodipine-HPMCAS (d) Felodipine-Soluplus® 
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In the case of felodipine systems, the  felodipine-Soluplus® miscibility and 
solubility curves (Figure 4.6 d) shifted towards low temperatures indicating the 
good miscibility of felodipine with Soluplus® than HPMCAS at lower 
temperatures. However, due to High Tg of felodipine-HPMCAS system the Zone 
I , III, V are broader and indicating good stability compared with felodipine-
Soluplus®.  The phase diagram identified the region in which large energetic 
barriers (kinetic hinderance) for recrystallisation are apparent i.e kinetically and 
thermodyanamically favoured.  
It was seen that ibuprofen has a good miscibility and solubility in HPMCAS 
compared Soluplus® on the other hand, the felodipine has good miscibility and 
solubility in Soluplus® compared to HPMCAS. For example, 10% w/w of 
felodipine  will be miscible in Soluplus® at 70oC and it will get solubilise at 90oC.  
For the same concentration the miscibility and solubility of the felodipine in 
HPMCAS were predicted at higher temperature 105oC and 120oC respectively. 
The drug-miscibility results obtained from phase diagram are in good accordance 
with previously calculated solubility parameters.  
This information on the drug polymer miscibility and solubility was very 
helpful to set the  HME and IM  processing parameters of the drug polymer 
systems.  
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Chapter 5 
 
 
 
5 Results and discussion: HPMCAS IM systems 
 
 
In this chapter results and discussion of HMCAS IM systems are provided. The 
chapter is subdivided into two main chapters Ibuprofen-HPMCAS and Felodipine-
PEO-HPMCAS injection moulded systems. The processing aspects of both the 
systems and product properties of pellets and moulded system is discussed in 
this chapter.  
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5.1 Ibuprofen-HPMCAS injection moulded systems 
The ibuprofen-HPMCAS (IBH) systems were processed using HME and IM 
with and without the addition of a release modifier (mannitol). The effect of drug- 
polymer composition on the process, product properties and drug release 
performance was studied at pre-formulation stage. The effect of IM process 
parameters such packing pressure and mould temperature on the surface 
crystallisation was studied in detail using 33% w/w Ibuprofen-HPMCAS (I33) 
systems.  
5.1.1 Processability during extrusion and injection moulding  
 Pure Ibuprofen exhibits a low glass transition temperature of -45.1oC 
(Dudognon et al., 2008) and a melting endotherrm at 76.8±0.23oC. Mannitol 
exhibits a melting endotherm at 168.9±0.24oC (Figure 5.1). The Tg of HPMCAS 
was characterised using conventional and modulated DSC. The MDSC condition 
used provided good separation of Tg of HPMCAS at 120oC using the reversing 
heat flow signal (Figure 5.1 d). HPMCAS is cellulose ether, explored mainly as a 
carrier for solid dispersions. Solvent evaporation (Tanno et al., 2004) and spray 
dried dispersions (Friesen et al., 2008) were the solid dispersion methods used 
for dispersion, however, fewer applications have been explored for thermal 
processing of HPMCAS.  Hence, the processibility of the polymer alone at 100oC 
using twin screw extrusion was evaluated, but excessive torque was observed 
and the extruder screws became blocked. The processing temperature was then 
increased in step of 10oC and at 160oC it was possible to extrude pure HPMCAS 
pellets. The mixture of ibuprofen and HPMCAS (1:2) processed using twin- screw 
extrusion at 100oC, smooth processing with torque of 30%, a flexible strand of 2 
mm diameter was obtained and pelletised into 2 mm pellets. This confirms the 
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plasticisation effect of ibuprofen on HPMCAS. Similarly, other plasticisers are 
also used for HPMCAS; in order to lower the Tg and to improve processibility with 
extrusion. Plasticisers such as triacetin, diethyl citrate, and dioctyl phthalate have 
been used. 25%w/w triacetin in HPMCAS lowers Tg to as low as 49.0oC   
(Mehuys et al., 2005). 
 
Figure 5.1: DSC thermo gram: (a) Pure Ibuprofen; (b) Mannitol; (c) HPMCAS 
heat flow (linear heating @5oC/min) (d) HPMCAS reversing heat flow 
(modulated heating @5oC/min) 
The extrusion of Ibuprofen batches (I33, I29, and I25) and Ibuprofen 
mannitol (IM33, IM29, IM25) batches with different loadings of drug in HPMCAS 
was operated at the experimental conditions mentioned in Table 3.6. The torque 
associated with all batches is summarised in the Table 5.1. No significant change 
in torque with different loadings of drug and/or mannitol was observed which 
indicates a good processability under the stated experimental conditions 
. 
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Table 5.1 Torque associated with the extrusion process 
Ibuprofen-HPMCAS 
Batches(I) 
Ibuprofen-D-mannitol-HPMCAS batches 
(IM) 
Percent 
Loading 
Torque 
(%)            
Motor 
power 
(kW) 
Percent Loading Torque 
(%) 
Motor 
power 
(kW) 
Ibuprofen Mannitol 
33  35-38 0.87-0.95 33 7 36-38 0.90-0.95 
29 40-43 1.0 - 1.07 29 11 42-44 1.05-1.1 
25 45-48 1.12-1.20 25 15 42-45 1.05-1.12 
 
The powder state has poor flowability and powder cannot be fed into the 
throat of the injection moulding machine easily; also the single screw of the 
moulding machine does not provide intimate mixing.  Hence, to ensure 
homogenous mixing and good feeding, the materials were pre-compounded into 
pellets using a twin screw extruder. In the case of injection moulding using the 
HAAKE MiniJet, processing parameters were kept constant except the packing 
pressure in order to understand the effect of densification on the properties of the 
moulded system. Here, the most important property considered was drug release 
from the tablet. Moulded tablets obtained using the HAAKE MiniJet are shown in 
the Table 5.2. 
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Table 5.2: Injection moulded tablets at packed at 600bar. 
Ibuprofen  
tablets 
33% Ibuprofen 
Tablet   
29% Ibuprofen 
Tablet  
 
 
25% Ibuprofen 
Tablet 
Ibuprofen-                
mannitol  
Tablets 
 
33% Ibuprofen,                 
7% Mannitol  Tablet 
 
 
29% Ibuprofen,                 
11% Mannitol  Tablet 
 
 
25% Ibuprofen,                  
15% Mannitol  
Tablet 
 
5.1.2 Characterisation of extruded pellets and injection moulded tablets 
Melt extruded pellets and injection moulded tablets were evaluated using 
thermal and spectroscopic techniques to understand the nature of amorphous 
drug dispersion and drug release from the polymer matrices. 
5.1.2.1  Modulated Differential Scanning Calorimetry 
Physical mixtures of Ibuprofen-HPMCAS and Ibuprofen-mannitol-
HPMCAS batches characterised by DSC exhibited a sharp melting endotherm of 
ibuprofen at 76.8±0.23oC; indicating the crystalline nature of ibuprofen. The 
physical mixture containing mannitol also showed a sharp melting enotherm at 
166.6±0.25oC indicating melting of the crystalline mannitol. Moreover, these 
results confirm that mannitol was did not solubilise in the molten ibuprofen-
HPMCAS mixture and remained dispersed in the crystalline form. Similar 
behaviour was observed for extruded pellets where mannitol exhibited a melting 
endotherm at 166oC (Table 5.3d). Extruded pellets showed an absence of a sharp 
melting endotherm of ibuprofen indicating an amorphous dispersion of ibuprofen 
in HPMCAS (Figure 5.2c). 
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(a)                                                                        
 
(b)                                                                       
 
(c)                                                                        
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(d)                                                                        
Figure 5.2:  DSC thermogram: (a) Physical mixture of ibuprofen in HPMCAS 
(I33, I29, I25) (b)Physical mixture of Ibuprofen-mannitol-HPMCAS (IM33, 
IM29, IM25) (c) Ibuprofen-HPMCAS(I33) extruded pellets; (d) Ibuprofen-
mannitol HPMCAS (IM33) extruded pellets  (modulated heating rate 
5oC/min) 
Figure 5.3 shows the thermal profiles of moulded tablets packed at 
different packing pressures. The tablets prepared at different packing pressures 
of 400, 600, and 800 bar did not show any significant differences in thermal 
profiles. However, the absence of an ibuprofen melting endotherm in all samples 
confirms the formation of amorphous solid dispersion or amorphous molecular 
dispersion of ibuprofen with HPMCAS.  
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(a) 
 
(d) 
 
(b) 
 
(e) 
 
(c) 
 
(f) 
Figure 5.3:  DSC Thermograms of injection moulded tablets packed at 
different packing pressures: (a) I33 Tablet; (b) I29 Tablet; (c) I25 Tablet (d) 
IM 33 Tablet e) IM29 Tablet  (f) IM 25 Tablet (modulated heating rate 5oC/min) 
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5.1.2.2  Mechanical properties of moulded systems 
 Mechanical properties of the tensile bars prepared using pellets containing 
different amounts of ibuprofen and mannitol were determined using Instron 
tensile tester.  The typical stress-strain profile was obtained by subjecting 
moulded bars at different extensions rates. The mechanical properties were such 
Young’s modulus; ultimate tensile strength and extension at break were 
calculated based on the strain-strain profiles (Figure 5.4).  
 
Figure 5.4: Stress-strain curve of injection moulded Ibuprofen-HPMCAS bar 
at ambient (RT) conditions 
 When comparing the I33 and the I25 mouldings at all experimental 
condition, the I25 moulded bars exhibited higher tensile strength and modulus 
than the I33 mouldings (Figure 5.4) 
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Table 5.3: Mechanical properties of injection moulded Bars 
Batch Extension 
Rate(mm/min) 
Tensile 
Strength 
(MPa) 
Young 
Modulus 
(MPa) 
Extension 
at Break  
(mm) 
I33 mould  
 
10 5.68 35.57 14.53 
100 9.29 44.82 15.65 
500 14.84 74.43 15.41 
I 29 mould  
 
10 11.86 75.75 10.33 
100 14.07 98.59 10.50 
500 23.24 386.99 9.21 
I 25 mould 10 13.31 135 10.04 
100 21.11 320 10.02 
500 27.84 447 10.03 
IM33 mould 
  
10 2.71 13.20 27 
100 5.90 22.84 24.03 
500 8.25 38.80 21.78 
    
 Low strength and stiffness in the case of the I33 mouldings can be 
explained by the plasticisation effect of the ibuprofen on HPMCAS.  Plasticisation 
significantly changed the mechanical properties of the moulded bar as shown in 
the stress-strain curve Figure 5.4. The higher level of plasticiser decreased the 
strength and modulus, but increased extension at break indicating the flexible 
nature of the I33 mouldings compared to the I25 mouldings. The rate of 
deformation also has a significant effect on the mechanical behaviour of both I33 
and I25 mouldings. For example, when I25 mouldings were extended at a low 
(10mm/min) rate it exhibited low strength (13.31MPa) and modulus (135MPa) 
however, when extended at moderate (100mm/min) to high (500mm/min) rate 
showed an increase in strength (27.84 MPa) modulus (447MPa) as shown in 
Table 5.3. The I29 moulded bar exhibited the tensile strength and modulus in 
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between the I33 and I25 mouldings. These results confirmed that the mechanical 
properties of Ibuprofen-HPMCAS injection moulded systems are dependent on 
the percentage of ibuprofen, which is responsible for the plasticisation of 
HPMCAS. 
 
Figure 5.5: Stress-strain curve of injection moulded Ibuprofen-mannitol-
HPMCAS bars at ambient (RT) conditions 
  Furthermore, different concentration of mannitol in the systems further 
decreased Young’s modulus and ultimate tensile strength of the bar with increase 
in an extension at break. This confirms the of effect addition of a low Tg (7.4°C) 
substance manntiol on the mechanical properties of the bar (Yoshinari et al., 
2003). When I33 bar compared with IM33 bar contains the same concentration 
of ibuprofen in the system except latter consists of 7% mannitol. The addition of 
mannitol had a significant effect on the mechanical strength of the bar where 
tensile strength and modulus of IM33 bar was reduced to approximately half than 
the I33 bar (Table 5.3). This indicates mannitol gets slightly dissolved in the 
molten mass of ibuprofen-HPMCAS at processing temperature (100oC). The 
stress-strain curve of IM33 and IM25 at all extension rates is presented in the 
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Figure 5.5. This clearly shows higher modulus and strength of IM 25 than IM33 
where, higher ibuprofen decreased mechanical properties of the bar.  
5.1.2.3 Raman Spectroscopy 
A Raman spectrum in the 50–150 cm−1 regions contains information about 
vibrations and translations of the entire molecule in the lattice providing an 
indication of the level of crystallinity. These vibrations are characteristic of the 
crystal structure and sensitive to local order or disorder (Saerens et al., 2011).  
The spectra obtained from the fingerprint region (600-1800 cm-1) composed of 
intra-molecular vibrations distinctive of atomic bonds, molecular conformations 
and the close molecular neighbouring (Hedoux et al., 2011). Ibuprofen shows a 
Raman band at 1608 cm-1 corresponding to a characteristic crystalline band 
(Figure 5.6). However, when ibuprofen is dissolved in solvent or processed as a 
hot melt extrudate with PVP it shows a peak at 1613 cm−1. This shift to 1613 cm−1 
is indicative of a molecular dispersion of ibuprofen in the polymer system 
(Breitenbach et al., 1999). The hot melt extruded pellets and injection moulded 
tablets displayed, this characteristic shift where the ibuprofen peak shifts to a 
higher wavelength of 1613 cm-1 (Figure 5.7 and Figure 5.8). This confirms that 
the ibuprofen has formed a molecular level dispersion with HPMCAS when 
processed into melt extruded pellets and injection moulded tablets. 
HPMCAS shows -C=O bond stretching vibrations at 1745cm-1 and 
ibuprofen shows -C=O bond stretching at 1655 cm-1. Ibuprofen shows the aryl     -
C=C stretching at two positions; 1575 cm-1 and 1608 cm-1  (Figure 5.9 and Figure 
5.10) whereas mannitol does not show any Raman band in this region as it neither 
contains a carbonyl functional group nor an aromatic ring.  
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Figure 5.6: Raman spectra of pure ibuprofen, HPMCAS-LF and mannitol 
 
Figure 5.7: Raman spectra of pure ibuprofen, HPMCAS and mannitol (1550-
1800cm-1)  
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Raman spectra of physical mixtures of ibuprofen 33%w/w ibuprofen-
HPMCAS (I33 physcial mix) showed the Raman band of functional groups 
present in both the ibuprofen and the HPMCAS molecules (Figure 5.9). The 
analysis of extruded pellets and injection moulded tablet showed distinct shifts in 
the Raman spectrum in the 1550 to 1800 cm-1 region which corresponds to the 
fingerprint region of a drug molecule. The pure crystalline ibuprofen and the 
ibuprofen present in a physical mixture shows two distinct Raman band first, 1608 
cm-1 corresponds to aryl –C=C stretching and second, 1650cm-1 bond 
corresponds to – C=O stretching vibrations . The hot melt extruded pellets (Figure 
5.8) and injection molded tablets (Figure 5.9) showed a distinct peak shift at both 
positions. The ibuprofen crystal phase I (form I) exhibits Raman band at 1608cm-
1 while Heduox et al. have reported Raman spectra of the low melting metastable 
phase II (form II) and glassy state, both exhibit the Raman band at 1613 cm-1, 
this attributed to the similar local order in glassy (amorphous)  and metastable 
states (Hedoux et al., 2011). 
 
Figure 5.8: 33% ibuprofen HPMCAS melt extruded pellets (I 33 pellets) 
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Figure 5.9: Raman shift for Ibuprofen-HPMCAS injection moulded tablets 
(spectra’s taken after 24 hr storage at RT) 
 
Figure 5.10: Raman shift for Ibuprofen-mannitol HPMCAS injection 
moulded tablets (spectra’s taken after 24 hr storage at RT) 
Rossi et al. have also studied vibrational properties of Ibuprofen-β 
cyclodextrin (CD) inclusion complexes using Raman scattering and explained the 
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numerical calculations.  The region between 1550 to 1750 cm−1 was selected to 
understand the complexation induced changes in the ibuprofen spectrum. The 
complexation of  ibuprofen with β-CD also showed the shift to 1613 cm−1 from 
1608 cm−1  this effect was explained due to the involvement of atom belonging to 
the aryl ring -C=C group of ibuprofen was affected by the complexation process 
(Rossi et al., 2009). Similar shifts in the melt extruded pellets and the injection 
moulded system suggest the formation of the disordered (amorphous) state. The 
mannitol containing injection moulded system (IM) showed similar behaviour 
(Figure 5.10).   
Carbonyl stretching of ibuprofen was seen at 1655 cm-1 due to the 
presence of ibuprofen dimer (two caboxylic acid functional groups of ibuprofen 
form a H-bond). The frequency downshift of this band was reported as a result of 
complexation. The extruded pellets and injection moulded system does not show 
the band at 1655 cm-1. It confirms the absence of a dimer between carboxylic acid 
functional groups of two ibuprofen molecules, rather, showed the large higher 
frequency shift to 1745 cm-1 in the same region as HPMCAS indicates the 
formation of a H-bond between the ibuprofen and HPMCAS (Figure 5.9)  
A comparison between spectra obtained from the surface and middle part 
of the tablets revealed an important phenomenon of surface crystallisation of 
ibuprofen from injection moulded tablets. A sample from the middle section of the 
tablet exhibited a Raman band at 1613.04 cm-1 however, surface samples 
exhibited at 1608.52 cm-1 with an increase in the relative intensity of the Raman 
band. Moreover, the localization -C=O stretching was seen at 1655 cm-1 (Figure 
5.10 and Figure 5.11 Figure 5.12). The back shifts of Raman bands and increased 
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relative intensity of peaks confirms the surface crystallisation of amorphous 
ibuprofen. Langkilde et al. have also explained the differences between Raman 
spectra from different crystal forms of a compound, or between crystalline and 
amorphous forms (Langkilde et al., 1997) . 
 
Figure 5.11: Surface spectra of Ibuprofen-HPMCAS injection moulded 
tablets (spectra’s taken after 24 hr storage at RT) 
The Figure 5.13 shows the clear difference in the Raman spectra of the 
surface crystallised tablets and the middle amorphous core. The difference in the 
spectrum indicates that ibuprofen dispersed inside the polymer matrix is in 
amorphous state, whereas phase separation leads to crystallisation on the 
surface.  
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Figure 5.12: Surface spectra of Ibuprofen-mannitol-HPMCAS injection 
moulded tablets (spectra’s taken after 24 hr storage at RT) 
 
Figure 5.13: Surface crystallisation from injection moulded tablets 
(spectra’s taken after 24 hr storage at RT) 
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5.1.2.4 Raman spectroscopy: Moisture induced surface crystallisation 
   Although the amorphous molecular dispersion of ibuprofen was 
achieved in HPMCAS through HME and IM processes, surface crystallisation 
was observed. It was important to understand the surface crystallisation under 
different humidity conditions at a constant temperature as moisture favours the 
crystallisation. Ibuprofen shows a crystalline band at 1608 cm-1 and the shift in 
this peak to 1613 cm−1 is indicative of a molecular level dispersion of the 
ibuprofen (Breitenbach et al., 1999). When moulded tablets were exposed to the 
different RH the shift back to 1608 cm−1 was observed with increased peak 
intensity over the period which confirms the tendency of amorphous drug to 
surface crystallise with moisture. Tablets exposed to 75%RH showed a higher 
relative peak intensity of 1608cm-1 peak than 43%RH (Figure 5.14). This 
suggests a higher crystallisation rate at 75% as well as the sensitivity of Raman 
signal to the degree of crystallinity. According to Langkilde, the differences in the 
Raman spectra can be seen for the different crystal and/or amorphous forms. 
These studies showed that amorphous, nanocrystalline and microcrystalline 
forms of ketoprofen showed an increase in the relative intensity of peaks as 
particle size increases (Langkilde et al., 1997). 
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Figure 5.14: Raman spectra- moisture induced surface crystallisation  
5.1.2.5 FTIR 
Infrared (IR) spectroscopy deals with the Infrared region of the 
electromagnetic spectrum. Mid-IR, ranging approximately ranging from 4000–
400 cm−1 (2.5–25 μm), is used to characterise the fundamental vibrations and 
associated vibration-rotations of a molecule.  IR spectroscopy is a well 
established technique for characterising inter-molecular interactions such as 
hydrogen bonding (H-bond) (Jeffrey, 1997) (Murthy and Rao, 1968) and has been 
extensively used to understand the drug-polymer interactions in amorphous 
dispersions (Taylor and Zografi, 1997; Taylor and Zografi, 1998) ((Miyazaki et al., 
2004; Weuts et al., 2005). In general, the H-bond between a drug and polymer 
can be formed when there is one proton donor and a proton acceptor. If these 
hetero interactions between drug and polymer differ in strength or extent relative 
to the self association of these systems, then that change will be reflected by a 
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change in peak position and shape of the IR spectrum for the functional groups 
in the specific interactions (Kestur et al., 2011) 
     Bras et al. studied the molecular motions in the amorphous ibuprofen 
using broadband dielectric spectroscopy (BDS), in order to probe inter-molecular 
H-bonding between the ibuprofen molecules. The IR spectroscopy was used to 
analyse both supercooled liquid (amorphous) and crystalline ibuprofen. The free 
C=0 group of carboxylic acid has a characteristic frequency of 1760 cm−1 appears 
as a sharp peak and in the presence of hydrogen bonds, these stretching is 
perturbed and shifts to lower wave numbers  (1700-1725  cm-1) (Bras et al., 2008) 
(Silverstein et al., 1981). When FTIR studies on supercooled (amorphous) and 
crystalline ibuprofen were done by Bras et al. it was observed that both 
amorphous and crystalline ibuprofen showed a downward shift at C=O stretching. 
The authors concluded that ibuprofen molecules in both phases exist almost in 
the form of hydrogen bonded aggregates (Bras et al., 2008). However the major 
difference seen was lowering the peak intensity and broadening of bands in the 
spectrum for the amorphous phase due to disorder or a less organised structure. 
The frequency shift at other positions in IR also gives valuable information on the 
amorphous phase formation and H-bond involvement.  
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Figure 5.15: FTIR spectra of pure ibuprofen, HPMCAS, 33% Ibuprofen 
HPMCAS physical Mix (I33), 33% ibuprofen-HPMCAS moulded system  
In the case of ibuprofen-HPMCAS systems, the pure crystalline ibuprofen 
showed a peak at -C=O stretching at 1708cm-1 and pure HPMCAS showed 
carbonyl stretching at 1735cm-1 this clearly indicates ibuprofen formed a inter-
molecular H-bond within ibuprofen molecules (dimer) and the presence of a free    
-C=O group in the case of HPMCAS (Figure 5.15, Figure 5.16b).  Vueba et al. 
assessed the conformational stability of ibuprofen using vibrational spectroscopy 
by both Raman and FTIR and marked the positions of functional group (Vueba 
et al., 2008). IR peaks of pure ibuprofen, physical mixture and moulded systems 
are summarised in Table 5.4, where changes at peak positions are also 
mentioned. Ibuprofen-HPMCAS moulded (I33) system showed -C=O  stretching 
at 1720 cm-1  and broadening  in the region suggests the formation of  H-bonds 
between Ibuprofen and HPMCAS Figure 5.16b. It might be because of the 
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formation of a dimer between and drug and polymer instead of two molecules of 
ibuprofen.  
 
 
Figure 5.16: FTIR of Ibuprofen, HPMCAS, Ibuprofen-HPMCAS PM and I33 
moulded system (a) 645 to 980 cm-1 region (b) 1350 to 1800 cm-1 region 
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Table 5.4: FTIR functional group of ibuprofen-HPMCAS 
Functional group  Ibuprofen  Ibuprofen-
HPMCAS  
Physical mix 
Injection 
moulded 
tablets 
CH3 rock; C=O out-of-plane wagg 778 778 780 
CH3 rocking,  
CO-H bending(H-bonded) 
921 944 950 
CO-H bending(H-bonded) 1419 1419 1420 
C-OH bending 1124 1124 1124 
C-OH CO-H bending (H-bonded) 1231 1231 1231 
C-OH bending modes 1365 1365 1365 
CO-H bending (H-bonded) 1420 1420 1418 
CH3 Assymetic deformation  1462 1462 1462 
C - C (aromatic) stretching 1507 1507 1509 
C = O  stretching  1708 1735 1720 
C-OH bending modes 1365 1361  1361 
 
The carbonyl stretching of surface samples of the I33 moulded systems 
after 7 day was observed at 1708 cm-1 whereas middle sample has shown at 
1720 cm-1. These results indicate surface crystallised ibuprofen caused the back 
shift due to dimer formation between two ibuprofen molecules (Figure 5.17 and 
Figure 5.18) 
 
Figure 5.17: Ibuprofen dimer  (H-bond) 
Surface crystallised ibuprofen showed identical FTIR spectra to that of 
pure ibuprofen. When ibuprofen- polyethylene glycol(PEG) solid dispersions 
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were analyzed using FTIR, it was seen that ibuprofen formed a molecular level 
dispersion with PEG and showed the carbonyl band at higher wave number (1732 
cm-1). When the drug was dispersed at more than 50% wt ratio in a polymer, this 
showed a shift back to a lower wavenumber (1705 cm-1). This has been 
interpreted as the saturation of the drug in a polymer and dimerisation of the 
ibuprofen becoming the precursor for crystallisation for the drug (Chan and 
Kazarian, 2006). 
 
Figure 5.18: FTIR of I33 surface crystallised sample after 7 day at RT (945 
to 1800 cm-1) 
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5.1.2.6 Hot stage microscopy 
Microscopic studies on the I33 Tab (33% ibuprofen- HPMCAS Tab) in 
0.1NHCL and in phosphate buffer pH 7.2 have provided an insight into the 
crystallisation behaviour of a dispersed amorphous drug during dissolution in the 
GI tract under non-sink conditions. Crystallisation of the ibuprofen was seen after 
3hrs in the case of tablets immersed in phosphate buffer pH 7.2 (Figure 5.19). 
Poor wettability of the tablet surface was observed in the first hour which could 
be attributed to the hydrophobicity of the HPMCAS and the surface properties of 
moulded systems. A slight improvement in wettablility was observed in the case 
of tablets with dispersed mannitol however, a significant effect was only observed 
in the drug release rate, which will be described later. Tablets immersed in 
0.1NHCL solution (pH 1.2) did not show any sign of the surface erosion and the 
absence of the surface crystals confirms the limited solubility of HPMCAS in an 
acidic environment (Figure 5.20). The HPMCAS has a pH dependent solubility 
and does not ionise below pH 5.5 therefore retards drug release at gastric pH and 
release the drug in the small intestine. The possibility of the ibuprofen 
crystallisation during dissolution under non-sink conditions was investigated 
using the microscopic studies.  
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33% Ibuprofen-HPMCAS  (I33)tablets 
5min 30mins 30mins 
   
120min 240 min 300 min 
   
350 min 380 min 420 min 
   
Figure 5.19: Hot stage microscopy: surface images of I 33 Tab (33% 
Ibuprofen- HPMCAS tablet) immersed in Phosphate buffer pH 7.2 at 37oC. 
 
Phosphate Buffer pH 7.2 
Tablet Surface  
 
18.43µm 
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33% Ibuprofen-HPMCAS  (I33)tablets 
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Figure 5.20:  Hot stage microscopy: surface images of I 33 Tab (33% 
Ibuprofen- HPMCAS tablet) immersed 0.1N HCL at 37oC. 
 
Phosphate Buffer pH 7.2 
Tablet Surface  
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5.1.2.7  In-vitro release studies 
Ibuprofen-HPMCAS and ibuprofen-mannitol-HPMCAS injection moulded 
tablets were subjected to the dissolution testing using USP II apparatus. The drug 
release from extruded pellets was also studied. Drug release from extruded 
pellets of ibuprofen (I33, I29, I25) and ibuprofen-mannitol-HPMCAS (IM33, IM29, 
IM25) batches in phosphate buffer showed the rapid release with almost 100% 
release in 2hrs in all the cases (Figure 5.21).  
 
Figure 5.21: In-vitro release from extruded pellets of (a) Ibuprofen-HPMCAS 
and (b) Ibuprofen-mannitol HPMCAS in phosphate buffer pH 7.2 (n=3) 
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Tablet dissolution and drug-release in phosphate buffer pH 7.2 using USP 
II method showed erosion of the tablet surface rather than swelling and diffusion 
(Figure 5.23). Surface imaging of ibuprofen and ibuprofen mannitol tablets 
showed a smooth tablet surface (Figure 5.22). In vitro-dissolution after 3 and 6 hrs 
showed no signs of the pore formation in the case of ibuprofen tablets. However, 
tablets containing mannitol showed surface roughness and pore formation after 
6hrs (Figure 5.24). 
 
 
 
Figure 5.22: SEM surface images of I33 and IM33 tablet before dissolution  
I33 Tab : 33% Ibu- HPMCAS  
 
IM 33 Tab: 33% Ibu 7% mannitol - HPMCAS  
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(a) Ibuprofen-HPMCAS tablets 
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(a) Ibuprofen-Mannitol HPMCAS tablets 
Figure 5.23: (a) Ibuprofen Tablet: Tablet erosion and surface at specific time 
after dissolution (I33) (I29); (I25) Tab; (b) Ibuprofen mannitol Tablet: Tablet 
erosion and surface at specific time after dissolution (IM33); (IM29); (IM25)  
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Hydrophilic mannitol causes some pore formation during dissolution and 
thus accelerates the drug release from the moulded tablet. Moulded tablets 
showed slower release of ibuprofen as compared to pellets; where almost 50% 
drug release was observed in 150 mins and 80% release in 240 mins (Figure 
5.25). 100% drug release was observed after 6 hrs for every injection moulded 
tablet. Ibuprofen tablets packed under the different packing pressures did not 
show any significant difference in the drug release (Figure 5.26). 
 
After 3hrs of dissolution  
 
After 6hrs of dissolution 
 
 
 (a) I33 Tab: 33% Ibuprofen- HPMCAS Tab  
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After 3hrs of dissolution  
 
After 6hrs of dissolution  
 
 
 
Figure 5.24: SEM images of (a) I33 and (b) IM33 Tablet after in-vitro 
dissolution  
(b) IM 33 Tab: 33% Ibu, 7% mannitol - HPMCAS  
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Figure 5.25: Drug release from 33% ibuprofen-HPMCAS systems: I33 
pellets, I33 tablets and IM33 tablets in phosphate buffer pH 7.2 (n=6)  
The controlled release behaviour of moulded systems can be explained by 
two reasons, firstly, hydrophobicity of HPMCAS and secondly, by densification 
during the injection moulding process. The nature of substituent’s i.e methoxy 
and acetyl makes HPMCAS hydrophobic and hence the polymer surface shows 
poor wettability. The particle size had an influential effect on the drug release 
where smaller extruded pellets provided higher surface area during dissolution 
than injection moulded tablets. 
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Figure 5.26: In-vitro release from injection moulded tablets of same 
strength and packed at different pressure; (a) Ibuprofen-HPMCAS and (b) 
Ibuprofen-D-mannitol HPMCAS in phosphate buffer pH7.2. (n=3) 
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5.1.3 Effect of processing parameters using DoE 
The crystallisation of ibuprofen on the surface of the tablets and tensile 
bar was observed, which was confirmed during Raman spectroscopy analysis. 
The 33% ibuprofen-HPMCAS (I33) system (moulded bars) was studied in detail 
to understand the effect of injection moulding process variables i.e the packing 
pressure and mould temperature, on the properties of the moulded systems. The 
surface crystallisation kinetic was studied using MDSC and NIR. The change in 
molded bar (4cm) surface area due to the shrinkage and change of mechanical 
properties was studied using DMA.  The data obtained using MDSC, NIR, 
shrinkage (surface area) and DMA was used to plot surface response curves to 
understand the effect of the injection moulding process variables on the 
crystallisation and shrinkage of I33 moulded bar.  
5.1.3.1 Modulated DSC (MDSC)  
The samples characterised immediately after moulding showed a single 
Tg at 38.1±0.23oC whereas the absence of a sharp melting endotherm confirmed 
the formation of an amorphous molecular dispersion of the drug within the 
polymer (Figure 5.27). The middle section of bar showed a similar behaviour 
when analysed after 24hrs.  However, the surface samples showed a small 
melting endotherm at 69.0±0.21oC indicating the melting of the surface 
crystallised ibuprofen. Modulated DSC allowed a separation of thermal events on 
a reversing, non-reversing and reversing heat capacity curves (Rev Cp) 
(Coleman and Craig, 1996; Moffat et al., 2014; Qi and Craig, 2012; Royall et al., 
1998) .  
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Figure 5.27: MDSC of ibuprofen-HPMCAS (I33) moulded tensile bar after the 
moulding (modulated heating rate 5oC/min) 
 
Figure 5.28: Phase separation of ibuprofen-HPMCAS (I33) moulded system:  
MDSC of surface sample of ibuprofen-HPMCAS (modulated heating rate 
5oC/min)   
   
The Reversing heat flow signals (Rev Cp) were monitored for the 
characterisation of Tg of the amorphous phase and the melting endotherm of the 
crystalline phase within the moulded samples. The increase in Rev Cp at 38oC 
represents the Tg and 69oC corresponds to crystalline ibuprofen (Figure 5.28). 
The specific heat capacity of the material is expected to increase at two steps 
during DSC heating; first, at Tg due to the higher molecular mobility and second, 
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at a fusion temperature of a compound.  Complimentary results were obtained 
using DMA where, two tan δ peaks were observed in the same temperature 
region (explained in the section 5.1.3.3). Modulated DSC and DMA provided a 
good understanding of the thermal behaviour and phase separation of the 
moulded systems. 
5.1.3.1.1 Crystallisation under stress conditions: prediction by MDSC 
The crystallisation kinetics predicted for the nine batches which were kept 
at different stress conditions (temperature and humidity) as described in Table 
3.13. Thermal analysis of surface samples taken for a period of one month at 
different intervals showed a melting endotherm of ibuprofen at 69-70oC with an 
increase in the melting enthalpy (Figure 5.29). The melting enthalpy (∆H) was 
calculated by integration of area under melting endotherm and the formula used 
to calculate degree of crystallinity or % crystallisation is mentioned in the equation 
5.1. 
% crystallsation  = 
∆𝐇𝐬
∆𝐇𝐜
 × 100                   (Equation 5.1) 
Where ∆Hs is the melting enthalpy of surface crystallised sample at the 
stability time point; ∆HC is the melting enthalpy of the 33%w/w ibuprofen 
HPMCAS physical mixture. 
A similar equation was used for prediction of the crystallisation kinetics 
from amorphous solid dispersion containing Cinnarizine-Soluplus®, efavirenz–
polyvinylpyrrolidone (Tian et al., 2014a; Yang et al., 2010), fenofibrate and 
ketoconazole– Kollidon® VA 64 (Kanaujia et al., 2011).  
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Figure 5.29: DSC thermograms of surface of ibuprofen-HPMCAS (I33) 
samples(B-02) exposed to stress condition: (A) 40oC 75%RH (B) 40oC 
60%RH (C) 25oC 60%RH   (modulated heating rate 5oC/min)   
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The  Tg of  of I33 system predicted by Fox equation indicated that the 
addition of ibuprofen would lower down the Tg of  HPMCAS and the overall Tg of 
the system after addition of 33% ibuprofen could possibly lower the temperature 
around 45oC (Figure 5.28, Figure 4.1). Practically observed of Tg of the system 
using MDSC was at around 38oC. Therefore, it was interesting to evaluate the 
systems crystallisation above and below the Tg of the system. 
Two storage temperatures were above the Tg of the system (40oC 75%RH and 
40oC 60%RH) and one condition was below the Tg (25oC 60%RH). From DSC 
thermal profiles (Figure 5.29) the effect of stress condition on the melting enthalpy 
(∆H) of the moulded system can be clearly seen. Calculated degrees of 
crystallinity (% crystallinity) of the moulded system at various stress conditions 
are displayed in the Figure 5.30. The predicted crystallization kinetics for all the 
batches have distinctively shown a higher degree of crystallization at 40oC 
compared to 25oC. Moreover, humidity also played an important role in the 
crystallisation i.e the higher %RH (75%) favoured the crystallisation kinetics than 
low RH (60%) when  stored at similar storage temperature (40oC). In general, the 
different stress conditions had a significant effect on crystallisation ate.   
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Figure 5.30: Crystallisation kinetics of I33 moulded systems stored at stress condition predicted by MDSC
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After 7th day of storage, sigificant crystallinity was developed irrespective 
of the processing condition. It was seen that % crystallinity in the range of 22-
23%, 7-9%, 3-4% at 40oC 75%RH, 40oC 60%RH, 25oC 60%RH respectivey. The  
rate of crystallisation at stress conditions from all molded systems was calculated 
using the linear regression analysis the using equation mentioned as below 
𝒀 = 𝒎𝑿 + 𝑪              ( Equation  5.2) 
Where Y  is the % crystallised at a time t, X = time measured in days, m  is 
the slope of the line, C  is the  intercept, Therefore, the slope of the line can be 
used to calculate the rate of % crystallisation/day. Batches (B-07, B-08, B-09) 
prepared at a high mould temperature (30oC) showed a marginally higher rate of 
crystallization than the batches prepared at 10oC and 20oC this could be 
attributed to the  melt quenching effect  or rate of cooling of the melt (Table 5.5). 
Cooling rate has a significant influence on the properties of amorphous materials 
and rate of cooling has an effect on the nucleation from an amorphous state 
(Kelton, 1998). Slow cooling allows the maintenance of a steady-state nucleation 
rate, whereas rapid cooling prevents a full development of viable nuclei. Hence, 
rapid cooling not only facilitates glass formation, but also enhances the glass 
stability against the crystallisation (Yu, 2001).  HPMCAS is relatively hydrophobic 
in nature due to its substitutients, however, when exposed to high RH (75%) 
conditions, it absorbs moisture and because of the platicisation effect of water, 
the Tg of the polymer decreases (Friesen et al., 2008). 
When 40oC 75%RH and 40oC 60%RH systems were compared, the rate 
of  crystallisation at 75%RH was observed to be the twice that of 60%RH (Table 
5.5). This suggests that moisture-favoured crystallisation where the Tg of the 
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system was further decreased, leading to an increase in the molecular mobility. 
There are several reports on moisture-favoured crystallisation of APIs (Marsac et 
al., 2008; Marsac et al., 2010; Tian et al., 2014a). The systems stored at 25 oC 
60%RH were least affected by the stress conditions as the storage temperature 
was below Tg of the system and the moisture level was similar to or less than the 
other conditions. Amorphous drugs shows higher molecular mobility above the 
Tg which favours crystallisation (Zhou et al., 2008). 
Table 5.5: Rate of crystallisation (%)/day of I33 systems at stress condition  
Batch  
number 
Pack  
pressure 
Mould 
Temp. 
Rate of crystallisation (%)/day 
40oC 75%RH 40oC 60%RH 25oC 60%RH 
B-01 300 10 2.08 1.00 0.15 
B-02 500 10 2.03 1.03 0.15 
B-03 700 10 2.14 1.27 0.14 
B-04 300 20 2.11 1.19 0.19 
B-05 500 20 2.06 1.16 0.19 
B-06 700 20 2.23 1.27 0.17 
B-07 300 30 2.13 1.18 0.25 
B-08 500 30 2.15 1.19 0.22 
B-09 700 30 2.21 1.36 0.27 
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5.1.3.2 Near infrared spectroscopy 
In NIR spectroscopy samples are irradiated with NIR light  and some of 
the light is absorbed by the molecules, bringing them to a higher vibrational state. 
Only vibrations resulting in changes in dipole movement of a molecule can absorb 
IR radiation. The molecules need a permanent dipole to be IR active while some 
atomic molecule shows dipole induced by vibration. In general, R-H group shows 
strongest overtone as a diople movement is high, therefore  O-H, N-H, C-H S-H 
groups are strong NIR absorbers (De Beer et al., 2011). In contrast H2 does not 
absorb NIR radiation as it does not show a change in dipole movement during its 
vibration. Stretching and bending are the forms of vibrations which molecules 
may exhibit upon absorption of NIR energy. Stretching is  a continuous change 
in bond length or interatomic distance along the axis while bending is due to a 
change in bond angle. For  example, C-H group shows stretching at 2960 cm-1 
and bending of C-H is at 1460 cm-1 (De Beer et al., 2011).  
Second derivative NIR spectra in the 4000 cm-1–10,000 cm-1 region for 
pure ibuprofen, HPMCAS and 33% ibuprofen-HPMCAS physical mixtures shown 
in the Figure 5.31. Pure crystalline ibuprofen shows intense NIR peaks while 
dilution with polymer (33% physical mixture) decreases the relative  intensity of 
the peaks. A selected region between 4000 cm-1– 4800 cm-1 is shown in Figure 
5.32 . The reduction of peak intensity with concentration suggests good sensitivity 
of NIR for identification of different drug concentrations. This forms the basis for 
setting up a calibration curve with a physical mixture containing the different 
ibuprofen concentrations ranging from 10% to 60% by weight.  
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Figure 5.31: Second derivative of NIR spectra of ibuprofen, HPMCAS, 33% 
physical mixture  
 
Figure 5.32: Second derivative of NIR spectra of ibuprofen, HPMCAS, 33% 
physical mixture in the 4000 cm-1– 4800cm-1 range 
Second derivative of NIR spectra of physical mixtures shown in Figure 
5.33 and the Figure 5.34 shows the calibration curve and results of partial least 
squares regression analysis of NIR spectra using whole range (wavenumber 
4000-10000 cm-1).  A good correlation was observed between the actual and 
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calculated concentrations of the ibuprofen (correlation coefficient 0.999). 
Validation standards containing known concentration of the ibuprofen (30%, 33% 
and 50% w/w) were accurately quantified using set calibration curve.   
 
Figure 5.33: Second derivative of NIR of calibration standards : Ibu-
HPMCAS physical mix 
 
Figure 5.34: NIR calibration curve of  ibuprofen-HPMCAS physical mixtures 
 NIR has been used as a process analytical tool (PAT)  for analysis of wet 
granulation (Wikstrom et al., 2005) crystalline phases, polymorphic 
transformation (Aaltonen et al., 2003; Li et al., 2005) and co-crystal formation 
(Kelly et al., 2012). A transmission NIR method has been used to estimate the 
ibuprofen content of tablets (Meza et al., 2006). Injection moulded systems (B01-
B09) analysed immediately after the moulding showed significant reduction in the 
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relative intensity of  NIR peaks, indicating the formation of amorphous dispersion 
of ibuprofen in the HPMCAS matrix.  The peak intensity of physical mixture 
containing similar drug-polymer weight ratio, i.e. 33% ibuprofen in HPMCAS 
(Figure 5.35,brown Line) showed sharp peaks due to the crystalline nature of 
ibuprofen, however moulded samples showed reduction in peak intensity due to 
the effect of the process on the material.  Similar observations of the peak height 
reduction have been reported for the amorphous dispersion of tarcolimus in 
HPMCAS and HPC (Zidan et al., 2012).  
 
Figure 5.35: Second derivative of NIR spectra of  I33 physical mixture and 
injection moulded samples 
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Figure 5.36: Second derivative of NIR spectra of surface crystallised bar     
(B-01) stored at (a) 40oC 75%RH (b) 40oC 60%RH (c) 25oC 60%RH  
The second derivative NIR spectra of batch B-01 stored at three stress 
conditions are shown in the Figure 5.36. An increase in the relative peak intensity 
(a) 
(b) 
(c) 
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with time was seen at all conditions. At 40oC 75% RH the relative increase in the 
peak intensity was high compared to 25 oC 60%RH due to the higher % 
crystallinity of the samples. The surface crystallisation measured by NIR was in 
good accordance with the MDSC results. The extreme condition (40oC 75% RH) 
favoured more rapid surface crystallisation compared to 40oC  60%RH which 
suggests an effect of moisture on the rate of the ibuprofen crystallisation. 
The percent crystallinity and the crystallisation rate was quantified using 
the NIR calibration curve. The % crystallisation was plotted against time to obtain  
the rate of crystallisation (Figure 5.37). The crystallisation rate at 25oC 60%RH 
was approximately 0.2 %/day whereas at 40oC 75% RH it was about 2%/day. 
These finding suggests that the crystallisation rate at 25oC 60%RH was 
approximately one tenth of that at 40oC 75%. This difference was evidenced by 
both the effect of both Tg  of moulded system and stress conditions (temperatures 
and moistures) on the crystallization rate as shown in Table 5.6 Batches (B-07, 
B-08, B-09) were prepared at a high mould temperature (30oC) showed a 
marginally higher rate of crystallization than the other conditions (10oC and 20oC). 
Similar trends were predicted earlier using MDSC suggesting that good sensitivity 
of the thermal and the spectroscopic techniques for the analysis of moulded 
systems.  
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Table 5.6: Rate of surface crystallisation (%)/day of I33 systems at stress 
condition measured by NIR 
Batch number Rate of crystallisation (%)/day 
40oC 75%RH 40oC 60%RH 25oC 60%RH 
B-01: 300Bar Pack, 10oC 
mould T 
1.70 0.56 0.11 
B-02: 500Bar Pack, 10oC 
mould T 
1.82 0.56 0.12 
B-03: 700Bar Pack, 10oC 
mould T 
1.93 0.51 0.14 
B-04: 300Bar Pack, 20oC 
mold T 
1.75 0.54 0.12 
B-05: 500Bar Pack, 20oC 
mould T 
1.86 0.57 0.12 
B-06: 700Bar Pack, 20oC 
mould T 
1.86 0.65 0.14 
B-07: 300Bar Pack, 30oC 
mould T 
1.96 0.69 0.20 
B-08: 500Bar Pack, 30oC 
mould T 
2.03 0.72 0.20 
B-09: 700Bar Pack, 30oC 
mould T 
2.00 0.75 0.20 
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Figure 5.37: Crystallisation kinetics of I33 moulded systems predicted by NIR 
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5.1.3.3 Dynamic Mechanical Analysis  
Dynamic mechanical analysis (DMA) can be used for the measurement of 
mechanical properties of a material as a function of temperature. Specifically, in 
DMA a variable sinusoidal stress is applied and the resultant sinusoidal strain is 
measured. In general, if the material being evaluated is purely elastic, the phase 
difference between the stress and strain sine wave is 0o i.e they are in phase, on 
the other hand, if the material is purely viscous the difference is 90o (Aitken et al., 
1991) (Menard, 2008) (Figure 5.38). However, most real world materials, 
including polymers are viscoelastic in nature and exhibit a phase difference 
between those extremes. This resultant phase difference, together with the 
amplitude of stress and strain waves can be used to obtain a variety of 
fundamental material properties including the storage and loss modulus, tan δ, 
complex and dynamic viscosity.  
 
Figure 5.38. Vicoelasticity and complex modulus  
In the case of the I33 moulded system DMA samples were analysed 
immediately after the moulding and also after the systems were kept at stress 
conditions. These showed significant changes in storage modulus and tan δ. 
Moulded bars analysed immediately after the moulding showed a single tan δ 
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around 58oC and a storage modulus of 11345 MPa. The storage modulus of the 
system has significantly fallen in the temperature region of 35 - 45oC. Fall in the 
storage modulus in the particular temperature range is indicative of glass 
transition. Tan δ is also sensitive to the molecular motion and correlated with the 
Tg of the systems (Menard, 2008).  Both the fall in storage modulus (E′) and 
increased height of tan δ were considered as the Tg of polymers or polymer 
composites, e.g. polypropylene (Li et al., 2002), polycarbonates polyethylene 
terephthalate, polyethersulphone (Price, 2002). I33 moulded systems showed a 
single tan δ when analysed immediately after moulding Figure 5.39. 
 
Figure 5.39: DMA of I33 injection moulded sample immediately after 
moulding  
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Figure 5.40: DMA of injection moulded sample after for 24hrs at RT 
However, DMA of the I33 sample stored for 24 hours at ambient conditions 
(RT) showed the presence of two tan δ peaks which suggests the phase 
immiscibility and the phase separation of the system (Figure 5.40) 
Moulded bars stored at stress conditions (40oC 75%RH and 25oC 
60%RH), showed the changes and shifts in tan δ associated with amorphous and 
crystalline phases. The first tan δ was attributed to the amorphous phase, 
whereas the second tan δ peak was attributed to melting of crystalllised ibuprofen 
at temperature around 76-78oC. Interestingly, the monitored tan δ peak for 40oC 
75%RH and for 25oC 60%RH samples showed a significant difference in height 
and position of tan δ peaks which could be clearly attributed to the rate of 
crystallization of the sample. Where, the 40oC 75% sample had approximately 
ten times higher crystallisation rate as compared to 25oC 60% (from MDSC and 
NIR results). The changes in tan δ at both the conditions are shown in Figure 
5.41. The prominent phase changes was observed at 40oC 75% condition where 
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the  first  tan δ peak  was gradually decreased from 45oC to 37oC whereas, slow 
crystallisation and the presence of major amorphous phase at 25oC 60% showed  
prominent first tan δ peak.  
  
Figure 5.41: DMA: Tan Delta of I33 from 1day to 7days at (a) 40oC 75%RH 
(b) RH 25oC 60%RH  
  In order to understand the effect of crytsallisation on the mechanical 
properties of moulded systems (B01-B09) the samples were analysed after 7 
days of exposure to the stress condition. The changes in storage modulus and 
45.67°C
76.88°C
37.29°C
0.4
0.5
0.6
0.7
0.8
0.9
T
a
n
 D
e
lt
a
10 20 30 40 50 60 70 80 90 100 110 120
Temperature (°C)
                  I33 40°C 75%RH 1day–––––––
                  I33 40°C 75%RH 2day–––––––
                  I33 40°C 75%RH 3day–––––––
                  I33 40°C 75%RH 4day–––––––
                  I33 40°C 75%RH 5day–––––––
                  I33 40°C 75%RH 6day–––––––
                  I33 40°C 75%RH 7day–––––––
Universal V4.5A TA Instruments
54.73°C
72.64°C
74.73°C
46.47°C
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
T
an
 D
el
ta
10 20 30 40 50 60 70 80 90 100 110 120
Temperature (°C)
                  I33 25°C 60%RH 1day–––––––
                  I33 25°C 60%RH 2day–––––––
                  I33 25°C 60%RH 3day–––––––
                  I33 25°C 60%RH 4day–––––––
                  I33 25°C 60%RH 5day–––––––
                   I33 25°C 60%RH 6day–––––––
                  I33 25°C 60%RH 7day–––––––
Universal V4.5A TA Instruments
(a) 
(b) 
 
 
191 
 
tan δ peaks were monitored to observe the effect of the physical aging process 
on the modulus and the molecular mobility of the moulded systems. The 
prominent effect of stress conditions was seen on tan δ. As observed using 
MDSC, on an average all batches were 20%, 8% and 2% crystallised at 40oC 
75%RH, 40oC 60% RH, 25oC 60% RH respectively, after 7 days of storage. Tan 
δ peak changes for the moulded samples are presented in the Figure 5.43. Table 
5.7 compares the storage modulus of the sample; immediately after moulding the 
sample was completely amorphous and there was no phase separation and the 
storage modulus was 11345 MPa. At 40oC 75% when the sample was 20% 
crystallised, storage modulus was decreased to 2000 MPa. These results 
suggest the adverse effect of the phase separation and crystallinity on the 
mechanical properties of the moulded systems.  
Table 5.7: Storage and Loss modulus of sample after 7 days of stability 
(B01) 
Stress condition 
(physical aging) 
Storage modulus 
(MPa) 
Tan Delta 
(tan δ) 
Before stability (0 day) 
RT 11345 55 
After storage (7 day) Peak 1 Peak 2 
40oC 75% 2000  78 
40oC 60% 3500 45.70 76.31 
25oC 75% 5000 47.41 74.21 
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Figure 5.42: Tan δ of of I33 moulded batches at 7 day of storage 
5.1.3.4 Shrinkage  
  In general, three types of shrinkage have been described in the injection 
moulding. Firstly, in-mould shrinkage occurs during processing; secondly, as-
mould shrinkage often referred to as “mould shrinkage” which occurs just after 
mould opening and thirdly, post-shrinkage. Post shrinkage phenomenon is time 
dependent shrinkage which is largely influenced by physical aging, 
recrystallisation etc (Jansen et al., 1998). Tensile shaped, moulded bar obtained 
using the 32 factorial designs are shown in the Figure 5.43. 
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Figure 5.43: Injection moulded I33 batches for stability and shrinkage  
I33 extruded and moulded bar (B-01-B-09) when kept at stress conditions 
showed a significant difference in shrinkage rate within 24hrs. Table 5.8 shows 
the comparative shrinkage from all I33 moulded batches and extruded bars. 
Extruded bar did not show any shrinkage even at extreme conditions. On the 
other hand, IM bars showed significant shrinkage at extreme conditions (40oC 
75%) where all bars showed approximately 1 cm shrinkage and relatively less 
shrinkage was observed at 25oC 60% (0.25 cm) and RT conditions (0.15 cm). 
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Table 5.8: Shrinkage from extruded and injection moulded systems 
Batches 
Original 
length 
(cm) 
Length (cm) 
After 24hrs/1Day 
40oC 75% 40oC 60% 25oC 60% 
RT 
(Ambient) 
Extruded 
bar 
4.06 4.01 4.02 4.01 4.05 
B-01 4.00 2.86 2.98 3.75 3.81 
B-02 4.00 2.96 2.99 3.77 3.82 
B-03 4.00 3.10 3.03 3.82 3.85 
B-04 4.00 2.99 3.00 3.79 3.82 
B-05 4.00 3.01 2.91 3.79 3.88 
B-06 4.00 3.08 3.11 3.80 3.85 
B-07 4.00 2.87 3.01 3.80 3.65 
B-08 4.00 3.03 3.03 3.75 3.81 
B-09 4.00 3.03 3.08 3.81 3.88 
 
  Batches B-03, B-06, B-09 packed at high packing pressures (700 bar) 
showed relatively less shrinkage compared to the other batches which were 
packed at low packing pressures this confirms the effect of packing pressure on 
the retardation of shrinkage rate. The effect of packing pressure on the shrinkage 
was previously reported for seven thermoplastic polymers and the key parameter 
for controlling the shrinkage was observed to be packing pressure (Jansen et al., 
1998). Extruded systems containing the same concentration of ibuprofen did not 
does not show any shrinkage although the rate of crystallisation was similar. This 
confirms that plasticisation and/or recrystallisation of ibuprofen does not have a 
significant effect on shrinkage. However, the processing method used for the 
manufacturing of the systems does have major effect on the shrinkage. Figure 
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5.44 illustrate the difference in the shrinkage between the extruded and the IM 
system. 
 
Figure 5.44: Comparative shrinkage of extruded and moulded system after 
14days of storage 
5.1.3.4.1 Surface area  
  Surface area of the moulded batches was calculated after the 1st day of 
moulding and exposure to the the stress conditions. As mentioned earlier, the  
batches kept at extreme stress temperatures (40oC) showed high shrinkage 
rates, and changes were mostly associated with the length of a bar.  The 
prominent change in surface area was seen after 24 hours of storage and higher 
surface area was seen in the bar kept at 25oC 60%RH compared to 40oC 75% 
and 40oC 60%RH due to a lower shrinkage of the system. Shrinkage rate was 
directly proportional to the storage temperature, which also has a major influence 
on the surface area of the mould (Figure 5.45) 
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Figure 5.45: Surface area of moulded systems analysed after 1 day of 
storage 
 
  The % length shrinkage ratio of moulded bars was calculated using the 
following formula (Fei et al., 2013) 
𝑹𝑺(%) =
𝑺𝒐−𝑺𝒑
𝑺𝒐
 𝑿 𝟏𝟎𝟎         (Equation  5.3) 
  Where, So is length of I33 moulded parts before exposure to stress 
conditions. Sp is length of I33 moulded parts at stress condition after specific time.  
  Figure 5.46 shows the % length shrinkage ratio plotted against time for the 
period of 6 months. After 24hrs, approximately 28%, 25% and 3.5% shrinkage at 
40oC 75%, 40oC 60%RH and 25oC 60%RH respectively, was observed  and 
thereafter only 8-10% change in the shrinkage was seen at all stress conditions 
(Figure 5.46b). 
 
 
197 
 
 
Figure 5.46:  Ibuprofen-HPMCAS (I33) shrinkage at different stability 
conditions:  (a) length (b) % length shrinkage ratio 
  The difference in shrinkage rate could be linked to glass transition 
temperature where higher temperature and humidity conditions favoured the 
decrease in Tg  of the system and hence allowed polymer chain relaxation at a 
different rate leading to higher shrinkage at extreme conditions (40oC 75%RH).  
The shrinkage after 6 months for full length and 4 cm bar is shown in the Figure 
5.47 
(a) 
(b) 
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Figure 5.47: I33 mould shrinkage after 180 days of stability  
  The physical appearance of the moulded bars was seen different due to 
different % surface crystallisatinity. Moulded bar immediately after moulding were 
transparent in nature, however, due to phase separation and crystallisation the 
opacity of the bar increased at extreme stress conditions.  
  When thermoplastics are processed by IM, the dimensions of moulded 
parts, change as the material cools, these changes are often called as shrinkage 
or warpage and can be used to predict the appropriate mould geometry (Fischer, 
2003). Although shrinkage is based on thermal contractions, there are other 
mechanisms which might be responsible for the dimensional changes after 
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demoulding (e.g. Inherent stresses, crysallisation, mechanical constrainst) 
(Zema et al., 2012). When HPMCAS was processed by IM using PEG1500 as a 
plasticiser to form the capsular shells the disk showed a similar tendency of 
shrinkage. The moulded disks thickness changed due to shrinkage and no 
significant effect of the amount of the plasticiser was observed. This indicates a 
shrinkage tendency of HPMCAS after IM.  
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5.1.3.5 Surface response methodology  
The data obtained from the studies described in the earlier sections were 
compiled in Table 5.9 and was processed to obtain the surface response curves. 
The crystallisation and surface area data were analysed  using multiple 
regression analysis and ANOVA.  
5.1.3.5.1 Multiple regression analysis  
The application of the statistical model analysis of variance (ANOVA) for 
processing of data provided information about the statistical significance of the 
results. ANOVA was applied for all the timepoints and regression coefficients 
were calculated and used when the P-value was significant (< 0.05). Non-
significant variables were eliminated using the backward elimination method. The 
multiple regression equation used is mentioned  below (Equation 5.4) 
𝐲 = 𝛃𝟎  + 𝛃𝟏 𝚾𝟏 + 𝛃𝟐 𝚾𝟐 + 𝛃𝟏𝟏 𝚾𝟏
𝟐 + 𝛃𝟐𝟐 𝚾𝟐
𝟐 + 𝛃𝟏𝟐 𝚾𝟏 𝚾𝟐            (Equation  5.4) 
The process variables used for injection moulding have shown the 
significant effect on crystallisation and shrinkage under stress conditions. 
Crystallisation and shrinkage data is provided in Table 5.9.
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Table 5.9: Crystallisation and surface area data at 40oC 75% and 40oC 60% 25 oC 60%RH stress conditions 
Batch 
name 
 
Process 
Variable
s 
% Crystallisation 
(MDSC) 
% Crystallisation (NIR) 
Surface Area (cm2) 
DMA 
40oC  
75% 
40oC 60% 
40oC 
 75% 
40oC 60% 25oC 
60% 
40oC 
75% 
40oC 60% 
25oC  
60% 
25oC 
60% 
*X1 
*X
2 
*C14 *C14 *C21 *C14 *C14 *C21 *C21 *SA14 *SA14 *SA21 *SA21 *tanδ7 
B-01 300 10 23.56 11.06 19.90 22.12 9.67 12.18 4.20 5.170 5.21 5.20 
5.45 
 
72.29 
 
B-02 500 10 21.79 11.15 23.71 21.5 9.21 12.83 4.20 5.184 5.24 5.21 
5.49 
 
73.37 
 
B-03 700 10 20.85 11.09 29.27 23.91 9.92 12.01 4.20 5.226 5.26 5.25 
5.53 
 
74.18 
 
B-04 300 20 25.83 13.57 21.30 24.74 9.89 12.68 4.21 5.165 5.20 5.21 
5.49 
 
72.5 
 
B-05 500 20 22.44 15.06 27.00 27.48 10.56 13.44 4.01 5.203 5.25 5.20 
5.54 
 
72.72 
 
B-06 700 20 23.24 14.43 28.45 26.54 10.27 13.12 4.67 5.224 5.28 5.20 
5.58 
 
73.7 
 
B-07 300 30 23.89 19.41 26.89 27.59 12.26 13.38 4.98 5.280 5.30 5.20 
5.57 
 
73.53 
 
B-08 500 30 22.83 20.57 27.50 29.92 13.57 13.87 5,01 5.320 5.32 5.25 
5.57 
 
74.4 
 
B-09 700 30 24.90 21.09 27.37 29.86 12.4 14.88 5.06 5.327 5.34 5.31 
5.64 
 
74.24 
 
*X1, X2 represents packing pressure and mould temperature; C14, C21, represents the crystallisation at 14 and 21 
days SA14, SA21, represents the surface area at 14 and 21 days; tanδ7 represents position of tan δ peak at 7 days 
at temperature 
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Table 5.10: Regression statistics and ANOVA table 
Regression 
coefficient 
% Crystallisation (DSC) % Crystallisation (NIR) Surface Area (cm2) DMA 
40oC  
75% 
40oC 60% 
25o
C 
60% 
40oC 
 75% 
40oC 60% 25oC 
60% 
40oC 
75% 
40oC 60% 
25oC  
60% 
25oC 
60% 
*C14 *C14 *C21 *C21 *C14 *C14 *C21 *C21 *SA14 *SA14 *SA21 *SA21 *tanδ7 
βo 
32.316 14.68 25.94 6.92 26.59 10.49 13.30 4.18 5.200 5.253 5.222 5.535 73.03 
β1 ** 0.428 2.830 ** ** ** ** ** 0.027 0.023 0.030 0.041 0.633 
β2 5.218 4.628 * 1.17 3.306 1.571 0.851 0.741 0.057 0.042 0.023 0.051 0.388 
β11 ** ** ** ** ** ** ** ** ** ** 0.024 ** ** 
β22 3.415 1.375 ** ** ** ** ** 0.648 0.054 0.023 0.008 ** 0.695 
β12 ** 0 -2.22 ** ** ** ** ** ** ** 0.005 ** ** 
Significance 
F 
0.002 0.00 0.037 0.23 0.042 0.050 0.049 0.023 0.004 0.002 0.00 0.031 0.0421 
R2 0.993 0.997 0.945 0.80 0.971 0.937 0.937 0.962 0.988 0.992 0.998 0.977 0.944 
*X1, X2 represents packing pressure and mould temperature; C14, C21, represents the crystallisation at 14 and 21 
days SA14, SA21, represents the surface area at 14 and 21 days; tanδ7 represents position of tan δ peak at 7 days 
at temperature ; ** insignificant 
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The multiple regression equation was used to plot surface response 
curves where the significant parameters were selected based on regression 
statistics. The statistical data and ANOVA table is provided in the Table 5.10. The 
equation 5.5 was further modified based on the results obtained after regression 
analysis. For example, based on the regression analysis of % crystallisation data 
at 40oC 75%RH condition after 14 days showed that  the factor X1 and X22 were 
found to be statistically significant and the following equation was used to plot the 
surface response curve (equation 5.5)   
𝒚 = 𝜷𝟎  + 𝜷𝟐 𝚾𝟐 + 𝜷𝟐𝟐 𝚾𝟐
𝟐       (Equation  5.5) 
Where βo, β2, β22 are the regression coefficients, X1, X2 are the process 
variables i.e packing pressure,mould temperature respectively.  
Similarly, all of the data mentioned in the Table 5.10 was processed and 
significant varibles were identified and used to generate the regression equation. 
The equations obtained was used to plot surface response curves. 
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For the batches kept at 40oC 75%RH, the surface response curve 
suggested that there is a more significant effect of the mould temperature used 
for the part cooling during processing on % crystallisation compared to the mould 
packing pressures.  
 
 
Figure 5.48 : Surface response curve for 40oC 75%RH 14 days (a) surface 
area (b) %crystallisation 
(a) 
(b) 
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 The surface response curve (Figure 5.48 a) also showed the higher surface 
area at the high packing pressures and mould temperatures. Hence, the 
influential parameter for the surface crystallisation of the ibuprofen was the mould 
temperature and the higher the mould temperature the faster was the rate of the 
crystallisation at 40oC 75%RH. This confirmed that the cooling rate of the 
moulded part and high plasticisation effect due to moisture caused the faster 
crystallisation of  batches stored at 40oC 75%RH and relatively less effect on the  
surface area and shrinkage.  
For the 40oC 60%RH stress conditions, surface area and % crystallisation 
response curves also suggested similar behaviour as at 40oC 75%RH. However 
the rate of crystallisation and shrinkage was slower compared to 40oC 75%RH 
confirming the role of moisture on the crystallisation process where higher 
moisture favoured the crystallisation. Mould packing pressures also showed an 
effect on shrinkage and effective surface area. At higher packing pressure, the 
higher surface area of the moulded bar was observed, suggesting that packing 
pressure has an influential effect on shrinkage (Figure 5.49). Interestingly, 
batches packed at high pack pressure and high mould temperature (30oC) 
exhibited a higher surface area which therefore provided greater area for surface 
crysallisation to occur under stress conditions. Similar response curves were also 
obtained for the NIR % crystallisation data (provided in Appendix I). 
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Figure 5.49: Surface response curve for 40oC 60%RH 14 and 21day (a, c) 
surface area; (b, d) %crystallisation 
 
 
 
 
 
 
Figure 5.50: Surface response curve for tan δ temperature 
 (a) 
 
(b) 
 
(c) 
 
(d) 
 
Surface area % Crystallisation 
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The surface response curve of moulded samples obtained using DMA 
testing (second tan δ peak ) suggested some correlation of the mould 
temperature and packing pressure with the temperature at which the tan δ peak 
was observed. At low packing pressures and low mould temperatures the tan δ 
peak was observed at lower temperature and increased at higher pack pressures 
and mould temperature (Figure 5.50). The position of tan δ peak temperature 
could be correlated with the melting point depression in the solid dispersion 
where a higher melting depression suggests the better interaction and miscibility 
between drug and polymer. 
 To summarise the discussion of crystallisation, at stress conditions, it was 
found that the surface response curve correlated with the surface area available 
for crystallisation. It was observed that as extreme stress conditions (40oC 
75%RH) crystallisation was predominantly  affected by the mould temperature 
and relatively less affected by packing pressure and shrinkage. On the other 
hand, at moderate stress condition (40oC 60%RH) the pack pressure, mould 
temperature combined to affect the surface area and thus influenced 
crystallisation.  
 To understand the morphology, crystal habits and surface crystallisation 
of ibuprofen; SEM, 3D laser microscopy and 2D Xray diffraction techniques were 
used. The results of these characterisation techniques are discussed in the 
foloowing sections.  
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5.1.3.6 SEM and 3D laser microscopy: Surface crystal orientation and 
roughness 
 The surface properties of I33 moulded bars were analysed at different 
positions. The representative positions of scanning are presented in the Figure 
5.51. The scanning points were equidistant and distance between the points was 
0.8 cm. 
 
Figure 5.51: I33 mould and 3D laser scanning area 
 The scanning positions on the bar were chosen to observe the crystal 
habits and surface crystal orientation. The particular interest was to progressively 
monitor the crystal length, size, and the diameter after exposure to different stress 
conditions. The 2D Xrd results (provided in the later section) have shown the 
change in the relative intensity of 2θ peaks at various regions on the bar. 
Moreover the specific Xrd pattern was observed at specific stress conditions. 
Surface scanning of samples was performed at intervals of 24 hrs for 7 days. The 
 
 
209 
 
stress conditions i.e 40oC 75%RH, 25oC 60%RH and RT have shown the 
preferred orientation of crystals on the surface at different conditions (Figure 
5.52). Moreover, from the point A1 (this is first point from mould filling side) to A5 
different crystal habits of ibuprofen were observed on the surface.  
 
Figure 5.52: Crystal habit of ibuprofen on I33 moulded bar surface at A1 
and A5 when exposed to 40oC 75%RH 25oC 60%RH and RT after 1day of 
exposure  
100µm
m 
100µm 
100µm 100µm
100µm 100µm
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 The different regions on the moulded bar have promoted the different 
orientation of the crystals on the surface. Figure 5.52 shows that, at 40oC 75%RH 
(point A1, 1day) larger rectangular crystals while, at the same time 25oC 60% RH 
bar showed small rectangular crystals and at RT smaller (needle shaped) 
crystals. Interestingly, the A5 position (middle region) of the bar showed different 
crystal habit with small in size with marked shrinkage marks. This indicates that 
different crystal habits were present on the different surface regions of the 
moulded bar. Especially, after A3 region (necking region) the smaller crystals with 
a distinct habit were observed at all the conditions (Figure 5.53).  
  
  (A)           (B) 
Figure 5.53: A3: Crystal habits after 7 days (A) 40oC 75%RH(B) 25o C 60%RH
  
 The surface roughness of the representative moulded bars was calculated 
based on height parameters at evaluation area of 646 X 646 µm. The roughness 
of the surface was found to be depending on the surface crystal habit. 
100µm
m 
100µm
m 
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Figure 5.54: Line profiling of I33 moulded systems of the surface before and 
after storage 
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 The line profiling of scanned 3D surfaces are presented in the Figure 5.54. 
The red line pattern shows the surface height in µm. A variation was seen at 25oC 
60% and RT samples compared to surface scan of sample analysed immediately 
after moulding these differences could be attributed to the surface crystals of the 
ibuprofen.  The representative 3D scan of 25oC 60%RH sample (A5 region) after 
7days has shown in the Figure 5.55 and the wave-like patterns were observed 
due to shrinkage of the mould.    
 
Figure 5.55: 3D Surface image of 25oC 60% A5 region after 7day 
 The surface roughness values after the 1st and 7th days of exposure to the 
storage conditions at different region on the bar are presented in the Figure 5.56. 
In general, higher surface roughness was observed at 40oC 75%RH condition 
where crystal growth on the surface and shrinkage rate was faster than the other 
conditions.  Higher roughness values were observed on the 7th day as compared 
to 1st mainly due to the % crystallised ibuprofen on the surface. Moreover, from 
A3 downstream region higher shrinkage values were observed due to marked 
µm µm 
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shrinkage as shown in the Figure 5.55. The surface after moulding showed 0.25 
µm surface roughness and after 24 hrs of exposure the roughness was increased 
to 3.1, 1.8, 1.3 µm at 40oC 75%RH, 25oC 60%RH, RT respectively (Figure 5.56). 
The least roughness was seen at RT due to small crystal size, crystal habit and 
less shrinkage.   
 
Figure 5.56: Surface roughness moulded bar at different region 
 Crystals at the A1 and A5 position were prominently different in their size 
and shape. Average crystal size for the 40oC 75%RH condition seen was 40 µm 
at A1 and 12 µm at A5 positions; which were doubled in size compared to those 
of RT (Table 5.11). 
Table 5.11: Crystal size of ibuprofen on the surface after 7days of storage 
(n=3) 
Stress Condition  Average Crystal size (µm) 
A1 A5 
40oC 75%RH 40.02 ± 0.5 12.2 ± 0.7  
25oC 60%RH 25.01 ± 0.4 10.4 ± 0.7 
RT 20.04 ± 0.6 8.78 ± 0.6 
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 Ibuprofen was crystallised using organic solvents such as methanol, 
ethanol, isopropanol, hexane have shown different crystal habits such as 
polyhedral, elongated, needle etc (Garekani et al., 2001). The marked difference 
in crystal habits of ibuprofen was obtained due to the different solvent properties. 
In the I33 moulded systems the predominant effect of the humidity and 
temperature was observed, however the different regions of the bars at same 
stress conditions shown different crystal habit suggesting effect of the IM process 
and shrinkage on the surface crystallisation and crystal habit. 
 
5.1.3.7 X-ray Diffraction 
  The crystalline nature of the pure ibuprofen was confirmed by XRD and it 
shows characteristic crystalline peaks at 2θ positions (6.09, 12.18, 16.78). The 
amorphous nature of HPMCAS was confirmed by the absence of crystalline 
peaks (Figure 5.57). Surface scanning of the moulded bars exposed to different 
stress conditions exhibited the preferred orientation of crystals. Moreover, 
changes in the relative intensity of XRD peaks were attributed to crystal habit and 
orientation. The 2D XRD pattern of moulded bars exposed to 40oC 75%RH and 
RT are shown in Figure 5.58.  
 
 
215 
 
 
Figure 5.57: XRD pattern of pure ibuprofen and HPMCAS 
40oC75%RH 
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RT 
Figure 5.58: XRD patterns of the surfaces of I33 moulded bar exposed to 
40oC 75%RH and RT  
 
 Prominent peaks at 40oC 75%RH were 20, 22.32 and 24.76 
whereas for RT samples 6.0, 14.70, 19 peaks were more dominant. The relative 
changes in the XRD patterns attributed to the crystal habits of ibuprofen. Pure 
ibuprofen (used for this study) shows the rectangular crystals with the average 
crystal size of approximately 150µm (ibuprofen in the physical mix). Figure 5.59 
shows the SEM images of different crystal habits of the ibuprofen on the surface 
at different stress conditions resembles to the some of the reported crystals 
habits of ibuprofen obtained using the solution crystallisation as mentioned 
earlier. The relative peak intensity changes in 2D XRD presented merely due to 
the different crystal habits on the surface of the moulded bar.  
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Figure 5.59: SEM of ibuprofen-HPMCAS physical mix and surface 
crystallised ibuprofen at different storage condition  
5.1.3.7.1 Depth profiling 
Depth profiling of injection moulded bars showed that sample stored at 
40oC 75 %RH and 40oC 60%RH were crystallised throughout the cross-section 
of the sample. XRD patterns of the 40oC 75%RH samples analysed from top to 
the bottom and from right to left has shown in the Figure 5.60. XRD pattern 
provides a clear understanding of the re-crystallisation of amorphous ibuprofen 
on the surface as well as in the middle of the sample at extreme stress conditions.  
 
 
218 
 
Interestingly, the XRD patterns of 25oC 60%RH samples have given more 
insight on the surface crystallisation phenomenon.  It was seen that the surface 
of the sample was crystallised but middle (core) of the system was still in an 
amorphous state. The absence of crystalline peaks of ibuprofen shows the 
ibuprofen-HPMCAS amorphous dispersion stable in middle of the bars even after 
1 year at 25oC 60% (Figure 5.61).  
 
Figure 5.60: Depth profiling of I33 moulded bar after 1 year of storage bar 
at  40oC 75% RH  
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Figure 5.61: Depth profiling of I33 moulded bar after 1 year of storage bar 
at 25oC 60%RH  
5.1.3.7.2 Calculation of degree of crystallinity 
 The XRD peaks obtained after analysis of physical mixture were used to 
calculate crystalline index of physical mixture (Figure 5.62). The crystalline index 
was calculated using following formula   
𝐂𝐫𝐲𝐬𝐭𝐚𝐥𝐥𝐢𝐧𝐞 𝐢𝐧𝐝𝐞𝐱 =  
𝐈𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲 𝐨𝐟 𝐜𝐫𝐲𝐬𝐭𝐚𝐥𝐥𝐢𝐧𝐞 𝐩𝐞𝐚𝐤 𝐚𝐭 𝟐𝛉 𝐩𝐞𝐚𝐤  
𝐃𝐢𝐟𝐟𝐫𝐚𝐜𝐭𝐞𝐝 𝐢𝐧𝐭𝐞𝐧𝐬𝐢𝐭𝐲 
             (Equation  5.6) 
 
 
Figure 5.62: Crystalline index of I33 physical mixture 
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Depth profiling of 25oC 60%RH samples from the top crystalline surface 
region to the core of the system until it reaches the amorphous region provided 
good XRD patterns where the relative peak intensity decreased as it was 
progressing from the top surface to the middle of the system (Figure 5.63).  
 
Figure 5.63: Depth profiling of I33 moulded bar  25oC 60%RH in crystalline 
region of ibuprofen  
The crystalline index of the sample decreased from its top surface to the 
core which shows that the crystallinity was decreased across the sample (Figure 
5.64). 
 
Figure 5.64: Crystalline index of I33 of moulded bar at 25oC 60%RH  
 
 
221 
 
The scanning area from T1 (top) to T8 (middle) was representative of the 
crystalline region and the distance between the each point was 0.085 mm (85 
µm). Percentage crystallisation was calculated using the crystalline index of the 
sample and the crystalline index of reference. Table 5.12 shows that the topmost 
region (T1) of the moulded bar was crystallised approximately to 83% and the % 
crystallinity decreased to 6.9% at point T8. After this point the sample has shown 
the absence of any crystalline peaks indicating that an amorphous core was 
present. The depth profiling studies using 2D XRD complement the Raman data 
which show the samples are only crystallized onto the surface and middle portion 
was still in this amorphous phase. Hence, the phenomenon was a predominantly 
surface crystallization however, at extreme condition due to higher crystallization 
rate (2%/day), crystallinity was observed in the core. 
Table 5.12: % Crystallisation of ibuprofen I33 bar of 25 oC 60%RH  
Scanning 
area  
Crystalline 
index of 
sample  
Crystalline 
index of ref  
CI of 
sample/CI of 
ref  
% 
Crystallisation  
T1  0.52  0.62  0.83  83.87  
T2  0.43  0.62  0.69  69.35  
T3  0.40  0.62  0.64  64.51  
T4  0.35  0.62  0.56  56.45  
T5  0.27  0.62  0.43  43.54  
T7  0.24  0.62  0.38  38.70  
T6  0.2  0.62  0.32  32.25  
T8  0.043  0.62  0.069  06.93  
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  The key findings of studies on the ibuprofen-HPMCAS moulded system 
where the firstly, phase separation; secondly, shrinkage; and thirdly surface 
crystallization. The phase separation at 33% drug loading was observed due to 
immiscibility of the two components at storage conditions. The system was 
completely miscible at processing conditions, however showed the immediate 
phase separation at stress conditions. Low Tg (38oC) of I33 extruded and IM 
systems decreased its stability as the higher glass transition temperature could 
have favoured amorphous phase stability. The rate of crystallisation was higher 
at extreme stress conditions; temperature and moisture played a significant the 
role in the crystallisation. The relationship between the crystallization and 
shrinkage was expected, however, no direct relationship was observed as the 
extruded systems crystallised at the same rate as that of moulded systems but it 
didn’t show any sign of shrinkage. IM process variables showed an influential 
effect on the crystallisation where the effect of mould temperature was 
predominant.  
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5.2 Felodipine-PEO-HPMCAS (FDH) IM systems  
Felodipine is a calcium channel blocker used in the treatment of 
hypertension. The daily dose of felodipine is 10 mg and being a BCS class II drug 
it has limited solubility and high permeability. Felodioine has high Tg (45oC) and 
high melting point (145oC) compared to ibuprofen (Figure 5.65). 33%w/w loading 
of felodipine in HPMCAS was achieved using HME however, IM was challenging 
due to melt flow of the system. The objective was to achieve a 10%w/w dispersion 
of felodipine in HPMCAS however; due to the high Tg of the mixture it becomes 
the necessary to add a plasticiser to the system. The final batch composition was 
the felodipine-PEON750-HPMCAS [FDH(10:20:70)] 
5.2.1 Processability via HME and IM  
 The reversing heat flow curve of MDSC of physical mixture of FDH shows 
the melting point of semi-crystalline PEO at 66 oC, Tg of amorphous HPMCAS at 
120oC±0.23 and melting point of felodipine at 145±0.22oC (Figure 5.66).  
  
Figure 5.65: Heat cool heat DSC thermogram of pure felodipine (sample 
heating rate was 10oC/min and cooling rate 20oC/min) 
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Figure 5.66: DSC thermogram of FDH physical mixture (modulated heating 
rate of 5oC/min) 
HME of PEO-HPMCAS (20% PEO-HPMCAS) and FDH systems was 
carried out at 140oC. Details of the HME processing parameters were mentioned 
previously in chapter (table 3.12).  PEON750-HPMCAS physical mixtures were 
initially processed to observe the miscibility of the polymer blends. Due to the 
very low Tg (-52oC) and melting at 66oC PEO acts as a good plasticiser for 
HPMCAS. The addition of 10%w/w felodipine further improves the processing; 
both torque and die pressures decreased indicating good mixing of drug with the 
PEO-HPMCAS mixture. Table 5.13 shows torque and die pressure during HME.  
Table 5.13: Torque and die pressure associated with extrusion process  
PEO-HPMCAS 
Felodipine-PEON750-
HPMCAS (FDH) 
Die 
pressure(bar) 
Torque (%) 
Motor 
power (kW) 
Die 
pressure 
(bar) 
Torqu
e (%) 
Motor 
power 
(kW) 
35 35-40 0.88 -1.0 30 31-35 0.78-0.88 
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Figure 5.67: melt extruded strand of FDH system at the end of extrusion 
barrel (die) and product obtained after pelletisation 
Approximately 2 mm diameter melt extruded pellets were obtained after 
cutting the extruded strand using a pelletiser (Figure 5.67). Pellets were used to 
produce the IM bar and IM tablets. At 140oC, the melt viscosity of the system was 
optimum to get sufficient melt flow inside the runner system to achieve mould 
filling. For initial trials of moulded tablets, mould filling was achieved with injection 
velocity and shot size was increased from 10 mm to 14 mm.         Figure 5.68 
depicts short-shots of FDH tablets. When the mould cavity was approximately 
95% filled, a packing pressure was applied to ensure 100% filling of the mould 
cavity. Packing pressure has significant effect on the filling of the mould cavity. 
Optimum quality parts were obtained when 900 bar of packing pressure was 
applied whereas in the case of I33 systems the optimum quality parts were made 
at 300 bar. To mould tensile bars a shot size of 23 mm was used. 
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Figure 5.68: (a) short shots of FDH tablets (b) FDH moulded bar and IM 
tablets  
5.2.2 Characterisation 
Melt extruded pellets and injection moulded components were 
characterised to understand the nature of felodipine dispersion and the drug 
release behaviour of the melt processed system.  
(a) 
(b) 
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5.2.2.1 Thermal behaviour (MDSC) 
Thermal analysis of melt extruded pellets and IM tablets using MDSC 
confirmed the absence of melting endotherm of the felodipine and the system 
exhibited a single Tg at 54.4±0.23oC (Figure 5.69) . Theoretically predicted Tg for 
FDH components using the Fox equation was 60.27oC which is closer to the 
practically estimated value. The single Tg of the system confirmed the formation 
of an amorphous molecular dispersion i.e solid solution (Caron et al., 2013). The 
Tg of the FDH systems was well separated on reversing heat flow curve of 
MDSC.  
  
Figure 5.69: MDSC of FDH melt extruded pellets and IM tablet (modulated 
heating rate of 5oC/min) 
It is known that the amorphous form is highly disordered and has a high-
energy, therefore it is often associated with the risk of drug recrystallisation 
(Hancock and Zograf, 1997). The FDH system kept at stress conditions to 
observe the stability of the amorphous form in solid dispersion. At various stress 
conditions, the system has not shown any sign of re-crystallisation confirming the 
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good stability of FDH systems. The reversing heat flow curves for the sample 
kept at 40oC 75%RH and 25oC 60%RH (Figure 5.70 and Figure 5.71) did not 
show a significant change in the thermal behaviour of the system. Neither was 
there a change in the Tg of the system nor any sign of phase separation due to 
stress conditions, suggesting that the system had both good miscibility and 
stability.  
 
Figure 5.70: Reversing heat flow of FDH IM moulded bar kept at 40oC 
75%RH (modulated heating rate of 5oC/min) 
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Figure 5.71: Reversing heat flow of FDH IM moulded bar kept at 25oC 
60%RH (modulated heating rate of 5oC/min) 
5.2.2.2 DMA 
The dynamic mechanical behaviour of moulded bars was analysed using 
dual-cantilever mode DMA. PEO-HPMCAS moulded bars at 25oC exhibited a 
storage modulus of 52,743 MPa whereas the temperature near to the Tg (62oC) 
modulus decreased to 22,572 MPa. A drastic fall in storage modulus indicates 
the Tg of the system. Similarly, FDH moulded bars showed a fall in storage 
modulus at a temperature around 55oC (Figure 5.72). The comparative properties 
such as storage modulus, tan δ, and stiffness at 25oC and temperatures near Tg 
of the system are mentioned in Table 5.14. The comparison provided in the Table 
5.14 suggested that the mechanical properties of the moulded bars (modulus and 
stiffness) decreased significantly near the Tg because of the higher molecular 
mobility and approximately half reduction in the modulus was observed. 
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Figure 5.72: DMA of (a) PEO_HOMCAS and (b) felodipine-PEO-HPMCAS 
moulded  bars 
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Table 5.14: Mechanical properties of injection moulded bars  
Materials 
Temperature 
(oC) 
Storage 
Modulus 
(Mpa) 
Loss 
Modulus 
(Mpa) 
Tan 
Delta 
Stiffness 
(N/m) 
PEO-HPMCAS 
25.08 52743 4329 0.08 755975 
62.31 22572 5298 0.23 323537 
FDH 
 
25.025 49446 7780 0.15 708718 
54.16 18132 5805 0.32 259898 
33% Ibuprofen – 
HPMCAS (I33) 
25.0 11345 4979 0.43 199456 
37.06 4825 3067 0.63 84826 
 
The decrease in mechanical strength can be attributed to the higher 
molecular mobility at glass transition temperature which can be also explained by 
an increment in tan δ. Karavas et al. reported  DMA studies on the felodipine 
nano-dispersions with PVP. The authors observed the two tan δ peaks; the first 
tan δ peak around 52 oC was attributed to the Tg of felodipine while the second 
tan δ peak at 165 oC was attributed to Tg of PVP. The presence of two tan δ 
peaks were considered as indication of incomplete miscibility of felodipine with 
PVP in other words, the system formed a single matrix but remained as a 
separate finely dispersed phases (Karavas et al., 2006). In the case of FDH 
systems the presence of a single tan δ confirms the complete miscibility of the 
system. FDH moulded system contains the 70%w/w of HPMCAS and 67% w/w 
of HPMCAS in the case of I33 moulded systems. However, it can seen that I33 
systems have shown the least storage modulus as compared to FDH and PEO-
HPMCAS systems where, the storage modulus exhibited by FDH systems was 
approximately 3.5 times higher than the I33 systems. This confirms the 
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plasticisation effect ibuprofen has decreased the mechanical strength of the 
moulded systems. 
5.2.2.3 FTIR: 
FTIR spectroscopy was used to investigate the intermolecular hydrogen 
bonding (H-bond) between the felodipine and the polymer in the solid dispersion. 
Felodipine has an –N-H functional group which is capable for forming H-bonds. 
Previous studies on felodipine have shown that the position of the –N-H peak is 
sensitive to the strength of H-bond formed (Tang et al., 2002). In the crystalline 
felodipine, a –N-H group is weakly bonded to the carbonyl function(-C=O) of 
another drug molecule i.e intermolecular H-bonding between two felodipine 
molecules (Fossheim, 1986). FTIR studies on felodipine have also shown that in 
the case of an amorphous felodipine, the H-bonding also occurs between the -N-
H group and the carbonyl functional group, but average H-bonding in the 
amorphous phase are stronger than in the crystalline felodipine (Tang et al., 
2002). Hence both - C=O and –N-H groups of the spectrum can be used to 
understand the H-bonding between the felodipine and the polymer. 
 Tang et al. have studied the hydrogen bonding pattern in crystalline and 
amorphous phases of the dihydropyridine series of the calcium channel blockers 
(felodipine, nimodipine, nifedipine nitrendipine etc). Crystalline and amorphous 
felodipine exhibit different spectra the –N-H stretch of crystalline felodipine 
observed at 3373 cm-1 and which was shifted by around 33cm-1 to a lower wave-
number (3341cm-1) in case of amorphous felodipine (Tang et al., 2002). 
Simultaneously, the -C=O stretching seen in crystalline sample at 1696 cm-1 splits 
into two peaks at 1701 cm-1 and 1682 cm-1 assigned to non-hydrogen bonded 
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and hydrogen bonded carbonyl, respectively. Figure 5.73 shows the FTIR spectra 
of the pure crystalline felodipine and the felodipine in physical mixture. This 
showed -C=O stretching at 1688 cm-1 and a small shoulder peak at 1698 cm-1 
attributed to hydrogen and non hydrogen bonded peaks of felodipine, 
respectively. In the case of FDH extruded and injection moulded systems the 
height of the 1698cm-1 non-hydrogen bonded carbonyl peak increases relative to 
the hydrogen bonded peak at 1688cm-1. 
 
Figure 5.73:  -C=O stretching of FDH systems  
This increase in the relative intensity  of the non-hydrogen bonded –C=O 
stretching peaks of the felodipine suggest an interaction between the two 
felodipine molecules was disturbed by a new interaction formed between the –N-
H groups of felodipine and –C=O group in HPMCAS  
Figure 5.74) (Konno and Taylor, 2006). The -NH stretching of FDH extruded and 
moulded systems showed weak signals but a decrease in the wavenumber by 26 
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cm-1 confirmed the formation of H-bond with the HPMCAS ((Konno and Taylor, 
2006). 
 
Figure 5.74: N-H stretching of FDH systems 
5.2.2.4 Raman spectroscopy 
The Raman peak of carbonyl stretching (–C=O) of crystalline felodipine in 
the physical mixture was observed at 1702 cm-1 and shifted to 1700 cm-1 in the 
case of FDH extruded pellets and moulded tablets. The opposite shift was 
observed at –C=C aryl stretching, where peaks shifts from 1643 cm-1 (physical 
mix) to 1649 cm-1 for extruded and moulded samples (Figure 5.75). The Raman 
spectrum of the pure crystalline and amorphous forms of felodipine have shown 
similar changes in the carbonyl and aryl –C=C stretching’s (Tang et al., 2002). 
This shift in the Raman band confirms the formation of amorphous solid 
dispersion of felodipine in HPMCAS.  
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Figure 5.75: Raman spectra of (a) felodipine, PEO N750 FDH physical 
mixture and (b) processed samples 
 
 
(a) 
(b) 
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5.2.2.5 Shrinkage 
The PEO-HPMCAS and FDH moulded bars kept at stress conditions have 
shown the different rate of shrinkage and the prominent effect of both the 
composition of moulded system and effect of the stress conditions was observed. 
PEO-HPMCAS systems containing PEO-HPMCAS (20:80 %w/w) showed 
comparatively lower shrinkage when to compared to FDH systems containing 
20%PEO, 10% felodipine 70% HPMCAS.  
 
Figure 5.76: % length shrinkage ratio of (a) PEO-HPMCAS and (b) FDH 
systems 
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The FDH system was different from the PEO-HPMCAS system in two 
aspects first, 10% felodipine and second, the difference in the Tg.                           
The Tg confirmed by MDSC of the FDH system was 54oC and Tg of PEO-
HPMCAS system was 64oC. The higher molecular mobility could possibly leads 
to higher shrinkage rate for the FDH system than PEO-HPMCAS. At 40oC 
75%RH, the PEO-HPMCAS system showed a maximum of 5% length shrinkage 
whereas the FDH system shrank by 30% of its original length (Figure 5.76). At 
RT conditions PEO-HPMCAS did not show any shrinkage and only 2.5% 
shrinkage for FDH was seen after 180 days. This suggests the temperature and 
humidity has major role in the shrinkage process as both have the strong 
influence on the molecular mobility of system. The least shrinkage was observed 
for the PEO-HPMCAS moulded bar suggesting PEO helps to retard the shrinkage 
of the HPMCAS. However, the 10% dispersion of the felodipine in the PEO -
HPMCAS polymer matrix made a significant impact of the shrinkage.  
5.2.3 In-vitro drug release using (USP IV) 
The dissolution testing using an open loop configuration of flow through 
cell provides an infinite sink condition for dissolution by maintaining a continuous 
flow of fresh dissolution medium. The dissolution behaviour of I33 pellets, I33 
moulded tablets, FDS pellets and FDS moulded tablets was studied drug release 
profiles are provided in figure 5.75. I33 pellets showed 50% release after 5 hrs of 
dissolution and complete release after 10 hrs of dissolution. In contrast the drug 
release from the I33 moulded tablets was erosion controlled hence the slower 
drug release was observed. From I33 tablets, 50 % release was observed after 
11 hrs and 70 % release after 18 hrs of dissolution (Figure 5.77).  
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Figure 5.77: Dissolution profiles for extruded pellets and injection moulded 
tablets of ibuprofen and felodipine using flow through cell (USP IV) (n=3) 
 The drug release from the PEO-HPMCAS matrix would be diffusion and 
erosion based as PEO is a highly water soluble polymer and it swells and drug 
release is primarily controlled either by diffusion or erosion based on the 
molecular weight of PEO (Figure 5.79). Therefore, the controlled release of 
felodipine from the PEO-HPMCAS matrix was considered to be due to diffusion 
and erosion based mechanisms. 
 FDH pellets showed 50% release after 5 hrs and 100% release after 
11hrs while in the case of FDH tablets 50% release was observed after 10 hrs 
and complete drug release was observed after 18hrs. The difference in the 
release profile from pellets and injection moulded tablet could be attributed to the 
surface area and densification during the injection moulding process. The 
extruded pellets were expected to give higher dissolution rate due to the higher 
surface area provided for the dissolution due to the particle size of the product 
i.e. pellets.   
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Figure 5.78: Dissolution images of I33 pellets and I33 moulded tablets (USP 
IV) 
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Figure 5.79: Dissolution images of FDS pellets and FDS moulded tablets 
(USP IV) 
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Chapter 6 
 
 
6 Soluplus® IM systems 
 
 
 
 
This chapter provides an insight into the processing of the Soluplus® IM systems 
using HME and injection moulding. The processing behaviour and the results of 
product characterisation using of thermal, spectroscopic and In-vitro drug release 
methods are discussed.  
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6.1 Processability using HME and IM  
Soluplus® is designed for use with HME and it is mainly used to obtain 
solid solutions with APIs as it is good solubiliser and stabiliser. Although 
Soluplus® has low Tg (72 oC) compared to other pharmaceutical polymers it has 
a very high shear viscosity. The Soluplus® has been recommended for HME over 
wide temperature range (120-180oC). When Soluplus® was alone extruded at 
150oC but generated a high torque (50-55%) which reduced to 20-25% with the 
10%w/w addition of ibuprofen and allowed extrusion to be carried out 130oC 
suggests the ibuprofen has a plasticisation effect on the Soluplus®. The addition 
of 10%w/w felodipine did not have a significant effect on the processing 
behaviour; however, it reduced the processing torque and the die pressure, 
indicating good miscibility with Soluplus®. The torque and die pressure 
associated with HME of the all three batches are listed in the Table 6.1. 
Table 6.1: HME parameters of Soluplus®, IBS and FDS batches   
Composition used for extrusion Torque 
(%) 
Motor 
power 
(kW) 
Die 
pressure 
(bar) 
Soluplus® 50-55 1.3-1.4 40 
 Ibuprofen-Soluplus®(IBS) 25-30 0.6-0.8 20 
Felodipine Soluplus®(FDS) 40-42 1.0-1.1 33 
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Soluplus®, ibuprofen-Soluplus® (IBS) and felodipine-Soluplus® (FDS) 
pellets were injection moulded into the two shapes; the tensile bars and the 
tablets. In general, The IM of amorphous material is challenging as compared to 
semi-crystalline materials as an amorphous material softens upon heating and 
posses poor lubricity hence melt flow inside the mould cavity becomes 
challenging (Zema et al., 2012).  The processing of Soluplus® alone was very 
challenging and filling inside the mould cavity was achieved with high injection 
speed of 120mm/s and with mould lubrication. The moulded parts obtained were 
very brittle in nature therefore the mould temperature was gradually increased to 
70oC from 20oC and the mould ejection speed was reduced to 2mm/sec from the 
5mm/s. This process modification helped to eject the parts without breaking as 
70oC was close to the Tg of Soluplus®.  
IBS pellets were injection moulded at 135oC and the mould temperature 
required for ejection of the moulded part was 50oC. Ejection was possible at 50oC 
mould temperature due to the Tg of the system being decreased to 54oC with 
addition of ibuprofen. Moulding of FDS systems was performed at a slightly 
higher temperature than IBS systems as the addition of 10%w/w felodipine did 
not significantly affect the Tg of the polymer.  The processing parameters used 
for IM are described in Table 3.15.  
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6.2 Characterisation of extruded pellets and IM systems 
Extruded pellets and injection moulded systems were characterised to 
understand the thermal, spectroscopic and drug release properties. 
6.2.1 Modulated DSC 
The reversing heat flow of pure Soluplus® and the products obtained using 
both HME and IM are presented in the Figure 6.1. The reversing heat flow of 
MDSC allows the separation of reversable phenomena such as Tg and melting 
on the reversing curve (Solarski et al., 2005). The Tg of Soluplus® was observed 
at 72.0±0.21oC. The absence of melting endotherms of ibuprofen at 76oC and 
felodipine at 145oC in the case of IBS and FDS systems, respectively, confirms 
the formation of amorphous solid dispersions. 
 
Figure 6.1: Reversing heat flow curve for Soluplus®, IBD and FDS systems  
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Figure 6.2: Reversing heat capacity curve for Soluplus®, IBS and FDS 
systems  
The presence of a single Tg in the case of pellets and IM tablets of IBS 
and FDS confirms the formation of a solid solution (molecular level dispersion) 
Moreover, changes in heat capacity of samples could be seen in Figure 6.2. The 
heat capacity of material should increase at the Tg of the system due to increased 
molecular mobility. At the respective glass transition the heat capacity of each 
sample increased and resembled a mirror image of the Tg curve. The 
plasticisation effect of ibuprofen and felodipine was clearly observed on the Tg of 
Soluplus® and it decreased to 54oC±0.19 for IBS systems and 63oC±0.22 for FDS 
systems. The higher decrease in the Tg for the ibuprofen containing pellets and 
IM tablets could be attributed to the lower Tg of ibuprofen than felodipine. 
Theoretical calculations of Tg by the Fox equation estimated similar values for 
IBS and FDS mixtures (Reported in chapter 4, equation 4.3).  
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6.2.2 Dynamic Mechanical Analysis (DMA) 
The moulded tensile bars were characterised using DMA to understand 
the dynamic mechanical properties as a function of temperature. A sharp 
decrease in the storage modulus of the Soluplus® moulded bar in the temperature 
region of 65 - 75oC and a small tan δ peak near 73oC (Figure 6.3, Figure 6.4) 
corresponds to the Tg of Soluplus® (Karavas et al., 2006). The mechanical 
behaviour of IBS and FDS moulded bars showed a similar behaviour where a 
decrease in the storage modulus was observed at 64oC and 72oC respectively.  
 
 
Figure 6.3: Storage modulus curves for Soluplus®, IBS and FDS systems 
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Figure 6.4: Tan δ curve of Soluplus® injection moulded systems 
The comparative mechanical properties of the three moulded system are 
presented in the Table 6.2.When the storage modulus and stiffness of the 
moulded bars at 25oC were compared to values at temperatures close to the Tg 
of system approximately a 50% reduction was observed (Table 6.2).  
Table 6.2 : Mechanical properties of Soluplus® injection moulded systems 
Materials 
Temperature 
(oC) 
Storage 
Modulus 
(MPa) 
Loss 
Modulus 
(MPa) 
Tan 
Delta 
Stiffnes
s 
(N/m) 
Soluplus® 25.07 65801 3724 0.05 943143 
72.25 22959 5726 0.25 329079 
Ibuprofen-
Soluplus® (IBS) 
25.061 39298 6361 0.16 563271 
64.41  14235 4831 0.33 196475 
Felodipine-
Soluplus®(FDS) 
25.06 40796 2844 0.07 584742 
72.91 21261 5012 0.26 304746 
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6.2.3 FTIR spectroscopy 
The FTIR spectra’s of pure drug, physical mixture and processed sample 
were compared to understand the interaction within functional groups of a drug 
and a polymer. In the case of the felodipine molecule the -N-H group acts as a 
hydrogen donor and is capable of forming a hydrogen bond (H-bond) with an 
appropriate acceptor molecule such as a carbonyl (-C=O) group. (Tang et al., 
2002). The FTIR spectra of pure felodipine, Soluplus®, and its 10%w/w physical 
mixtures are shown in the Figure 6.5. The Soluplus® exhibits characteristic peaks 
at 1732 cm-1 due to -C=O stretching, 2925 cm-1 due to aliphatic C-H stretching 
and 3452 cm-1 due to the -O-H stretching. The FTIR spectra of FDS physical 
mixture appears as a summation of the peaks of the Soluplus® and the felodipine 
where -C=O stretching of the felodipine at 1688 cm-1 and 1699 cm-1 and -C=O 
stretching of the Soluplus® at 1732cm-1 was observed (Figure 6.5). Moreover, the 
physical mixture shows the -N-H stretching of felodipine at 3368cm-1 and free -
O-H stretching of Soluplus® at 3452cm-1 (Figure 6.6). This suggests that there 
was no interaction between felodipine and Soluplus® when they were physically 
mixed with each other.  
IR spectra of melt extruded pellets and IM tablets showed changes in the        
–N-H stretching vibrations where –N-H stretching was observed at 3288 cm-1. 
This large downward shift suggests the involvement of the –N-H group of the 
felodipine for the H-bonding with Soluplus®. Felodipine is known to form a H-bond 
with the other felodipine molecules and IR spectra of the FDS pellets and 
moulded tablet have shown two peaks first at 3230cm-1 second at 3294cm-1 both 
are attributed to the N-H stretching. The frequency shift at –N-H stretching was 
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observed due to the involvement of N-H group for H-bonding with another 
felodipine molecule and/or with polymer as shown in fig (Figure 6.6). 
 
Figure 6.5:FTIR spectra of Felodipine-Soluplus® systems (1300-1800 Cm-1)  
 
Figure 6.6: -N-H stretching of FDS systems 
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A similar observation was also reported when the felodipine has formed  
solid dispersions with other polymers such as HPMCAS, PVP Kollidon V64 (Song 
et al., 2013) (Tian et al., 2014b). The functional group peaks of the Soluplus® and 
FDS systems are presented in the Table 6.3.  
Table 6.3: Funtional groups of Soluplus ® and FDS moulded systems 
Sample Wavenumber  
(cm-1) 
Assignment 
Amorphous 
felodipine 
3339 N-H, H-bonded with other molecules 
1701 C=O, non-H-bonded 
1684 C=O, H-bonded 
Soluplus®–FD 
3452 free OH from Soluplus® 
3294 
N-H, H-bonded with other drug 
molecule 
3230 N-H, strong H-bonding with Soluplus® 
1701 C=O of felodipine, non-H-bonded 
1732 Unbonded C=O from Soluplus® 
 
In the case of IBS systems the pure crystalline ibuprofen and the ibuprofen 
present in the physical mixture has shown –C=O stretching at 1708 cm-1 whereas 
–C=O stretching of the Soluplus® was observed at 1732 cm-1 (Figure 6.7). Only 
the – C-H stretching vibrations were observed at 2954 cm-1 and no peaks in the 
region of 3000-3500 cm-1 due to the absence of –N-H functional groups and free 
–O-H functional groups in the ibuprofen (Figure 6.8). IBS pellets and IBS tablets 
showed the identical spectra to the Soluplus® with no change in the peak intensity 
or broadening of peaks, suggesting that ibuprofen was dispersed in the Soluplus® 
matrix in the amorphous state. However, this does not involve in any interactions 
with Soluplus® to form the intermolecular H-bonding. 
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Figure 6.7: FTIR spectra of IBS systems (1300cm-1 – 1800 cm-1) 
 
Figure 6.8: FTIR spectra of  IBS systems (2200 cm-1 – 3600 cm-1) 
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6.2.4 Raman spectroscopy 
The crystalline and amorphous forms of ibuprofen and the felodipine show 
distinct changes in their Raman spectra. Raman shifts are associated with the 
molecular arrangement and drug- polymer interactions. As described in the 
previous chapter (section 5.1.2.4) the ibuprofen shows characteristic peak 
changes when dispersed in the amorphous form and when it interacts with the 
polymer. The shift in the characteristic band at 1608 cm-1 to 1613 cm-1 confirms 
that ibuprofen has formed a molecular level dispersion with Soluplus® (Figure 6.9 
and Figure 6.10) 
 
Figure 6.9: Raman Spectra of Ibuprofen-Soluplus® (IBS) systems 
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Figure 6.10: Raman Spectra of Ibuprofen-Soluplus® (IBS) systems 
(carbonyl stretching region: 1500 – 1800 cm-1)  
The Figure 6.11 shows the full Raman spectra of pure felodipine, 
Soluplus®, FDS physical mixture and processed samples. –N-H stretching of 
felodipine was observed at 3370cm-1. In general, when the felodipine converted 
into the amorphous form it showed a shift by approximately 33cm-1 to lower 
Raman shifts due to the presence of stronger H-bond in the amorphous form than 
the crystalline form (Tang et al., 2002). The aryl ring -C=C stretching at 1643cm-
1 showed an upward shift to 1649 cm-1 and carbonyl stretching at 1702cm-1 was 
shifted to 1700cm-1 with a broad peak suggesting that a different molecular 
association was present in the pellets and moulded tablets (Figure 6.12). Similar 
changes were reported earlier (section 5.2.3) due to the amorphous form of the 
felodipine and due to the possibility of involvement with the Soluplus® for an H-
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bond. Although a distinct change in the -N-H stretching was not observed, this 
may be because the peak intensity was too small to detect. However, conjugated 
-C-H stretching vibration in the moulded tablets suggested the strong molecular 
interaction between the felodipine and Soluplus® (Figure 6.13).  
 
Figure 6.11: Raman Spectra of Felodipine-Soluplus® systems  
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Figure 6.12 Raman Spectra of Felodipine-Soluplus® (FDS) systems 
(carbonyl stretching region: 1500 – 1800 cm-1)  
 
Figure 6.13 Raman Spectra of Felodipine-Soluplus® (FDS) systems (2600-
3600cm-1) 
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6.2.5 In-vitro drug release 
Drug release from pellets and moulded tablets was characterised using 
the flow through cell (USP IV). The melt extruded pellets and injection moulded 
tablets of IBS and FDS systems were subjected to dissolution testing to 
understand the drug release bheaviour. The drug-release profile for pellets and 
moulded tablets is shown the Figure 6.14. 
 
Figure 6.14:  Dissolution profiles for IBS and FDS pellets and tablets using 
a flow-through method (USP 4) with an open-loop configuration (n = 3) 
In general pellets showed a faster dissolution than the moulded tablets 
attributed to the higher surface area of the pellets for the dissolution. Felodipine 
release from the FDS systems was faster and complete compared to the release 
of the ibuprofen from the IBS systems. FDS pellets showed a faster drug release 
among all the products where 50% drug release was observed after 90 mins and 
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100% release within 240mins. The FDS moulded tablets showed the controlled 
release where approximately the 10% drug release was observed after every 60 
mins Figure 6.14. Tablets showed a controlled drug release due to the constant 
surface erosion of the dosage form. The dissolution process of the FDS pellets 
and moulded tablet have shown in the Figure 6.15. 
 
Figure 6.15: Dissolution images of FDS pellets and FDS moulded tablets  
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Neither the pellets nor the tablets showed the complete drug release from 
the IBS systems (Figure 6.14). Crystallisation of the amorphous drug during 
dissolution can adversely affect the dissolution rate and solution concentration 
required to maintain supersaturation. The dissolution advantage of amorphous 
solid dispersions can be negated either by crystallisation of the amorphous drug 
in contact with the dissolution media or rapid crystallisation of the supersaturated 
solution. In the case of IBS systems, crystallisation during dissolution should have 
decreased the dissolution rate of the ibuprofen and clear surface whitening was 
seen during the dissolution.  
The Raman spectra confirmed the crystallisation at the pellets and a tablet 
surface during the dissolution. The surface Raman spectra taken after 3 hrs of 
dissolution showed the  characteristic crystalline band of ibuprofen at 1608cm-1 
which was at 1613cm-1 due to the amorphous molecular dispersion within the 
Soluplus® matrix (Figure 6.16) 
 
Figure 6.16: Raman spectra of surface of IBS pellets and tablets after 3hrs 
of dissolution 
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The 60 min and 180 min photographs in Figure 6.17 clearly shows the 
surface changes of samples and this suggests the ingress of the water in the 
dosage form could have decreased the Tg of the system and thus favoured 
crystallisation. Indomethacin pioglitazone and nifedipine are some of the drugs 
known to crystallise or phase transform during the dissolution process. (Alonzo 
et al., 2011; Alonzo et al., 2010; Raina et al., 2014; Shi et al., 2014) 
 
Figure 6.17: Dissolution images of IBS pellets and IBS moulded tablets  
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To summarise the results and discussion of this chapter, the injection 
moulded systems of the Soluplus® were achieved without the addition of 
processing aids. An addition of the low Tg drug (ibuprofen) and the medium Tg 
drug (felodipine) assisted the processing by HME and IM as a result of their 
plasticization effect. The molecular level dispersion of both the drugs was 
achieved within the Soluplus®matrix using the HME and IM processes. Thermal, 
mechanical and spectroscopic studies suggested that the FDS systems would be 
more stable compared to the IBS systems due to high Tg and H-bonding. These 
results can also be correlated with the good drug polymer miscibility which was 
predicted the higher miscibility of the felodipine with Soluplus® using van 
Krevelens group contribution and the F-H theory. The clear difference observed 
in the drug release performance of both IBS and FDS systems where, ibuprofen 
crystallized during the dissolution whereas felodipine released at a constant rate 
over the time and released 100% of the drug. Soluplus® IM systems are also 
discussed in the next global discussion chapter. 
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Chapter 7 
 
 
7 Discussion: HPMCAS and Soluplus® moulded systems 
 
 
A combined discussion of results presented in chapters 4, 5 and 6 is provided. In 
particular, the properties of HPMCAS and Soluplus® IM systems are discussed 
in relation to API and polymer properties, moulding and storage conditions. 
Global findings from this research work are highlighted.   
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7.1 Pre-formulation  
Physicochemical properties of the materials and pre-formulation studies 
were used to predict the miscibility, solubility and stability of the selected drug-
polymer pairs. The APIs (ibuprofen and felodipine) and polymers (HPMCAS and 
Soluplus®) have several distinguishing properties such as Tg, melting point, 
solubility parameter etc. The Tg of mixtures was calculated using the Fox 
equation and MDSC whereas rheological properties were measured using 
capillary rheometry. These indicated a high level of plasticisation by ibuprofen on 
the polymers compared to felodipine. Theoretically predicted Tg curves for IBH, 
IBS, FDH and FDS mixtures were shown in Figure 4.1 (Chapter 4) 
 The logarithmic relationship between apparent shear viscosity and wall 
shear rate for HPMCAS and Soluplus® with and without the addition of ibuprofen 
and felodipine was shown in Figure 7.1. The shear viscosity of HPMCAS at 170oC 
at low shear rate (50s-1) was approximately 1300 Pa.s while FDH mixture (10% 
felodipine, 20% PEO) was similar. However, the addition of 33% ibuprofen 
significantly decreased the shear viscosity to 480 Pa.s at 120oC. This result 
suggests a higher plasticisation effect of ibuprofen on HPMCAS than felodipine 
and PEO. HPMCAS, IBH and FDH showed shear thinning behaviour where a 
linear decrease in the log shear viscosity with log shear rate was observed.  
Figure 7.1b shows the shear viscosity of Soluplus®, IBS and FDS mixtures 
at 140oC in the low shear rate range 20- 100 s-1. Soluplus® exhibited Newtonian 
behaviour followed by shear thinning behaviour at higher shear rates (> 500 s-1). 
10% addition of felodipine has shown similar behaviour while 10% ibuprofen 
addition showed a significant decrease in the shear viscosity with shear thinning 
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behaviour. However, at high shear rates (2000 s-1) the Soluplus® and all the 
mixtures have shown the shear viscosity in the range of 150-400 Pa.s. 
 
Figure 7.1: Shear viscosity of (a) HPMCAS with addition of ibuprofen and 
Felodipine (b) Soluplus® with addition of ibuprofen and felodipine  
During the injection moulding process higher shear rates generated in the 
nozzle and gate during the injection will further decrease the viscosity and thus 
allow better filling of the mould cavity. The precise level of shear rate generated 
in a particular mould will depend upon mould tool geometry and injection velocity.  
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Melt rheology studies of both polymers suggested HPMCAS shows shear 
thinning behaviour of HPMCAS and Soluplus® needs high shear in order follow 
shear thinning behaviour. At a very high shear rate (2000 s-1) however, both the 
polymers have shown the decrease in viscosity (50-200Pa. s) suggests the 
adaptability of polymer for IM. The plasticisation effect of APIs was also very 
prominent where a low Tg ibuprofen reduced polymer viscosity at least by order 
of 2 and thus suggesting better performance during IM.  
7.1.1 Stability prediction using temperature-composition phase diagram  
Using phase diagrams, the solubility and miscibility of APIs in both 
polymers were calculated with respect to temperature. The estimation of 
miscibility and solubility of drugs in different polymers was reported earlier by 
various groups using the melting point depression method combined with Flory-
Huggins lattice based theory (Marsac et al., 2006) (Nishi and Wang, 1975) (Yang 
et al., 2015).  The miscibility of felodipine was reported in various polymers such 
as polyvinyl pyrrolidone (PVP) (Marsac et al., 2006); Eudragit EPO (Yang et al., 
2015), HPMCAS and Soluplus® (Tian et al., 2013), Poly acrylic acid (PAA) (Lin 
and Huang, 2010).  Tian et al. reported at room temperature (25oC) 7% wt 
miscibility of felodipine in HPMCAS compared to 12% wt miscibility in Soluplus®.  
In this research, the ibuprofen miscibility and solubility in HPMCAS and Soluplus® 
was obtained.  
The phase diagram based on the F-H theory provides an interesting 
platform to understand the drug-polymer system performance and stability of the 
amorphous form of the drug within the polymer matrix. The liquid-solid phase 
transition curve represents the equilibrium solubility of drug crystals within the 
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polymer matrices with respect to temperature (Figure 7.2; blue line). Above this 
curve the drug is dissolved in the polymer and forms an unsaturated solution 
while below this curve the solid dispersion is above the equilibrium solubility. The 
region between the solubility and miscibility curves is called the meta-stable 
region (Lin and Huang, 2010).  
 
Figure 7.2 Temperature composition phase diagram (a) ibuprofen-
HPMCAS; (b) felodipine-HPMCAS (c) Ibuprofen-HPMCAS (d) felodipine-
Soluplus® , IM processing temperature  (    ), Stress temperatures (    );and 
Miscibility and solubility temperature (   )  
The phase diagram shown in the Figure 7.2 provides information about 
the processing temperatures used for the injection moulding of all four systems 
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(green dot).  All systems were processed above the thermodymically established 
solubility curve (blue line) indicating that the systems formed a homogenous 
dispersion as processed above the solid-liquid transition temperature and which 
also suggests the strong possibility of the formation of amorphous molecular 
dispersions. The miscibility and solubility temperatures of both the ibuprofen and 
felodipine in the HPMCAS and Soluplus® are provided in the Figure 7.2 (red 
dots). It was seen that, at the same weight fraction ibuprofen becomes miscible 
and soluble in both polymers at lower temperatures than felodipine. For example 
10%wt ibuprofen shows miscibility with HPMCAS and Soluplus® at 25oC. 
However 10%wt felodipine shows miscibility with HPMCAS at 100oC and 
miscibility with Soluplus® at 74oC.  
The solubility of an API in a polymer will be a function of its melting 
temperature and heat of fusion as well as a sign of mixing enthalpy as reflected 
in the interaction parameter (Marsac et al., 2006). It is reported that APIs with a 
high heat or temperature of fusion will therefore be less soluble in a polymer. This 
is apparent from comparing data for ibuprofen and felodipine where it can be 
seen that the lower melting and lower heat of fusion of ibuprofen is predicted to 
have a greater solubility in the polymers (HPMCAS and Soluplus®) than 
felodipine. The effect of fusion properties on the solubility of small molecule in 
conventional solvents has been discussed in detail previously (Yalkowsky, 1999). 
Therefore, high melting point/ high enthalpy of fusion compounds which do not 
have substantial interaction with the polymer will display less solubility. 
Conversely, a negative enthalpy of mixing (and FH interaction parameter χ) will 
display higher solubility (Marsac et al., 2006). Similarly, the calculated FH 
interaction parameters for ibuprofen and felodipine in HPMCAS at 25oC were 
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1.29 and 5.26 respectively, which suggest higher solubility of low melting 
ibuprofen than felodipine (details are provided in Table 4.4).  
According to the phase diagrams provided in the Figure 7.2,  if the 
felodipine (10%wt) containing injection moulded systems formed with HPMCAS 
and kept at stress temperature, it will show higher stability due to broad 
supersaturated glassy state (zone V). Moreover, practically and theoretically 
predicted Tg (brown curve) of the felodipine-HPMCAS system is very high 
compared to stress temperatures hence system stability would be higher due to 
the kinetic barrier offered by Tg. In general, the thermodynamic stability of the 
system predicted using the binary phase diagram shows a Tg curve which 
defines the kinetic boundary of molecular mobility and defines the glass and the 
equilibrium liquid below and above the Tg curve, respectively. For comparing 
data between felodipine-HPMCAS (FDH) and felodipine-Soluplus® (FDS) the 
miscibility and solubility curve suggest the felodipine-Soluplus® systems would 
be thermodynamically more stable than felodipine-HPMCAS however the broad 
glassy region of the felodipine-HPMCAS will offer greater kinetic stability. 
In the case of the ibuprofen containing system the miscibility and solubility 
curves for ibuprofen-Soluplus® and ibuprofen-HPMCAS systems were almost 
identical. However, the broad supersaturated glass region (Zone V) of ibuprofen-
HPMCAS suggests it would be a more stable system than the ibuprofen-
Soluplus®. In this research, 33% ibuprofen dispersion was obtained with 
HPMCAS (I 33) and theoretically predicted Tg of the system was 38oC. I33 
systems kept at stress condition (25o and 40oC) showed spontaneous 
crystallisation. The reason for crystallization can be explained based on the 
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phase diagram (Figure 7.2a). When I 33 moulded systems were stored at 40oC, 
the system was stored above the Tg and behaved like a supersaturated 
immiscible liquid (Zone VI of phase diagram). Hence the driving forces for 
crystallisation were amorphous phase separation and crystallisation of the 
supersaturated drug (Qian et al., 2010). Moreover the kinetic effect for stability 
was negligible as the stress temperature > Tg. At the lower stress condition 
(25oC) I33 moulded systems   were practically stored below the Tg therefore it 
was behaving like a supersaturated immiscible glass (zone v). I33 moulded 
systems should crystallise at a slower rate at 25oC compared to 40oC and this 
crystallisation behaviour was confirmed by MDSC and NIR crystallisation studies.  
7.2 Formulation and chracterisation  
Processing considerations and a combined discussion on the properties of 
the four injection moulded systems is provided in this section 
7.2.1 HME and IM Processing  
Melt processing of HPMCAS alone was not possible below 160oC using 
HME and the addition of ibuprofen allowed the extrusion to be carried out at 100-
120oC with a reduction in measured torque and die pressure highlighting the 
plasticisation effect of ibuprofen. The medium Tg drug (felodipine) was not an 
effective plasticiser for HPMCAS hence the low Tg polymer (PEO) was 
incorporated with 20% concentration. This allowed melt processing to be carried 
out at 140oC.  
HME and IM of HPMCAS required the addition a low Tg drug and/or 
polymer. Conversely, Soluplus® was developed for HME processing and its 
feasibility for IM was explored at 140oC. Mould filling was performed at high 
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injection speed and a higher set mould temperature (70oC) allowed better 
ejection from the mould.  Soluplus® showed Newtonian behaviour in low shear 
rate and shear thinning behaviour at high shear rate. Better mould filling at higher 
injection speed was attributed to a decrease in the shear viscosity. 10% addition 
of ibuprofen and felodipine decreased the Tg of the systems to 54oC and 63oC 
respectively, which favoured melt processing.  
7.2.2 Characterisation  
Moulded ibuprofen-HPMCAS systems were produced with different drug 
loadings of ibuprofen and with/without a hydrophilic additive (mannitol). Mannitiol 
containing systems slightly increased the ibuprofen release from the moulded 
tablets due to the formation of pores. However, the tablet surface was eroding at 
constant rate and the limited surface area was available for the dissolution. It 
might be possible that the small pores formed due to the dissolution of mannitol 
at the tablet surface could have promoted the ibuprofen release to only small 
extent. 33% ibuprofen-HPMCAS (I33) systems were studied in detail using 32 
factorial designs for the IM process. When kept at stress conditions moulded 
samples exhibited a surface crystallisation phenomenon. Crystallisation kinetics 
were quantified using the NIR and MDSC; results suggested that the 40oC 
75%RH condition produced a crystallisation rate of  2%/day approximately 10 
times higher than compared to the 25oC 60%RH condition (0.2%/day). FTIR and 
Raman spectroscopy confirmed molecular association and formation of H-bonds 
between the drug and the polymer. Amorphous and crystalline phase separation 
was observed using DMA which complimented the MDSC results.  
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Earlier reports showed that Ibuprofen and felodipine can form 
intermolecular hydrogen bonding (Kestur and Taylor, 2010; Konno and Taylor, 
2006) (Bras et al., 2008). Ibuprofen is known to form a dimer by involvement of 
two -C=O functional of groups whereas the –N-H functional group of felodipine 
form H-bonding with –C=O of other felodipine molecule (Figure 7.3). The 
HPMCAS and Soluplus® used in these studies are proton acceptors hence they 
can possibly form H-bonds with a proton donor of APIs. Felodipine formed a 
strong H-bond with both polymers through involvement of -N-H functional groups 
of felodipine and –C=O functional groups of HPMCAS and Soluplus® (details of 
IR shift provided in sections 5.2.2.5 and 6.2.3). Similarly, Ibuprofen formed an H 
- bond with HPMCAS however, no changes in –C=O stretching’s were seen when 
ibuprofen formed an amorphous solid dispersion with Soluplus®. 
 
Figure 7.3: H-bondings of ibuprofen and felodipine  
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 The stability of an amorphous solid dispersion can be correlated with the 
nature of H-bonding between the drug and a polymer. Solubility parameters (δ) 
calculated using Van Krevelen and Hoftyzer’s group contribution method by 
measuring their cohesive energy density (CED) also considered a contribution 
from hydrogen bonding (equation 4.2). The calculated solubility parameter 
difference (∆δ) for ibuprofen-Soluplus® was 12.41. The higher difference in ∆δ 
indicated immiscibility and unlikeness to a form H-bonding. Solubility parameter 
difference (∆δ) (MPa1/2) of the four systems predicted the order of miscibility as 
follows; felodipine-HPMCAS > felodipine-Soluplus® > ibuprofen-HPMCAS > 
ibuprofen-Soluplus®.  The observed stability of IM systems was in accordance 
with the H-bonding measured by FTIR and calculated from solubility parameters.  
The solubility parameters, glass transition temperature, drug-polymer 
miscibility and solubility, H-bonding and concentration of the drug all played 
important role in understanding stability of the injection moulded amorphous 
molecular dispersions.  
7.2.3 Drug release 
Release profiles for ibuprofen and felodipine were obtained from the 
HPMCAS and Soluplus® matrices. Although the release was primarily governed 
by the nature of the polymer matrix, the product properties and processing history 
also affected the dissolution rate. As per the Noyes-Whitney equation (equation 
2.1) the surface area is one of the prominent factors governing dissolution rate. 
Therefore, the product particle size and the densification during processing have 
a significant influence on the surface area and consequently the dissolution rate. 
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For example, extruded pellets will provide higher surface area for dissolution than 
the moulded tablet due to the smaller particle size. 
HPMCAS has a pH dependent solubility and amphiphilic nature whereas 
Soluplus® has amphiphilic nature, water soluble and also known to form micelles 
above certain concentrations. PEO is a highly water soluble polymer and has 
swelling properties, thus exhibits drug release either by swelling followed by 
diffusion or erosion depending on the molecular weight (Apicella et al., 1993).  
Ibuprofen release from I33 pellets and tablets were observed to be 
controlled release. Extruded pellets showed the faster release where (100% 
within 6 hrs) whereas moulded tablets showed only 50 % release in 6hrs 
indicating the controlled release behaviour of the tablets (Figure 7.4).   IBS pellets 
and IBS tablets showed erratic and incomplete drug release due to the 
crystallisation of ibuprofen during dissolution (Figure 7.4).  The decrease in Tg of 
the product upon contact with dissolution media led to crystallisation and thus 
affected the dissolution. The Raman spectroscopy confirmed the crystallisation 
of ibuprofen after 3hrs of dissolution.   
For the felodipine-HPMCAS systems two different polymer matrices 
dictate the drug release. PEO polymer matrix governs the release by and 
diffusion whereas HPMCAS exhibit release by surface erosion. Figure 7.4 shows 
the drug release profile of HPMCAS and Soluplus® IM systems. FDH pellets have 
showed faster release where the 50% release was observed within 5 hrs 
whereas; FDH tablets have shown only 25% drug release within 5 hrs of 
dissolution and 50% release after 10 hrs. 
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Figure 7.4: dissolution profiles of extruded pellets and moulded tablets 
studied using flow-through cell (USP IV): I33 and IBS  systems  in 
Phosphate buffer pH 7.2; FDH and FDS systems in Phosphate buffer pH 6.5 
(n=3)  
The release from FDH pellets and FDH tablet completed within 11hrs and 
18hrs of the dissolution, respectively. When compared to the release of the 
felodipine from the Soluplus®, it was comparatively faster and the dissolution rate 
was almost twice that of FDH. FDS pellets and tablets showed 50% release in 
1.5 hrs and 4 hrs respectively. The complete drug release was seen after 4 hrs 
and 11 hrs of dissolution of FDS pellets and tablets respectively. The drug release 
from Soluplus® matrix was faster than the HPMCAS matrix which could be 
attributed to the pH dependent solubility of HPMCAS. 
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7.2.3.1 Dissolution model fitting  
The % drug release data obtained was used for dissolution model fitting. 
The representative model fitting profile of I33 pellets is shown in Figure 7.5. 
 
Figure 7.5 Dissolution model fitting for I33 pellets 
The Peppas developed the  equation to analyze both Fickian and non-
Fickian release of drug from swelling as well as non- swelling polymeric drug 
delivery systems (Peppas, 1985).  
𝑴𝒕
𝑴∞
= 𝒌𝒕𝒏                                             (Equation 7.1) 
Where, Mt/M∞ is the fraction of drug released at time t, n is diffusion 
exponent indicative of the mechanism of transport of drug through the polymer; 
K is a kinetic constant incorporating structural and geometric characteristics of 
the drug delivery systems.  The value of n provided in the Table 7.1 suggests 
that, for the cylindrical sample when n < 0.5 the drug release mechanism follows 
a fickian diffusion whereas n > 0.89 suggests anomalous transport. 
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Table 7.1: Interpretation of diffusional release mechanisms from controlled 
release polymeric systems (Costa and Sousa Lobo, 2001) 
Release exponent 
(Films) (n) 
Release exponent 
(Cylindrical) (n) 
Drug transport 
mechanism 
Rate as a 
function 
of time 
0.5 0.45 Fickian diffusion t−0.5 
0.5<n<1.0 0.45<n<0.89 Anomalous transport tn−1 
1.0 0.89 Case-II transport Zero order 
release 
 
Drug release from the injection molded tablets, followed the Korsmeyer-
Peppas model. The release mechanism obtained from I33, FDH, FDS pellets and 
moulded (cylindrical) tablets showed n values higher than 0.89 or equal to 1 
suggesting that the drug release follows zero order except for IBS tablets which 
showed an anomalous transport mechanism (Table 7.2).  
The zero order release from moulded systems confirmed that drug 
dissolution from the tablets that do not disaggregate released the drug slowly 
assuming that no equilibrium condition is obtained (Costa and Sousa Lobo, 
2001). These release profiles also suggests that the release of the same amount 
of drug by unit of time was achieved, which is an ideal method of drug release to 
achieve prolonged pharmacological action. The densification during injection 
moulding leads to dissolution of dosage forms at constant rate, providing a 
constant surface area for drug diffusion and the amount of drug released was 
independent of initial drug concentration. For IBS systems crystallisation during 
dissolution caused erratic behaviour and anomalous drug release. 
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Table 7.2:  The model fitting and mechanism of release from HMPCAS and 
Soluplus® pellets and moulded systems 
Drug-polymer 
system 
Model fitting Release 
mechanism 
Zero 
order 
1st 
Order 
Matrix 
Hix. 
Crow Pappas 
33%Ibuprofen- 
HPMCAS (I33) 
Pellets 
0.9969 * 0.9392 
 
 
0.9303 
 
 
0.9974 
n = 1.09 
k = 
0.096 
Peppas, 
zero order 
release 
 
33%Ibuprofen- 
HPMCAS (I33) 
Tablet 
0.9865 
 
0.9451 
 
0.9910 
 
0.940 
0.999 
n = 
1.023 
k = 
0.069 
Peppas, 
zero order 
release 
 
10%Felodipine- 
PEO-HPMCAS 
(FDH) pellets 
0.9142 * 0.9654 0.9725 
0.9780 
n = 
1.165 
K = 
0.056 
Peppas, 
zero order 
release 
 
10%Felodipine- 
PEO-HPMCAS 
(FDH) Tablet 
0.9923 * 0.9180 0.8462 
0.9971 
n = 
1.384 
k = 
0.007 
Peppas, 
zero order 
release 
 
10% Ibuprofen- 
Soluplus® (IBS) 
Pellets 
0.9283 .9801 .9872 0.9785 
0.9878 
n= 
0.727 
k = .656 
Peppas  
Anomalous 
10% Ibuprofen- 
Soluplus® (IBS) 
Tablet 
0.9925 0.9847 0.9319 0.9882 
0.9944 
n = 
0.842 
K = 
0.090 
Peppas, 
Anomalous; 
 
10% Felodipine 
- Soluplus® 
(FDS) Pellets 
0.9298 * 0.9678 0.9752 
0.9893 
n= 1.04 
k= 
0.410 
Peppas, 
zero order 
release 
 
10% Felodipine 
- Soluplus® 
(FDS) Tablet 
0.9929 * 0.9566 0.9539 
0.9878 
n= 
1.152 
k= 
0.743 
Peppas, 
zero order 
release 
 
* Insignificant  
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The preformulation, processing, stability and drug release studies 
performed here on the four injection moulded systems suggested that Felodine-
PEO-HPMCAS (FDH) and feloddipien-Soluplus® (FDS) were the most stable 
systems in term of stability of amorphous solid dispersion. Moreover, the 
controlled drug release from these systems was achieved with 100% release 
within 18 hrs.  
Ibuprofen formed a homogenous amorphous solid dispersion with polymer 
matrices and provided a good plasticisation effect during HME and IM compared 
to felodipine. However, higher drug loadings (33%) with HPMCAS formed a 
supersaturated dispersion which leads to crystallsation. Stable amorphous solid 
dispersion was achieved with Soluplus®, however crystallisation of ibuprofen was 
observed during dissolution.  
These studies have provided a sound understanding of the material 
properties, processability and performance of injection moulded dosage forms 
containing an amorphous solid dispersion. The significant factors affecting the 
performance and stability of injection moulded drug delivery systems consist of 
the solubility parameter difference (∆δ), glass transition temperature of the drug 
and polymer (Tg), drug-polymer miscibility and solubility (χ, ∆G), and processing 
variables such pack pressure and mould temperature during IM.  
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    Chapter 8 
8 Conclusion 
This work provides a detailed study of formulation development of 
pharmaceutical dosage forms using the injection moulding process. Four API-
polymer formulations were successfully developed using IM. The findings of 
present work suggest that IM may have extensive applications in 
pharmaceuticals either as a downstream manufacturing process for melt 
extruded formulation or as an independent single unit operation. From the current 
research, the following conclusions could be drawn: 
 Material behaviour during melt processing was found to be heavily 
dependent upon physicochemical properties. The combination of a low Tg, 
low melting temperature drug (ibuprofen); with a low Tg polymer 
(Soluplus®) was found to be most suitable combination for processing by 
injection moulding.  
 IM of pharmaceutical grade amorphous polymers was successfully 
performed; however in order to mould HPMCAS, the addition of low Tg 
plasticisers was required to lower the processing temperature and 
viscosity. Soluplus® was found to be suitable for injection moulding and 
could be moulded alone or in combination with model APIs. 
 Low and medium Tg APIs, ibuprofen and felodipine, respectively were 
found to act as sufficient plasticisers for HPMCAS and Soluplus® to be 
moulded. Amorphous polymers soften above the Tg and exhibit higher 
heat capacity and molecular mobility. Based on this study it can be 
 
 
279 
 
concluded that for injection moulding of amorphous materials the most 
important consideration is the glass transition temperature of the total 
system. 
 Each API - polymer formulation studied formed a solid solution after 
extrusion.  IM was also found to be suitable for manufacturing a final 
dosage form from these solid solutions.   
 Although the drug was molecularly dispersed in both the cases extruded 
pellets and moulded tablets, the rate of drug release from pellets was 
faster compared to moulded tablets suggesting an effect of processing 
history on the product properties. This was attributed to the effect of 
particle size and densification during injection moulding on the drug 
release rate. 
 All of the moulded systems studied were stable after processing and when 
held at stress conditions. However, surface crystallisation under stress 
conditions was observed for one drug-polymer pair (ibuprofen-HPMCAS) 
where supersaturated drug dispersion led to drug crystallisation. 
Crystallization on the surface and stability in the bulk (amorphous phase) 
suggested that phase separation of the moulded system was a time 
dependent process. Stress condition also had a significant influence on 
the crystallisation rate. Moulding parameters such as pack pressure and 
mould temperature were identified as important process variables 
affecting product properties and stability.  
 Shrinkage of moulded drug delivery systems was observed, and results 
suggest that shrinkage could be used as a quality control parameter for 
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injection moulded systems. A higher shrinkage tendency of HPMCAS 
mouldings was observed compared to Soluplus® mouldings. Shrinkage 
rate was quantified at various stress conditions and temperature and 
moisture were found to affect the rate and extent of shrinkage. 
 All injection moulded tablets, except IBS, showed a controlled release of 
drug and the release mechanism primarily followed the Peppas model of 
zero order release, suggesting diffusion of drug molecule at a constant 
rate with drug release being independent of concentration. 
 Overall, this study presents a successful attempt to develop and 
understand controlled release from amorphous solid dispersions using 
injection moulding  
The currently developed injection moulded systems (tablets) were 
specifically designed with the objective of obtaining the oral drug delivery 
systems. IM has commonly been used for making pharmaceutical packaging 
materials and recently for the production of biomedical devices such as scaffolds, 
microneedles, microfluidic devices, implants. Only a limited number of studies 
have been performed to investigate the applications of injection moulding for the 
oral drug delivery. Moreover, the polymers used were semi-crystalline in nature, 
e.g. Polylactic acid, polycaprolactone etc. These polymmers are  relatively 
suitable for injection moulding compared to the currently investigated amorphous 
polymers i.e HPMCAS and Soluplus®. The main challenges associated with the 
current product development was the material suitability for the injection 
moulding. The pre-compounding of drug-polymers mixtures using the HME and 
use of plasticisers for amorphous polymers became the necessity prior to the 
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injection moulding.  This investigation has helped to the identify some of the 
important material attributes (e.g Tg, miscibility and solubility) and critical process 
parameters (e.g., pack pressure, mold temperature) for the pharmaceutical 
product development using IM.   
The drug delivery systems developed in this research have limitation in 
term of the dissolution and drug release from the dosage forms. In general, drug 
delivery products developed using injection moulding are highly dense, non-
disintegrating and potentially challenging for oral drug delivery. However, the 
potential application of IM technique was seen for the development of the 
controlled release oral dosage forms. All of the moulded systems studied have 
shown the shrinkage at various stress conditions, therefore this study 
recommends that the shrinkage should be used as a quality assessment 
parameter for the injection moulded pharmaceutical products.   
Injection moulding offers many advantages over the current 
pharmaceutical product manufacturing; especially tabletting. The pharmaceutical 
industries are currently using solvent assisted, batch processing which often 
involves use of organic solvents and number of unit operations. Injection 
moulding could be a viable technology for the continuous manufacturing as it can 
be transferred to the industrial scale and it has an ability to produce components 
with excellent dimensional accuracy.  The versatility of IM technique can be 
exploited for the production of novel drug delivery systems with defined shape 
and/or dimension characteristics. 
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Chapter 9 
9 Suggested further work 
 To develop immediate release injection moulded oral drug delivery systems. 
Due to densification during injection moulding, tablets do not readily 
disintegrate and the use of suitable material properties and process 
parameters to develop disintegrating dosage forms is suggested. 
 Development of two component injection moulded systems using co-
injection moulding  
 To understand the micromoulding process.  
 Surface structuring of injection moulded tablets to understand the effect of 
surface roughness and surface area on drug dissolution. 
 To develop ultrasound assisted injection moulding method for 
pharmaceutical dosage forms to reduce the effect of exposure to high 
temperature and understand the effect process on the properties.  
 To understand the behaviour of a range of pharmaceutical polymers such 
cellulose, polyacrylates, vinyl polymers, Poly(ethylene oxide) & their 
derivatives. 
 To study the effect of injection moulding process variables on to shrinkage 
of moulded system and to optimise process parameters to control shrinkage.  
 To develop different intermediate compounding processes such high shear 
granulation or direction compaction to prepare drug-polymer mixtures for 
injection moulding. To characterise material properties to understand the 
effect of IM on polymer molecular weight distribution using GPC.  
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Appendix 1 
NIR surface response curves 
 
 
Figure: Surface response curves for % crystallisation of ibuprofen-
HPMCAS moulded system at different stress conditions  
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